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Abstract 
The urothelium, the epithelial lining of the bladder, is exposed to urinary-excreted 
carcinogens from environmental, occupational and dietary sources. These 
carcinogens include heavy metals such as cadmium. As cadmium is a weak mutagen, 
this suggests that genetic mechanisms are not responsible for cadmium-induced 
carcinogenesis. Non-genotoxic carcinogenesis is relatively poorly understood, 
however recent advances show that epigenetic dysregulation of gene expression may 
play an important role. The aim of my research was to investigate epigenetic 
dysregulation as the candidate mechanism underlying cadmium carcinogenesis of 
human urothelial cells. 
Normal human urothelial (NHU) cells were cultured as finite cell lines following 
isolation from surgical specimens. When established in vitro, NHU cells have a 
highly proliferative phenotype and can be induced to differentiate using two 
published methods: either through PPARγ-mediated differentiation or serum-
mediated differentiation.  
Exposure of NHU cells to cadmium inhibited expression of the tumour suppressor 
genes, p16, APC and RASSF1A. As dysplasia is axiomatic of carcinoma in situ, the 
precursor to muscle invasive urothelial carcinoma, the potential of NHU cells to 
differentiate in the presence of cadmium was investigated. Following exposure to 
cadmium, there was a failure to upregulate archetypical differentiation-associated 
genes, including uroplakin 1A and 2, and cytokeratins 13 and 20. Trichostatin A, a 
histone deacetylase inhibitor was able to reverse some of these changes. 
Mass spectrometry and immunoblotting were utilised to investigate post-translational 
histone modification changes caused by cadmium exposure. Data showed that there 
was a change in histone modification marks present in NHU cell cultures exposed to 
cadmium that failed to upregulate differentiation markers. An increase in repressive 
histone marks such as methylation at H3K9 was found alongside a decrease in active 
marks such as acetylation at H3K18 and H3K23.  
This study presents evidence that cadmium exposure changes the epigenome of NHU 
cells and leads to compromised urothelial differentiation and downregulation of 
tumour suppressor genes.   
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1 Introduction 
1.1 Urothelium 
The urothelium is a transitional epithelium that lines the mammalian urinary tract, 
including the renal pelvis, ureter, bladder and proximal urethra.  It functions to 
provide a permeability barrier to urine thereby protecting the underlying stroma 
(Fellows & Marshall, 1972).  
The urothelium is stratified into three cell layers; basal, intermediate and superficial 
(Figure 1.1) with each layer having a morphologically distinct cell type (Richter & 
Moize, 1963). The basal layer is composed of small closely packed cells of diameter 
5-10 µm which form a single layer of cells that are in contact with the basement 
membrane. The basal cells support one to four layers of larger, polygonal 
intermediate cells that have a diameter of 20 µm. The most luminal layer consists of 
terminally differentiated superficial cells, otherwise known as umbrella cells because 
they cover several underlying intermediate cells.  Superficial cells have a hexagonal 
shape, are often binucleated and have a diameter ranging from 50-120 µm (Lewis, 
2000). The three cell zones can be distinguished through the differential expression 
of cytokeratin and claudin isotypes and the expression of uroplakins by the 
superficial cells. 
 
Figure 1.1. A haematoxylin and eosin stained section of human bladder tissue showing the 
multiple cell layers.  
The urothelium is a mitotically-quiescent tissue in situ, but in response to injury or 
infection it possesses a high regenerative capacity (Hicks, 1975; Jost, 1989; Lavelle 
et al., 2002). This proliferation response to bladder injury is believed to be regulated 
by signal feedback between basal cells of the urothelium and the stromal cells that 
underlie them. Shin et al. (2011) showed that basal urothelial cells express the 
Lumen 
Lamina	propria 
Urothelium  
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secreted protein signal Sonic hedgehog (Shh), and in response to injury Shh 
expression in these basal cells increases and results in increased stromal expression 
of Wnt protein signals that lead to the proliferation of both urothelial and stomal 
cells. An additional study using a rodent damage model identified the involvement of 
the BMP4 signalling pathway during urothelial regeneration (Mysorekar et al., 
2009).   
1.1.1 Cytokeratins 
Cytokeratins (CK) are keratin-containing intermediate filaments within the 
cytoplasm of epithelial cells. They exist as heterodimers which come together to 
form a tetramer by anti-parallel binding; these tetramers then form protofilaments 
which intertwine in pairs to form protofibrils. Four protofibrils represent one 
cytokeratin filament.  
There are at least 20 different CK isotypes in humans and their expression profiles 
can be used to classify epithelia and to determine the differentiation stage (reviewed 
by Chu & Weiss, 2002; Southgate et al., 1999). CK20 is an indicator of terminal 
differentiation and is only found in the superficial cell zone of urothelium (Moll et 
al., 1992; Harnden et al., 1996). CK13 is an indicator of transitional differentiation 
and is expressed in the basal and intermediate cell zones (Achtstatter et al., 1985; 
Moll et al., 1988; Varley et al., 2004). CK7, CK8, CK18 and CK19 are expressed 
throughout the three cell layers (Schaafsma et al., 1989). CK14 is an indicator of 
squamous differentiation and is expressed in cases of squamous metaplasia (Harnden 
& Southgate, 1997).   
1.1.2 Uroplakins 
The apical surface of superficial cells is highly specialised, containing multiple 
thickened plaques of asymmetric unit membrane (AUM), which are comprised of the 
products of the urothelium-specific uroplakin genes (Wu et al., 1994; Sun et al., 
1999).  The AUM is thought to strengthen the urothelial apical surface, preventing 
the cells from rupturing during bladder distension and act to help prevent 
transcellular diffusion (Hu et al., 2002). Individual AUM plaques are surrounded by 
‘hinge’ regions of normal symmetrical plasma membrane. There are five uroplakin 
proteins that have been identified in man: UPK1A, UPK1B, UPK2, UPK3A and 
UPK3B (Figure 1.2; Wu et al., 1990; Wu et al., 1994; Deng et al., 2002). UPK1A 
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and UPK1B are members of the tetraspanin family of proteins, which are a family of 
membrane proteins that have four transmembrane domains, whereas UPK2, UPK3A 
and UPK3B are single transmembrane domain proteins (Yu et al., 1994). UPK1A 
pairs with UPK2, and UPK1B pairs with either UPK3A or UPK3B to form the AUM 
plaques (Wu et al., 1994; Deng et al., 2002). Urothelial barrier function can be 
affected by impaired formation of the AUM plaques as demonstrated by UPK2 and 
UPK3A knockout mice, which showed increased water and urea permeability across 
the urothelium (Hu et al., 2000; Hu et al., 2002; Kong at al., 2004). 
 
 
Figure 1.2. The uroplakins. UPK1A and UPK1B are members of the tetraspanning family of 
proteins. UPK2, UPK3A and UPK3B are single transmembrane proteins. The brackets denote 
known pairing interactions between UPK isoforms. Solid circles represent N-linked glycan sites. 
Figure adapted from Deng et al., 2002. 
In normal human urothelium uroplakins are only expressed in terminally 
differentiated superficial ‘umbrella’ cells (Lobban et al., 1998; Varley & Southgate, 
2008).  
1.1.3 Tight junctions 
Tight junction complexes prevent paracellular diffusion and help to establish polarity 
in mammalian epithelia. The tight junction barrier is formed by integral 
transmembrane proteins that seal the paracellular spaces. These proteins include 
occludin, junctional adhesion molecule and claudins (Figure 1.3). These 
transmembrane proteins attach to cytoplasmic proteins such as the zona occluden 
(ZO) proteins that act to cluster the barrier-forming proteins and link the tight 
junction to the actin cytoskeleton (Schneeberger & Lynch, 2004). 
! !!!!!!!UPK1A! !!!!!!!UPK2!! ! !UPK3A! ! !!!!! !UPK1B! ! !!!UPK3B!
Lumen!
Cytoplasm!
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Claudins are small (20-27 kDa) transmembrane proteins. They are tetra-spanning 
proteins that have two extracellular loops and their N- and C-termini located in the 
cytoplasm (Schneeberger & Lynch, 2004; Krause et al., 2008). In humans there are 
24 members of the claudin family. Claudins can interact homotypically and 
heterotypically to form fibrils; for example claudin 3 and 5 interact (Coyne et al., 
2003; Angelow et al., 2008). Immunohistochemical localisation of claudins in human 
urothelium has shown that claudin 3 is expressed only at ‘kissing points’ between 
superficial cells. Claudin 4 and 5 were expressed at intercellular junctions in the 
superficial cell zone with claudin 4 also being expressed by the basal and 
intermediate cell zones and Claudin 7 was expressed by intermediate cells (Varley et 
al., 2006; Smith et al., 2015). 
Zona occludens (ZO) proteins are part of a large family of membrane-associated 
guanylate kinase homologues. The C-terminus of all claudins except claudin 12, 
binds to proteins that contain a PDZ domain, which includes ZO-1, ZO-2 and ZO-3 
(Itoh et al., 1999). ZO-1 and ZO-2 have been shown to be essential for spatial 
organisation of claudins in epithelial cells (Umeda et al., 2006). 
 
Figure 1.3. Structure of tight junctions. 
JAMs 
Claudins 
Occludins 
ZO-1 
ZO-2 
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1.2 Bladder stem cells and progenitor cells 
Traditionally, epithelial stem cells reside in the basal cell layers as seen in skin, oral 
mucosa and the prostate (Bickenbach, 1987; Tsujimura et al., 2002). A DNA 
nucleotide labelling (BrdU) study in rats showed that potential bladder 
stem/progenitor cells were localised to the basal cell layer (Kurzrock et al., 2008). 
Additionally, Shh-expressing cells that have been shown to have long term 
regenerative capacity are proposed to be Keratin 5-expressing basal cells (Shin et al., 
2011; Thangappan & Kurzrock, 2009).  
However, from the use of fate mapping studies, Gandhi et al. (2013) observed that 
Keratin 5-expressing basal cells rarely produce intermediate or superficial cells. They 
found that P-cells, a transient urothelial cell type, are progenitors in the embryo and 
intermediate cells are progenitors in the adult urothelium and that both cell types 
require retinoids for their specification. Sun et al. (2014) found that label-retaining 
cells (BrdU or EdU) were distributed in all three cell layers of the urothelium and 
were most concentrated in the bladder trigone. 
Wezel et al. (2014) used the expression of nerve growth factor receptor (NGFR), a 
cell surface-expressed marker that is restricted to basal cells, to isolate basal NGFR+ 
and suprabasal NGFR- urothelial cells. Both basal and suprabasal cell populations 
showed long term proliferation and the capacity to form hierarchically organised 
differentiated urothelium similar to native urothelium. Colopy et al (2014) showed 
that UPEC-induced injury resulted in the loss of the superficial cell layer followed by 
the proliferation of label retaining cells in the basal and intermediate cell layers. This 
suggests that two distinct progenitor cell populations may exist in the basal and 
intermediate cell layers (Castillo-Martin et al., 2010; Colopy et al., 2014). 
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1.3 Urothelial cells in vitro 
Numerous techniques for the growth of normal human urothelium in vitro have been 
reported (Reznikoff et al., 1983; Kirk et al., 1985; Dubeau & Jones, 1987; Rahman et 
al., 1987; Hutton et al., 1993; Southgate et al., 1994; Southgate et al., 2002). Human 
urothelium can be isolated from surgical specimens, disaggregated and then grown in 
monolayer culture as finite Normal Human Urothelial (NHU) cell lines (Southgate et 
al., 1994; 2002). When established in a low calcium keratinocyte serum-free medium 
(KSFM), NHU cells have a highly proliferative phenotype which is driven by the 
mitogen-activated protein kinase (MAPK) signalling cascade downstream of an 
epidermal growth factor receptor (EGFR)-activated autocrine signalling loop (Varley 
et al., 2005).  Analysis of CK, claudin and uroplakin expression shows that in serum 
free conditions NHU cells are non-differentiated and adopt a squamous basal-like 
phenotype (Southgate et al., 1994; Lobban et al., 1998; Varley et al., 2006). 
1.3.1 Differentiation of NHU cell cultures 
Differentiation of NHU cell cultures can be induced by two methods: one involves 
subculture of NHU cell cultures in medium containing serum (Cross et al., 2005), 
while the other involves pharmacological activation of peroxisome proliferator-
activated receptor gamma (PPARγ) and concurrent inhibition of the EGFR autocrine 
signalling loop (Varley et al., 2004).   
1.3.1.1 Serum- mediated differentiation 
NHU cells subcultured in medium supplemented with 5% bovine serum and near 
physiological calcium (2 mM) reproducibly differentiate to form a stratified 
urothelium, consisting of basal, intermediate and superficial cells, with an efficient 
barrier function demonstrating low diffusive permeability to urea and water (Cross et 
al., 2005). Barrier function can be assessed by transepithelial electrical resistance 
(TER) to determine the potential difference across an epithelial sheet. An epithelia is 
considered to have a ‘tight’ barrier function with a resistance >500 Ω.cm2, whereas a 
‘leaky’ epithelia has a TER <500 Ω.cm2 (Fromter & Diamond, 1972; Lewis, 2000). 
The urothelium has one of the highest recorded TER for any tissue with a TER 
typically greater than 2500 Ω.cm2 (Lewis & Diamond, 1975; 1976; Hu et al., 2002). 
When NHU cells were seeded on permeable membranes and maintained in 5% 
bovine serum and physiological calcium, cultures developed a high TER greater than 
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3000 Ω.cm2 (Cross et al., 2005). Cells differentiated using 5% bovine serum and 
2mM calcium switch from a proliferative/squamous phenotype to a transitional cell 
phenotype confirmed by the expression of tight junction components ZO-1, occludin, 
claudin 4 and an increase in the number of cells expressing CK13 alongside a 
decrease in those expressing CK14 (Cross et al., 2005).  
1.3.1.2 PPARγ-mediated differentiation 
PPARγ is a member of the nuclear receptor family and is a ligand-activated 
transcription factor. It is the highest expressed PPAR isoform in human urothelium 
(Guan et al., 1997). The heterodimerisation of ligand-bound PPARγ with retinoid X 
receptor results in formation of an active transcription factor that binds specific 
regions of DNA in the promoters of target genes called peroxisome proliferator 
response elements (PPRE) (Blanquart et al., 2003). PPARγ activation has been 
shown to have roles in the differentiation of numerous cell types including 
adipocytes (Lowell, 1999). 
Activation of PPARγ in NHU cell cultures with troglitazone (TZ) can induce 
upregulation of the urothelial differentiation marker UPK2 (Varley et al., 2004a) and 
induce transitional differentiation as demonstrated by the gain of CK13 and loss of 
CK14 protein expression (Varley et al., 2004b). Due to autocrine EGFR activity in 
NHU cells (Varley et al., 2005) which phosphorylates and inhibits PPARγ, PPARγ-
mediated differentiation requires the concurrent inhibition of EGFR with PD153035 
(PD) or the downstream MAPK/ERK protein inhibitor U0126. This allows for a 
more robust expression of uroplakins as well as cytokeratins and tight junction 
proteins (Varley et al., 2006). 
1.3.1.3 Transcription factors involved in urothelial differentiation 
Transcription factors upregulated by PPARγ activation have been shown to be 
involved in the expression of differentiation markers. The hypothesis that 
intermediary factors may be involved came about because the differentiation marker 
UPK2 does not contain a PPRE in its promoter region and because upregulation of 
UPK2 mRNA levels does not occur until 24-48 hours after PPARγ activation. This is 
later than other markers of differentiation such as FABP4 and AQP3 that contain a 
PPRE in their promoter region and are upregulated within six hours (Flemming, 
2008). Varley et al. (2009) identified several transcription factors including 
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interferon regulatory factor (IRF1) and forkhead box A1 (FOXA1) that were 
upregulated within 12 hours of induction of differentiation and which had PPREs in 
their promoter regions. Both IRF1 and FOXA1 were shown to bind the promoter 
region of UPK2 and their knockdown inhibited differentiation. Other transcription 
factors that have been shown to be involved in urothelial differentiation include 
grainyhead-like protein 3 homolog (GRHL3), ETS-related transcription factor Elf-3 
(ELF3), krueppel-like factor 5 (KLF5) and GATA-binding protein 3 (GATA3) (Yu 
et al., 2009; Bell et al., 2011; Bock et al., 2014). 
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1.4 Bladder Cancer 
The majority of bladder cancers arise from the urothelium and in its most aggressive 
form, where urothelial carcinoma (UC) invades the detrusor smooth muscle of the 
bladder wall, it is associated with a high mortality (<50 % 5yr survival).  The 
classical understanding of UC is based on clinical and genetic evidence which 
suggests that UC develops via two pathways: the Ta tumour pathway and the 
carcinoma in situ (CIS) pathway (Figure 1.4). The Ta/T1 pathway is characterised by 
low-grade frequently recurrent superficial tumours, which rarely progress to the 
muscle invasive stage (70–80% of human UC cases), whereas CIS lesions are high 
grade and often progress to muscle invasive carcinomas (20–30% of human UC 
cases). The two pathways are associated with different initiating mutations. Low 
grade superficial UCs frequently have activating mutations in the fibroblast growth 
factor receptor 3 (FGFR3) gene (75%) (Cappellen et al., 1999; Billerey et al., 2001), 
or in genes of the RAS pathway (10-15%) (Jebar et al., 2005) both of which activate 
the MAPK pathway. By contrast the high-grade muscle invasive tumours contain 
mutations in genes encoding the tumour suppressor p53 and/or retinoblastoma 
protein (RB) leading to a loss of function (Hartmann et al., 2002; Hopman et al., 
2002; Hurst et al., 2008). Loss of PTEN function and activation of the Wnt signalling 
pathway have also been proposed to play a role in muscle-invasive bladder tumours 
(Puzio-Kuter et al., 2009). 
Recent genome-wide expression and sequencing studies have identified distinct basal 
and luminal molecular subtypes of muscle-invasive bladder cancer (MIBC) that 
share molecular features with basal and luminal breast cancers (Sjodahl et al., 2012; 
2013; Choi et al., 2014; Damrauer et al., 2014). Luminal MIBCs are enriched for 
uroplakins, KRT20, ERBB2 and differentiation markers such as FOXA1, GATA3, 
TRIM24 and PPARγ, while basal MIBCs are enriched for KRT5, KRT6, KRT14, 
CD44 and CDH3. Luminal MIBCs frequently have papillary morphology and 
FGFR3 upregulation or mutation.  
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Figure 1.4. Diagram of urothelial carcinoma progression. Low grade, non-invasive papillary 
tumours are associated with activating mutations in FGFR3 and RAS. High grade muscle-
invasive tumours are associated with loss of p53 or RB function.  Later stage and carcinoma in 
situ tumours express extracellular matrix remodelling genes. (Cappellen et al., 1999; Billerey et 
al., 2001; Jebar et al., 2005; Hartmann et al., 2002; Hopman et al., 2002; Hurst et al., 2008). 
Human&Bladder&Tissue&
Hyperplasia& Dysplasia/CIS&
Ta/T1& Invasive UC&
Metastasis&
70%$
recurrence$
10%$
70+80%$ 20+30%$
FGFR3↑&
RAS&↑&
p53↓&
RB↓&
ECM&
remodelling&
genes&
p53↓&
RB↓&
  Chapter 1 
 
26 
 
1.5 Epigenetics 
Epigenetics is defined as heritable changes in gene expression that are not 
accompanied by changes in DNA sequence (Jones & Baylin, 2007). Major epigenetic 
mechanisms include DNA methylation, post-translational modifications of histones 
and non-coding RNA-mediated gene silencing. Epigenetic mechanisms are essential 
for normal development as they regulate the expression of genes involved in key 
biological processes. However epigenetic changes have also been shown to play a 
role in cancer; this was first shown back in the 1980s when global DNA 
hypomethylation was reported in human tumours (Feinberg & Vogelstein, 1983).  
Since then many other epigenetic mechanisms have been implicated in cancer 
including histone modifications, microRNA expression and nucleosome positioning. 
1.5.1 DNA methylation 
DNA methylation is the most well studied epigenetic alteration. The DNA 
methyltransferase  (DNMT) family mediates the methylation of cytosines through 
the transfer of a single methyl group from S-adenosyl methionine (SAM) to cytosine 
forming 5-methyl cytosine (5-MeC). DNA methylation silences genes by preventing 
access of transcription factors to their respective binding sites either directly by 
methylation of transcription factor binding sequences or indirectly through the 
recruitment of methyl-CpG-binding domain (MBD) proteins. MBD proteins can 
directly block transcription factor binding or they can recruit chromatin modifiers 
that alter the chromatin structure into a more repressive environment (Newell-Price 
et al., 2000). 
1.5.2 Histone modifications 
DNA is packaged into chromatin, which may be partitioned into condensed regions 
called heterochromatin or into more relaxed accessible regions called euchromatin 
(Felsenfeld & Groudine, 2003). The fundamental repeating unit of chromatin is the 
nucleosome, consisting of 147 bp of DNA wrapped approximately 1.7 superhelical 
turns around a core histone octamer, comprising two H2A/H2B dimers and a H3/H4 
tetramer (Luger et al., 1997). Chromatin structure affects every DNA-based process 
including gene transcription, DNA replication and DNA repair (Kouzarides, 2003). 
One approach to establish, maintain and modulate chromatin structure involves post-
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translational modification of histones, particularly of histone N-terminal tails 
(Bannister & Kouzarides, 2011). 
The N-terminal tail domains of the core histones contain an extraordinary number of 
sites that can be subjected to post-translational modification (Grant, 2001; Goll & 
Bestor, 2002; Turner, 2002). Some modifications, such as acetylation and 
phosphorylation, can alter the charge of the tails and, therefore, have the potential to 
influence chromatin through electrostatic mechanisms. However, the primary 
mechanism by which histone modifications act appears to be through altering the 
ability of non-histone proteins to interact with chromatin (Martin & Zhang, 2005; 
Grewal & Moazed, 2003; Iizuka & Smith, 2003; Jenuwein & Allis, 2001). 
The acetylation of histone tails by histone acetyltransferases (HATs) induces 
chromatin decondensation, whereas the removal of acetyl groups by histone 
deacetylases (HDACs) promotes a tighter binding of the histone to the DNA. 
Methylation of histones can be associated with either euchromatin or 
heterochromatin depending on the target histone residue. For example, the tri-
methylation of histone H3 lysine 27 (H3K27me3) is implicated in gene repression by 
promoting a compact chromatin structure (Ringrose et al., 2004), whereas di/tri-
methylated histone H3 lysine 4 (H3K4me2/me3) is associated with transcriptional 
activation, with the highest levels of this modification being observed near 
transcriptional start sites of highly expressed genes (Shi et al., 2004). The enzymes 
that add or remove methylation marks on lysine residues are known as lysine 
methyltransferases (KMTs) and lysine demethylases (KDMs) (Allis et al., 2007). 
1.5.3 Epigenetic modifiers 
Trichostatin A and 5-aza-deoxycytidine are two epigenetic modifiers that are widely 
used in studies to examine epigenetic mechanisms. Trichostatin A (TSA) is a 
Streptomyces metabolite, which specifically inhibits mammalian histone deacetylase 
at nanomolar concentrations and causes accumulation of highly acetylated histone 
molecules in mammalian cells (Yoshida et al., 1995). 5-aza-deoxycytidine (5aza) is 
an epigenetic modifier that inhibits DNA methyltransferase activity, which results in 
DNA demethylation (hypomethylation) and gene activation by remodelling 
chromatin (Creusot et al., 1982; Taylor & Jones, 1982; Christman et al., 1983). This 
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remodelling of chromatin structure allows transcription factors to bind to the 
promoter regions, assembly of the transcription complex, and alters gene expression. 
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1.6 Epigenetic Silencing in Bladder Cancer 
In 2006, Stransky et al. developed a systematic approach, using a combination of 
transcriptome correlation map analysis and comparative genomic hybridization array 
data, to identify regional transcriptional deregulation that occurs independently of 
DNA-copy number changes. Using this approach they were the first to identity the 
long range silencing of numerous chromosomal regions by epigenetic silencing. In 
2011, Vallot et al., extended this approach to identify seven chromosomal regions of 
genes that were silenced by epigenetic mechanisms in bladder tumours; they defined 
this simultaneous silencing of several chromosome regions as a new phenotype 
termed the multiple regional epigenetic silencing (MRES) phenotype and showed 
how the genes associated with this phenotype overlapped with the 100 genes of a 
gene expression signature for carcinoma in situ found by Dyrskjot et al. (2004). 
Vallot et al. showed that the mechanism of epigenetic silencing of these regions was 
associated with histone H3K9 and H3K27 methylation and H3K9 hypoacetylation 
and not DNA methylation. This study also highlighted that the silenced regions in the 
MRES phenotype contained known or potential tumour suppressor genes such as 
PLCD1, DLEC1 and HOXA5. 
Nishiyama et al. (2010) carried out DNA methylation studies comparing urothelia 
from normal urothelium, non-cancerous urothelium from patients with UC and 
samples of urothelial carcinoma. They found that non-cancerous urothelia from 
patients with UC had methylated regions similar to UC samples, but distinct from 
normal urothelium samples. Methylation patterns were able to discriminate patients 
who suffered from recurrence after surgery from patients who did not. This study 
showed that DNA methylation profiling could provide indicators for carcinogenic 
risk estimation and prognosis.  
Several groups have described differential methylation of promoters of genes known 
to have altered expression in UC such as RASSF1A, APC and p53 (Maruyama et al., 
2001; Catto et al., 2005). This has been linked to the altered expression of DNMT1 
during urothelial carcinogenesis as reported by Nakagawa (2005). Dhawan et al. 
(2006) found that aberrant promoter methylation occurs early in urothelial 
carcinogenesis. A follow up study by the same group was performed investigating 
the relationship between DNA methylation, histone methylation and gene expression 
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(Dudziec et al., 2012). They profiled two repressive histone modifications 
(H3K9me3 and H3K27me3) using ChIP-Seq, cytosine methylation using MeDIP and 
mRNA expression in normal and malignant urothelial cell lines. H3K27me3 was 
found to occur around genes with low expression in all cells, whereas H3K9me3 was 
only weakly associated with repression in a subset of genes with DNA methylation. 
DNA methylation itself was more closely related to gene expression in malignant 
rather than normal cell lines. 
Chromatin-remodelling genes have been found to exhibit genetic mutations in 
bladder cancer. These include KDM6A, which encodes a histone demethylase; 
MLL/KMT2A, MLL2/KMT2D and MLL3/KMT2C, which encode histone 
methyltransferases; AT-rich interactive domain 1A (ARID1A) which encodes a 
component of the SWI/SNF chromatin-remodelling complex; E1A-binding protein 
p300 (EP300) and CREB-binding protein (CREBBP), which encode histone 
acetyltransferases; and nuclear receptor co-repressor 1 (NCOR1), which encodes a 
histone deacetylase (Gui et al., 2011; Guo et al., 2013). 
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1.7 Non-coding RNAs in Bladder Cancer 
Many non-coding RNAs have been reported to show abnormal expression in bladder 
cancer tissue. Micro RNAs (miRNAs) are small (18-25 nucleotides) molecules that 
regulate gene expression post-transcriptionally. Altered miRNA expression in 
bladder cancer was first reported in 2007 with ten miRNAs (miR-221, -223, -23a, -
185, -103-1, -205, -23b, -26b, -203 and -17-5p) found to be upregulated in bladder 
cancers compared to normal bladder mucosa (Gottardo et al. 2007). The majority of 
studies involving miRNA and bladder cancer have compared miRNA expression 
between normal bladder tissue, muscle-invasive bladder cancer (MIBC) and non 
muscle-invasive bladder cancer (NMIBC). The general trend is that miRNAs are 
upregulated in MIBC and downregulated in NIMBC (Catto et al., 2009; Veerla et al., 
2009; Neely et al., 2010; Han et al., 2011; Guancial et al., 2014). Catto et al. (2009) 
found that MIBC was characterised by miRNA upregulation, including miR-21, 
which has previously been shown to downregulate the p53 pathway 
(Papagiannakopoulos et al., 2008), and miR-373, which promotes tumour invasion 
and metastasis (Huang et al., 2008). NMIBC tumours exhibited downregulation of 
many miRNAs including the loss of miR-99a and miR-100, which led to the 
upregulation of FGFR3 (Catto et al., 2009).  
Recent studies have shown how miRNAs may promote bladder cancer progression. 
These include a study that has shown miR-96 may function as an onco-miRNA and 
that the upregulation of miR-96 may contribute to aggressive malignancy via 
suppressing CDKN1A protein expression in bladder cancer cells (Wu et al., 2015). 
Sun et al. (2015) found that the suppression of miR-138 in bladder cancer may 
promote ZEB2-mediated cancer invasion and metastasis.  
Long non-coding RNAs (lncRNAs) are RNA molecules with a length of more than 
200 nucleotides. Han et al. (2013) reported upregulated expression of the lncRNA 
MALAT1 in high-grade versus low grade carcinomas and also in invasive compared 
to non-invasive carcinomas. The long intergenic non-coding RNA UBC1 was 
upregulated in bladder cancer tissues compared with normal adjacent tissues, and 
linc-UBC1 overexpression was shown to correlate with lymph node metastasis and 
poor survival (He et al., 2013). Functional studies found linc-UBC1 associates with 
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polycomb repressive complex 2 (PRC2) and regulates the histone modification status 
of target genes.  
H19 is a long non-coding RNA that harbours pro-tumorigenic properties (Barsyte-
Lovejoy et al., 2006; Matouk et al., 2007; Yang et al., 2012). Luo et al. (2013) found 
that H19 expression is increased in bladder cancer tissues and was associated with 
disease progression, with functional studies suggesting H19 may regulate metastasis 
by associating with enhancer of zeste homolog 2 (EZH2) and inhibiting E-cadherin 
expression.  
  Chapter 1 
 
33 
 
1.8 Metals in Cancer 
Epidemiological, animal and cell culture experimental studies have shown that an 
increase in cancer incidence is associated with exposure to non-genotoxic metals 
such as nickel, arsenic and cadmium.  
Nickel compounds are known human non-mutagenic carcinogens that target the 
respiratory system. This targeting is due to bioavailability rather than a tissue-
restricted effect, as the route of exposure of the nickel compounds is through 
inhalation. Both water soluble and insoluble nickel compounds have been implicated 
in human lung and nasal cancers, with insoluble nickel compounds shown to be more 
potent carcinogens (NTP 1996a, 1996b).  Epigenetic changes implicated in nickel-
induced carcinogenesis include gene silencing by DNA hypermethylation (Lee et al., 
1995), decreased histone acetylation of H2A, H2B, H3 and H4 (Broday et al., 2000; 
Golebiowski & Kasprzak, 2005; Ke et al., 2006), increases in histone H3 Lysine 9 
dimethylation (Chen et al., 2006) and increases in histone ubiquitination H2A and 
H2B (Karaczyn et al., 2006).  
Arsenic and inorganic arsenic compounds are known human carcinogens which 
target multiple sites including the lung, skin and urinary bladder.  Inorganic arsenic is 
able to be methylated during its metabolism in the liver using S-adenosyl methionine 
(SAM) as the methyl donor to form monomethylarsonic acid and dimethylarsinic 
acid (DMA(V)). DMA(V) has been shown to induce urinary bladder carcinomas in 
rats that were orally exposed in either their water supply or by addition to their food 
(Wei et al., 1999).  Epigenetic changes implicated in arsenic-induced carcinogenesis 
include increased DNA methylation of the p53 promoter (Mass & Wang, 1997), and 
alterations in global histone H3 methylation, with decreases in H3K27 trimethylation 
and increases in di- and trimethylated H3K4 (Zhou et al, 2008).  
Arsenic treatment has also been shown to increase cell proliferation through the 
activation of signal transduction pathways. Mice that were treated with sodium 
arsenite in their drinking water developed hyperplasia of the bladder urothelium 
within 4 weeks of exposure. In the same study, it was found that arsenic can 
stimulate the growth of UROtsa cells, an immortalized human urothelial cell line 
(Simeonova et al, 2000).  It had also been shown using the UROtsa cell line that 
arsenic exposure leads to c-Src-dependent activation of the EGFR and MAPK 
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pathway (Simeonova et al., 2002). This proliferation-enhancing effect of arsenic may 
also contribute to its ability to cause cancer. 
1.8.1 Cadmium 
Cadmium is a toxic transition metal that has been classified as a known human 
carcinogen by both the International Agency for Research on Cancer and the 
National Toxicology Program of the USA (IARC, 1993; NTP, 2000). The 
classification of cadmium as a human carcinogen is based on epidemiological studies 
in humans (Waalkes, 2000) and experimental studies in animals which show 
cadmium as a multiple tissue carcinogen (Takenaka et al., 1983; Waalkes et al., 
1999). Cadmium has a long biological half-time in humans which is estimated to be 
between 15-20 years (Jin et al., 1998). The human body has a limited capacity to 
limit the harm of cadmium exposure as the metal cannot be metabolised to less toxic 
species and is poorly excreted, effectively making it a cumulative toxin (Goering et 
al., 1994). 
1.8.2 Sources of Exposure  
Occupational exposure to cadmium comes from activities such as lead and zinc 
smelting, melting or welding cadmium-coated steel, using cadmium-containing 
solders and the use, processing and production of cadmium powders for nickel-
cadmium batteries (IARC, 1993). Recently diesel fumes, which contain cadmium, 
have been shown to be carcinogenic to humans (IARC, 2012). It is thought that 
people in high-risk industries exposed to diesel fumes, such as miners, railway 
workers and truck drivers have about a 40% increased risk of developing cancer. The 
general population can be exposed to cadmium via contaminated food or drinking 
water and by the inhalation of cigarette smoke (Jarup & Akesson, 2009; Adams et 
al., 2011). It is believed that the smoking of cigarettes can double the lifetime body 
burden of cadmium (Tokar et al., 2011).  
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1.9 Cadmium and Bladder Cancer 
High-grade bladder cancer is particularly common in South Yorkshire, with some 
health regions having higher-than-average incidence rates (Figure 1.5). This reflects 
local clinical observations of increased high-grade bladder cancer risk amongst metal 
workers exposed to cadmium (J Catto, personal communication).  
 
Figure 1.5. Bladder cancer risk for men in Yorkshire. From the Environment and Health Atlas 
for England and Wales (www.envhealthatlas.co.uk) produced by the UK Small Area Health 
Statistics Unit at Imperial College London. 
A meta-analysis looking at the association between bladder cancer incidence and 
occupation found that metal workers were at an increased risk (Reulen et al., 2008). 
1.9.1 Epidemiological and clinical studies 
Evidence in support of cadmium being a bladder carcinogen includes a 1994 
population-based case-control study of the associations between various cancers and 
occupational exposures which found evidence suggesting a link between cadmium 
exposure and cancer of the urinary bladder (Siemiatycki et al., 1994). This is 
supported by a Belgian case-controlled study which suggested that individuals with 
increased exposure to cadmium have an increased risk of bladder cancer, using blood 
cadmium levels as a marker for cadmium exposure (Kellen et al., 2007). Blood 
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cadmium is considered to reflect current exposure rather than whole body burden, 
while urinary cadmium reflects the total burden of cadmium (ATSDR, 1999). A 
further case-controlled study from Tunisia observed that an increased risk of bladder 
cancer was associated with an increase in cadmium blood concentrations (Feki-
Tounsi et al., 2013). A follow up study by Feki-Tounsi et al. (2014) investigating 
levels of toxic metals in patients with bladder tumours was performed. It was found 
that cadmium concentrations were significantly elevated in normal tissues adjacent to 
tumours compared to controls. 
A study in 1998 based on ten patients with bladder cancer used atomic spectrometry 
to measure urinary cadmium concentrations. It was found that in 60% of the patients 
urinary cadmium was increased, implying an involvement of cadmium in bladder 
cancer (Darewiczet al., 1998).  
An investigation measuring metallothionein-bound cadmium concentration in urine 
using size exclusion chromatography coupled to inductively-coupled mass 
spectrometry found that in bladder cancer patients MT-bound cadmium was 
significantly elevated compared to the control group (Wolf et al., 2009). 
Finally a case-control study that examined the association between the expression of 
metallothioneins and bladder tumours, and also compared cadmium levels in tissue 
and hair of 37 bovine bladder tumours against 17 controls, found that increased 
expression of metallothioneins was associated with bladder tumours and that 
cadmium concentrations in hair were significantly higher in the bladder tumour 
group compared to the control group (Amaral et al., 2009). 
1.9.2 Experimental studies  
Few animal studies have focused on cadmium-induced cancers. Injection, inhalation 
or ingestion of cadmium into animal models has been shown to cause cancer in 
several sites (Waalkes et al., 1999a; 1999b), however, only one study has showed 
that injection of cadmium led to the development of a bladder tumour (Waalkes et 
al., 2000). 
In vitro studies indicating cadmium as a potential human bladder carcinogen include 
a study which demonstrated that cadmium is able to induce malignant transformation 
of immortalized human urothelial cells in vitro (Sens et al., 2004). It was 
demonstrated that long-term exposure to 1 µM Cd resulted in UROtsa cells that were 
  Chapter 1 
 
37 
 
able to form colonies in soft agar and tumours when heterotransplanted into nude 
mice. Tumour heterotransplants produced by these cadmium-transformed cells were 
epithelial in character and had features consistent with urothelial carcinoma (Sens et 
al., 2004). 
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1.10 Cadmium Carcinogenesis 
Cadmium compounds are not mutagenic in bacterial assays (Beyersmann & Hartwig, 
1994) and cadmium salts did not cause DNA damage in cell extracts or with isolated 
DNA (Valverde et al., 2001). This implies cadmium-induced carcinogenesis may be 
mediated through non-genotoxic or indirect genotoxic mechanisms. Proposed 
mechanisms for cadmium carcinogenesis have been outlined below (Figure 1.6). 
 
Figure 1.6. Proposed mechanisms involved in cadmium-induced carcinogenicity. 
1.10.1 Oxidative stress 
Cd2+ does not catalyse the Fenton-type production of free radicals because it does not 
accept or donate electrons under physiological conditions. However, increased levels 
of reactive oxygen species have been observed in vitro and in vivo (Liu et al., 2009). 
This is believed to be caused by the inhibitory effect of cadmium on antioxidant 
enzymes such as catalase, superoxide dismutase, glutathione reductase and 
glutathione peroxidase (Stohs et al., 2001; Valko et al., 2006). Cadmium compounds 
have been shown to induce DNA strand breaks and oxidative DNA base 
modifications in mammalian cells, but effects were small and restricted to high 
concentrations (Dally & Hartwig, 1997; Schwerdtle et al., 2010). The induction of 
DNA strand breaks and chromosomal aberrations by cadmium in mammalian cells 
could be suppressed by antioxidants and antioxidative enzymes (Ochi et al., 1987; 
Stohs et al., 2001; Valko et al., 2006). Oxidative DNA damage does not appear to be 
sufficient to explain the carcinogenicity of cadmium. 
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1.10.2 Induction of genes 
Exposure to cadmium has been shown to induce the expression of many genes 
including immediate early response genes (IEGs) and stress response genes including 
metallothionein genes and heat-shock genes.  
Immediate early response genes are genes that are activated rapidly and transiently 
after a variety of cellular stimuli. IEGs encode transcription factors and DNA-
binding proteins that regulate cell growth and differentiation. The IEGs most studied 
with respect to cadmium toxicity and carcinogenesis are c-fos, c-jun and c-myc. 
These genes are overexpressed in response to cadmium exposure in vitro and in vivo 
(Achanzar et al., 2000; Jin & Ringertz, 1990; Matsuoka & Call, 1995).  
Cadmium exposure to cells and whole animals has been shown to result in the 
induction of several stress response genes, including those involved in 
metallothionein synthesis (Hart et al., 1996), genes involved in the synthesis of 
glutathione (Hatcher et al., 1995), and genes encoding heat shock proteins (Lee et al., 
2002). Cadmium has been shown to induce heat shock protein genes by generating 
denatured or abnormal proteins by reacting with thiol groups or by substituting for 
zinc in proteins (Parsell & Lindquist, 1994). Both metallothionein and glutathione 
play a role in cellular defence against cadmium toxicity and carcinogenesis by 
scavenging and sequestering the Cd2+ ion to prevent its interaction with critical 
cellular targets.  
Metallothioneins (MTs) are a family of cysteine-rich low molecular weight proteins 
that bind heavy metals. There are eleven functional MT isoforms in humans that are 
divided into four classes, MT1 to MT4. MT1 and MT2 are expressed in many cell 
types and their function is to maintain cellular zinc homeostasis and protect against 
heavy metal and oxidant damage. MT1/2 transcription is regulated by the metal 
regulatory transcription factor 1 (MTF1), a zinc-sensing zinc-finger transcription 
factor that binds to short DNA sequence motifs termed metal response elements 
(MREs) present in the promoter region of metallothionein genes (Stuart et al., 1985). 
Upon cadmium exposure, MT-bound Zn2+ is replaced by Cd2+ which then activates 
MTF1 (Figure 1.7; Günther et al., 2012). 
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Figure 1.7. Proposed molecular mechanism of MT transcription in response to cadmium 
exposure. MTF1 can be activated directly by zinc or indirectly by release of zinc from 
metallothioneins upon cadmium exposure (Zhang et al., 2003). Upon zinc binding MTF1 
translocates to the nucleus where it binds to metal response elements (MRE) located upstream 
of the MT gene coding sequences. MTF1 interacts with other transcription factors and recruits 
the histone acetyltransferases p300 resulting in increased MT transcription. 
1.10.3 Inhibition of DNA repair 
Inhibition of DNA repair has been identified as a mechanism contributing to the 
carcinogenic potential of cadmium. DNA damage can be caused by environmental 
agents or endogenous factors and is repaired by DNA damage repair pathways. 
These include base-excision repair, nucleotide-excision repair, recombinational 
repair and mismatch repair.  Low concentrations of cadmium have been 
demonstrated to inhibit the repair of oxidative damage in mammalian cells (Dally & 
Hartwig, 1997). During nucleotide-excision repair cadmium was shown to inhibit the 
removal of thymine dimers generated by UV-irradiation by interfering with the first 
step of the repair pathway. Cadmium was shown to inhibit two proteins, Fpg and 
XPA (Asmuss et al., 2000); these proteins are zinc-finger proteins and the inhibitory 
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effect of cadmium was believed to be due substitution of zinc by cadmium (Hartwig, 
2001). 
1.10.4 Epigenetic mechanisms 
Although cadmium can induce oxidative stress, it is poorly mutagenic and has a 
weak DNA binding affinity; therefore it is believed that another way cadmium may 
promote carcinogenesis is through epigenetic mechanisms.  
1.10.4.1 DNA methylation 
To date, the most reported epigenetic changes associated with cadmium exposure 
relate to changes in DNA methylation; however cadmium exposure has been shown 
to cause both hypermethylation and hypomethylation. Takiguchi and colleagues 
showed that cadmium is an effective inhibitor of DNA methyltransferases (DNMTs) 
and initially induced DNA hypomethylation in TRL1215 rat liver cells in vitro. 
However prolonged exposure led to the emergence of cadmium-transformed cells 
which exhibited increased DNA methylation and DNMT activity (Takiguchi et al., 
2003). The study showed that acute cadmium exposure led to reduced DNA 
methyltransferase activity both in vitro, in TRL1215 liver cells, and in an ex vivo 
system using purified bacterial DNA methyltransferase. Kinetic analysis performed 
indicated that cadmium interacts with enzymes at sites other than the catalytic site. 
The authors put forward the DNA binding site of the DNMTs as a strong candidate 
as it contains numerous cysteines, which are known to bind cadmium. A later study 
using cadmium-transformed human prostate epithelial cells showed that increased 
DNMT enzymatic activity was associated with over-expression of DNMT3b without 
changes in DNMT1 (Benbrahim-Tallaa et al., 2007). The over-expression of 
DNMT3b correlated with reduced expression of the tumour suppressor genes, 
RASSF1A and p16. It was reported that the promoter regions of these genes were 
heavily methylated, indicating gene silencing due to DNA hypermethylation. 
Additionally the expression of these genes could be restored by treatment of the cells 
with 5-aza-2’-deoxycytidine, a DNA demethylating agent, giving evidence that 
chronic cadmium exposure induces gene-specific DNA hypermethylation and gene 
silencing. The overall effect of cadmium exposure on DNA methylation suggests that 
short exposures are associated with DNA hypomethylation whereas chronic 
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exposures are associated with DNA hypermethylation (Martinez-Zamudio & Ha, 
2011). 
1.10.4.2 Histone modifications 
Few studies have been performed investigating histone modification changes due to 
cadmium exposure. One study looking at changes in histone modifications caused by 
direct cadmium exposure, used cadmium-transformed immortalized human urothelial 
cells to determine if epigenetic modifications control urothelial metallothionein 3 
(MT-3) gene expression (Somji et al., 2011). The study found that in non-
transformed UROtsa cells the MT-3 gene is silenced by a mechanism involving 
histone modification of the MT-3 promoter. Transformation of the UROtsa cells with 
Cd2+ modified the chromatin of the MT-3 promoter to a bivalent state with both 
active (H4 acetylation, H3K4 methylation) and repressive (H3K9 and H3K27 
methylation) histone marks present. 
However, other changes in histone modifications have been reported due to 
cadmium. In a study reporting the epigenetic and genotoxic effects of cadmium 
telluride quantum dots in human breast carcinoma cells, free cadmium ions released 
in the cells led to chromatin condensation and histone hypoacetylation (Choi et al., 
2008). The hypoacetylation of histone H3 was detected by both immunofluorescence 
and western blotting, with the hypoacetylation being reversed by treatment with 
trichostatin A, a histone deacetylase inhibitor. 
1.10.4.3 Non-coding RNA expression 
Peripheral blood leukocytes from 63 workers at an electric-furnace steel plant were 
analysed after exposure to particular matter containing cadmium. miR-146a was 
found to be negatively correlated to occupational cadmium exposure while miR-222 
and miR-21 were significantly increased after 3 days exposure to the metal-rich 
particulate matter (Bollati et al., 2010). Cadmium has been shown to affect miRNA 
levels in vitro. miRNA expression was analysed after cadmium exposure in a human 
hepatocellular carcinoma cell line using an Agilent microarray. Several differentially 
expressed miRNAs were found, some of which were members of the let-7 family, 
which exhibit oncosuppressor functions (Fabbri et al., 2012). 
Two studies have reported changes in lncRNA expression upon cadmium exposure. 
Human-induced pluripotent stem cells treated with cadmium showed an increase in 
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the expression levels of two lncRNAs GABPB1-AS1 and LINC00152 (Tani et al., 
2014). Zhou et al. (2015) reported aberrant expression profiles of lncRNAs in Cd2+-
transformed human bronchial epithelial cells (16HBE) compared to untreated 16HBE 
cells with lncRNA-ENST00000414355 showing the highest expression out of ten of 
the most significantly upregulated lncRNA when validated by real time PCR. The 
authors showed that expression of ENST0000041435 was detected in the blood and 
urine of workers exposed to cadmium, with a strong positive correlation between 
found blood ENST0000041435 and urine cadmium. Additionally, expression of 
ENST00000414355 increased in a dose-dependent manner in the lungs of Cd2+-
exposed rats. 
 
  
  Chapter 1 
 
44 
 
1.11 Thesis aims 
The urothelium is exposed to urinary-excreted carcinogens from environmental, 
occupational and dietary sources. These carcinogens include heavy metals such as 
cadmium; however, cadmium is a weak mutagen suggesting that genetic mechanisms 
are not responsible for cadmium carcinogenesis. Non-genotoxic carcinogenesis is 
relatively poorly understood, however recent advances show that epigenetic 
dysregulation of gene expression may play an important role. 
The aim of this thesis was to investigate cadmium carcinogenesis of human 
urothelial cells and the role that epigenetic dysregulation of gene expression may 
play. 
The working hypothesis is that exposure of the urothelium to cadmium leads to 
epigenetic dysregulation of gene expression, including down-regulation of tumour 
suppressor genes, causing field changes within the urothelium characteristic of 
dysplasia/carcinoma in situ (loss of differentiation), which is the best characterised 
precursor of invasive carcinomas.  
The specific objectives of this thesis were to: 
• Determine the effect of cadmium exposure on proliferative and differentiated 
NHU cells in vitro. 
• Investigate whether the effects of cadmium can be reversed using two well-
characterised epigenetic modifiers (TSA and 5-azacytidine).  
• Assess the effect of cadmium on tumour suppressor gene expression. 
• Analyse Agilent microarrays to identify gene expression changes that occur 
when urothelial cells are differentiated in the presence of cadmium and TSA. 
• Examine proliferative and differentiated cadmium-treated NHU cell cultures 
for changes in global levels of post-translational histone modifications.
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2 Materials and Methods 
2.1 Practical work and collaborations 
All practical work was carried out in the Jack Birch Unit for Molecular 
Carcinogenesis in the Department of Biology at the University of York with the 
following exceptions. Microarray experiments were carried out in the Genomics 
Department of the Technology Facility at the University of York. The quantification 
of post-translational histone modifications by LCMS/MS was carried out in 
collaboration with Dr Mark Dickman and Tom Minshull from the Department of 
Chemical and Biological Engineering at the University of Sheffield. 
2.2 Suppliers 
Commercial suppliers and manufacturers are indicated at the first mention of the 
reagent or equipment in the text. A complete list of suppliers’ names and web 
addresses is provided in Appendix 1. 
2.3 Stock Solutions 
Recipes for all stock solutions are listed in Appendix 2. General laboratory solutions 
were prepared using deionised water (dH2O). Tissue culture grade solutions were 
prepared with ultra-pure water from a Purelab Ultra Genetic (Elga) ultra violet water 
purification unit. Heat stable solutions were sterilised by autoclaving at 121°C (1 
bar) for 50 minutes, and other solutions were sterilised by syringe filtration through 
filters with 0.2µm pore size (VWR).   
2.4 Reagents 
2.4.1 Antibodies 
Primary antibodies used in this study are listed in (Table 2.1). Antibodies were 
titrated on known positive cell or tissue controls in order to establish the optimal 
concentration prior to use. Primary antibodies were aliquotted and stored as 
recommended by the manufacturer. Fluorophore-conjugated secondary antibodies 
were titrated prior to use and stored in the dark at 4°C (Table 2.2). Representative 
western blot images for each antibody are shown in Appendix 3.  
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Table 2.1. Primary Antibodies. Table listing primary antibodies used throughout this study 
along with their use (WB: western blotting, IF: immunofluorescence, IHC: 
immunohistochemistry, ChIP: Chromatin Immunoprecipitation). Antibodies used for western 
blotting also include molecular weight of protein. 
Antigen Host Supplier Catalogue 
Number 
Use Molecular 
Weight  
β-actin Mouse Sigma A5441 WB (1:250000) 42 kDa 
CK13 Mouse Abnova MAB1864 WB (1:1000) 
IF (1:500) 
IHC (1:500) 
50 kDa 
CK14 Mouse Serotech MCA890 WB (1:1000) 50 kDa 
CK14 Mouse ICRF  IF (1:5)  
CK20 Mouse Cymbus 
Bioscience Ltd 
 IF (1:100)  
Claudin 4 Mouse Zymed 32-9400 WB (1:1000) 22 kDa 
Claudin 5 Mouse Invitrogen 35-2500 WB (1:250) 22-24 kDa 
H2AK5ac Rabbit Cell Signalling 2576 WB (1:1000) 14 kDa 
Histone H3 Rabbit Abcam ab1791 WB (1:1000) 
ChIP: 2.4 µg 
for each ChIP 
17 kDa 
H3K4me3 Rabbit Cell Signalling 9751S WB (1:1000) 17 kDa 
H3K9ac Rabbit Cell Signalling 9671 WB (1:1000) 17 kDa 
H3K9me2 Rabbit Diagenode 060-050 WB (1:1000) 
IF (1:500) 
17 kDa 
H3K9me2 Mouse Abcam ab1220 WB (1:1000) 17 kDa 
H3K9me3 Rabbit Diagenode 056-050 WB (1:1000) 
IF (1:500) 
ChIP: 2.4 µg 
for each ChIP 
17 kDa 
H3K9/14ac Rabbit Diagenode 005-050 WB (1:1000) 17 kDa 
H3K18ac Rabbit Millipore 07-354-S WB (1:10000) 17 kDa 
H3K23ac Rabbit Millipore 07-355-S WB (1:10000) 17 kDa 
H3K27me3 Rabbit Cell Signalling 9733S WB (1:1000) 17 kDa 
H4K8ac Rabbit Cell Signalling 2594 WB (1:1000) 11 kDa 
H4K20me3 Rabbit Diagenode 057-100 WB (1:1000) 11 kDa 
p16 Mouse Santa Cruz Sc-1661 WB (1:1000) 16 kDa 
Rabbit IgG Goat Rockland 611131122 ChIP: 2.4 µg 
for each ChIP 
 
SOX9 Goat Santa Cruz  Sc-17341 IF (1:50)  
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Table 2.2. Secondary Antibodies. 
Antigen Conjugate Host Supplier & Cat. Number Application 
Mouse IgG Alexa 680 Goat Life Technologies, A21057 WB (1:10000) 
Rabbit IgG IR Dye 800 Goat Rockland, 611-132-122 WB (1:10000) 
Goat IgG Alexa 594 Donkey Life Technologies, A11058 IF (1:500) 
Mouse IgG Alexa 488 Goat Life Technologies, A11001 IF (1:500) 
Mouse IgG Alexa 594 Goat Life Technologies, A11005 IF (1:700) 
Rabbit IgG Alexa 488 Goat Life Technologies, A11008 IF (1:400) 
Rabbit IgG Alexa 594 Goat Life Technologies, A11012 IF (1:500) 
 
2.4.2 Chemicals and Agonists/Antagonists 
Chemicals and agonists/antagonists were reconstituted in sterile H2O or tissue culture 
grade dimethyl sulfoxide (DMSO; Sigma) according to the manufacturer’s 
instructions and stored in single use aliquots at -20°C. Prior to use, dilutions were 
made from the stock solutions into growth medium, for vehicle controls 0.1% DMSO 
(v/v) was added to medium (Table 2.3). 
Table 2.3 Chemicals and Agonists/Antagonists 
Compound Target Supplier & 
Catalogue 
Number 
Stock 
concentration 
Effective 
concentration in 
medium 
 PD153035 
(PD) 
EGFR inhibitor Calbiochem, 
234490 
10 mM in 
DMSO 
1 µM 
Troglitozone 
(TZ) 
PPARγ agonist Tocris, 3114 100 mM in 
DMSO 
1 µM 
Cadmium 
chloride 
(CdCl2) 
- Sigma, 
202908 
0.1 M in 
ddH2O 
10 nM - 20 µM 
Trichostatin A 
(TSA) 
Histone 
deacetylase 
inhibitor 
Sigma, T8552 4 mM in 
DMSO 
400 nM 
5-Azacytidine 
(5aza) 
DNA 
methyltransferase 
inhibitor 
Sigma, A1287 500 µM in  
KSFMc 
1 µM 
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2.5 Cell Culture 
2.5.1 General 
All tissue culture work was undertaken using aseptic techniques within a class II 
laminar flow safety cabinet with HEPA filtration (Envair or Medical Air 
technology). Surfaces were cleaned with 70% (v/v) ethanol before and after use.  
Waste media and cells which did not contain cadmium chloride were aspirated by 
vacuum into a Buchner flask containing 10% (w/v) Virkon® sterilising agent (SLS) 
for decontamination. Waste medium containing cadmium chloride was aspirated 
using disposable sterile pipettes (Sarstedt) then put into bottles containing 10% (w/v) 
Virkon® for decontamination of medium and cells and disposed of via Biology 
Department internal chemical waste disposal. All used plastic-ware contaminated 
with cadmium chloride was placed in a double-bagged clinical waste bag for disposal 
by incineration. 
Cultures were maintained in HeraCell 240 incubators (Thermo Scientific) at 37°C in 
a humidified atmosphere of 5% CO2 in air. Culture medium was replaced on cell 
monolayers every 2 to 3 days. 
All tissue culture centrifuge steps were carried out in a Sigma benchtop swing-angled 
centrifuge (Philip Harris) at 250 g for 5 min at ambient temperature. 
An inverted Nikon phase-contrast microscope was used for observation of cell 
cultures. Monochrome images were captured using a Nikon Coolpix 4500 digital 
camera. 
2.5.2 Primary Urothelial Cell Culture 
2.5.2.1 Plastic-ware 
Primary urothelial cell lines were maintained in Primaria® (Becton Dickinson) or 
Cell+ (Sarstedt) flasks and dishes. These flasks and dishes have a mixture of 
negative, positive and nitrogen containing functional groups on the polystyrene 
surface that help to support the attachment of the primary urothelial cells to the 
surface. 
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2.5.2.2 Tissue Specimens  
Human urological specimens of urinary bladder, ureter and renal pelvis were 
obtained from patients with no history of urothelial neoplasia. All specimens were 
collected following ethical approval from an NHS Research Ethics Committee and 
with the patient’s written informed consent where required. On arrival each tissue 
sample was allocated an arbitrary laboratory record number (Y-number, e.g. Y1019). 
Details of tissue samples and subsequent cell lines used in this study are listed in 
Table 2.4. Specimens were collected in 25 mL plastic universal tubes containing 
sterile transport medium (Appendix 2) and were stored at 4°C until processed. 
Table 2.4. Source and demographics of tissue samples and subsequent NHU cell lines. 
Cell 
line 
Surgical 
Procedure 
Origin of 
Tissue 
Donor Age 
(years) 
Donor Sex 
(M/F) 
Y1019 Unknown Ureter 43 F 
Y1054 Unknown Ureter 57 M 
Y1075 Pyeloplasty Bladder 21 M 
Y1141 Pyeloplasty Renal pelvis 32 M 
Y1160 Pyeloplasty Ureter 25 M 
Y1183 Nephrectomy Ureter 75 M 
Y1197 Pyeloplasty Renal pelvis 73 M 
Y1202 Nephrectomy Ureter 56 F 
Y1226 Nephrectomy Ureter 78 M 
Y1233 Nephrectomy Ureter 81 F 
Y1236 Nephrectomy Ureter 57 M 
Y1237 Nephrectomy Ureter 73 M 
Y1244 Pyeloplasty Renal pelvis 43 M 
Y1270 Nephrectomy Ureter 76 F 
Y1279 Pyeloplasty Renal pelvis 52 F 
Y1335 Nephrectomy Ureter 70 M 
Y1357 Nephrectomy Ureter 38 F 
Y1441 Renal transplant Ureter 57 M 
Y1445 Renal transplant Ureter 79 F 
Y1451 Nephrectomy Ureter 61 F 
Y1456 Renal transplant Ureter 78 F 
Y1529 Nephrectomy Ureter 68 F 
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2.5.2.3 Isolation and culture of primary human urothelial cells 
Primary Normal Human Urothelial (NHU) cell lines were established from 
urological specimens as previously described (Southgate et al., 1994; Southgate et 
al., 2002). Samples were removed from the plastic universal tubes by pouring into a 
clean sterile Petri dish (Nunc) along with the transport medium the sample came in. 
Unwanted connective and fatty tissue was removed using sterile scissors and forceps. 
A small representative sample of each specimen was fixed overnight in 10% (v/v) 
formalin in PBS for routine histology. The remaining tissue was cut into 1 cm2 pieces 
and incubated in 10 mL stripper medium (Appendix 2) for 4 hours at 37 °C or 16 
hours (overnight) at 4 °C. Sheets of urothelial cells were gently separated from the 
stroma using forceps, collected by centrifugation and then resuspended in 2 mL (100 
U/mL) collagenase type IV (Appendix 2) and incubated for 20 minutes at 37 °C. 
Cells were collected by centrifugation, counted with a haemocytometer and seeded at 
a minimum density of 4 x104 cells/cm2 in Keratinocyte Serum-Free Medium (KSFM; 
Invitrogen), supplemented with 5 ng/mL recombinant human epidermal growth 
factor (rhEGF; Invitrogen), 50 µg/mL bovine pituitary extract (BPE; Invitrogen) and 
30 ng/mL cholera toxin (Sigma). This complete medium (KSFMc) was used for all 
experiments. 
2.5.2.4 Subculture of NHU cell lines 
NHU cell cultures were passaged when they reached near confluence by incubating 
cell monolayers in PBS with 0.1% (w/v) EDTA (Sigma) for 5 minutes at 37 °C, until 
the cells began to round up and dissociated from each other. Cultures were then 
incubated in a minimal volume (0.3 - 1 mL, dependent on size of dish or flask) 
0.25% (w/v) trypsin (Sigma Aldrich) and 0.02% (w/v) EDTA in Hank’s balanced 
salt solution (HBSS; Invitrogen) for 2 minutes at 37 °C. Cells were harvested into 5 
mL KSFMc containing 1.5 mg/mL soybean trypsin inhibitor (Sigma). Cells were 
collected by centrifugation and resuspended into KSFMc before being seeded into 
fresh sterile dishes or flasks. NHU cells were passaged at split ratios between 1:3 and 
1:6. All experiments were performed on NHU cells of passage 2-5.  
2.5.2.5 Cryopreservation 
NHU cells from one T75 cm2 flask were harvested as for passaging, collected by 
centrifugation and resuspended in 6 mL ice-cold KSFMc containing 10% (v/v) FBS 
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(Seralab) and 10% (v/v) tissue culture grade DMSO, which inhibits the formation of 
ice crystals during cryopreservation. 1 mL of cell suspension was aliquoted into 1 
mL polypropylene cyrovials (Greiner) and transferred to an isopropanol-filled 
freezing container (Sigma Aldrich) at -80°C. This allowed cells to cool at a rate of 
approximately 1°C per minute. Cells were kept at -80°C overnight and transferred to 
a liquid nitrogen-containing storage dewar at -196°C. Cells were recovered by rapid 
thawing in a 37°C water bath. Cells were then diluted with 5 mL pre-warmed 
KSFMc, centrifuged and resuspended in KSFMc and plated at the required density. 
Medium was changed after 24 hours to remove any unattached cells. 
2.5.3 In vitro differentiation of NHU cell cultures 
Differentiation of NHU cell cultures was induced by two established methods: 
1) pharmacological  activation of peroxisome proliferator-activated receptor 
gamma (PPARγ) by the PPARγ agonist, troglitazone, and concurrent 
inhibition of the EGFR autocrine signalling loop, through the use of an EGFR 
tyrosine kinase inhibitor, PD153035 (Varley et al., 2004)  
2) a ‘biomimetic model’ that involves subculture of NHU cell cultures in 
medium containing adult bovine serum and a near physiological calcium 
concentration of 2 mM (ABS/Ca2+) (Cross et al., 2005). 
2.5.3.1 Pharmacological Differentiation  
Troglitazone (TZ) (Sigma Aldrich) was solubilised in tissue grade DMSO (Sigma), 
to a final molarity of 100 mM. PD153035 (PD) (Calbiochem) was solubilised in 
DMSO, to a final molarity of 10 mM.  
NHU cells were cultured to 80% confluence in KSFMc. For differentiation, medium 
was replaced with KSFMc containing 1 µM TZ and 1 µM PD diluted in DMSO 
totaling 0.1% of the medium volume. For control experiments performed without the 
presence of TZ and PD, KSFMc with 0.1% DMSO (v/v) was added as a vehicle 
control. After 24 h, medium was replenished with KSFMc containing 1 µM PD for 
differentiation-induced cells, or with 0.1% (v/v) DMSO for control cells. Cells were 
cultured up to 7 days with medium replaced every 2-3 days. 
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2.5.3.2 Biomimetic Differentiation 
NHU cells were cultured to 80% confluence in KSFMc. Medium was then replaced 
with KSFMc supplemented with 5% (v/v) adult bovine serum (ABS, Seralab). Cells 
were cultured in 5% ABS for five days with media changed after 2/3 days. Cells 
were harvested and then either seeded into more flasks or onto Snapwell™ culture 
inserts (Fisher Scientific) or ThinCert 0.4 micron transparent inserts (Greiner Bio-
One) for electrophysiological studies. Cells were seeded at 5x105 cells per insert in 
500 µL volume and 3 mL culture medium placed into the basal chamber. After 24 
hours the exogenous calcium concentration was increased to 2 mM using a 1M CaCl2 
stock. Cell cultures were then maintained in medium containing 5% ABS and 2 mM 
Ca2+ with medium being replaced every 2-3 days. 
2.5.4 Treatment of NHU cell cultures with Cadmium Chloride, TSA and 5-
azacytidine 
Cadmium chloride was solubilised in ddH2O then sterilised by syringe filtration 
through filters with 0.2µm pore size (VWR), TSA was reconstituted in tissue grade 
dimethyl sulfoxide (DMSO, Sigma) and 5-azacytidine was solubilised in KSFMc. 
5-azacytidine and TSA treatments were applied to NHU cell cultures at the same 
time point as TZ/PD treatments, with TSA being added to stock concentrations of TZ 
and PD in DMSO to give a final concentration of 0.1% DMSO in growth medium. 
2.5.5 Proliferation Assay 
An alamarBlue® assay quantitatively measures proliferation by using a fluorometric 
growth indicator based on mitochondrial enzyme activity. NHU cells were seeded at 
a concentration of 2x104 cells mL-1 in to 96-well plates, treated with cadmium 
chloride concentrations and underwent alamarBlue® assays at 1, 3, 5, 7 and 9 days 
post cadmium treatment. alamarBlue® solution was diluted 1:10 with KSFMc and 
then incubated with the cells for four hours at 37°c. Absorbance was measured at 570 
and 630nm. Results were normalised against no cell controls and the percentage 
reduction in alamarBlue® calculated.  
2.5.6 Population Doublings 
Cell counts were performed using an “Improved Neubauer” haemocytometer (VWR) 
by placing 10 µL of cell suspension under each side of the coverslip on to a 
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haemocytometer. Cells were counted in four grids and the average cell number was 
equivalent to the cell density in 1x10-4 mL of medium. Once cells were counted they 
were seeded onto Primaria® flasks. When cultures reached 80% confluence cells 
were passaged, counted and then seeded onto new Primaria® flasks. Number of 
populations doublings equals log2 (CMF), where CMF (cell multiplication factor) 
equals the final cell number divided by the initial cell number. 
2.5.7 Fixation of cultured cells in formaldehyde for ChIP experiments 
Cells were cultured in 10 cm Primaria® dishes and treated with 10 mL medium 
containing required compounds. Dishes were placed on an orbital shaker and 189 µL 
of 37% (w/v) formaldehyde added drop-wise directly to the medium to a final 
concentration of 1%. After 10 min, cross-linking was quenched by addition of 798 
µL 125 mM glycine to a final concentration of 12.5  mM, followed by incubation at 
ambient temperature for 5 min. Cells were rinsed and scrape harvested in PBS and 
then transferred to 15 mL centrifuge tubes. Cells were pelleted by centrifugation at 
800 g for 5 min, and the supernatants thoroughly aspirated and cell pellets stored at -
80°C until use. 
2.5.8 Measurements of transepithelial electrical resistance (TER) 
TER can be used as an indicator of barrier function by cultured epithelial cells. 
Differentiation was induced using the “biomimetic” protocol as described above 
(section 2.5.3.2). The barrier function of cultured urothelium established on 
Snapwell™ or Griener membranes was monitored over 6-9 days using an EVOM™ 
Epithelial Voltohmmeter (World Precision Instruments) under sterile conditions.  
2.5.9 Scratch-wounding 
Differentiated NHU cell cultures grown on Snapwell™ or Griener membranes were 
scratched with a P10 pipette tip. Barrier recovery was monitored by measuring 
transepithelial electrical resistance. 
2.5.10 Dispase (II) lifting of differentiated cell sheets 
To conserve differentiated sheets for histological analysis, culture medium was 
removed from the Snapwell™ or Greiner inserts, before cell cultures were washed 
twice with 1x Dulbecco’s phosphate-buffered saline (DPBS) (without Mg2+ and Ca2+ 
ions; Gibco) heated to 37 °C. Wells were flooded with 2% dispase II (Sigma) and 
  Chapter 2 
 
54 
 
incubated at 37 °C for 30-60 minutes, until intact sheets were detached and able to be 
lifted from the membrane. Differentiated sheets were collected in a Cellsafe Capsule 
(Cell Path), before being fixed in 10% (v/v) formalin in PBS overnight. After 
overnight fixation, samples were placed in 70% (v/v) ethanol until embedding took 
place. 
2.6 Western Blotting 
2.6.1 Protein Extraction 
Culture medium was aspirated and cells were washed twice with cold PBS before 
aspirating PBS. Cells were scrape-harvested in 100 µL 2% (w/v) SDS sample buffer 
containing protease inhibitors (Appendix 2) and transferred to a cold 1.5 mL micro-
centrifuge tube. Lysates were sonicated on ice for two ten-second bursts with a ten 
second rest between bursts, using a Branson Sonifier set to 25 W, 40% amplitude. 
Whole cell lysates were left to chill on ice for 30 minutes before centrifuging at 
18,000 g for 30 minutes in a centrifuged chilled to 4 °C. Supernatant was collected, 
aliquoted and stored at -80 °C until use. 
2.6.2 Protein Quantification 
Total protein concentration of each sample was determined using a Coomassie® 
protein assay reagent kit (Pierce), which is based on the Bradford colorimetric assay. 
Samples were diluted 1:12.5 in dH2O. 10 µL of each sample was aliquoted in 
duplicate into a 96-well plate with 200 µL Coomassie reagent. The absorbance of 
samples was measured at test and reference wavelengths of 570 and 630nm, 
respectively using a MRX II 96-well plate spectrophotometer (Dynex). Samples were 
measured alongside bovine serum albumin (BSA) (Pierce) diluted to concentrations 
ranging from 0 to 1000 µg/mL in dH2O. The Revelation software package (Dynex) 
was used to plot the BSA standard curve and calculate the R2 value. The average of 
duplicate absorbance readings from each sample was used to estimate the protein 
concentration by comparison with the BSA standard curve.  
2.6.3 SDS-Polyacrylamide Gel Electrophoresis 
Protein samples were mixed with 4x LDS (Lithium Dodecyl Sulfate) (Life 
Technologies) and 10x reducing agent (Life Technologies). Reagents were diluted to 
a final concentration of 1x with dH2O into volumes suitable to fit into wells (10-well 
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gels have a 40 µL maximum limit per well and 15-well gels have a 26 µL maximum 
per well), and then heated at 70 °C for ten minutes. 
Proteins were resolved by electrophoresis through 1 mm thick 10 or 15 well 4-12% 
Bis-Tris NuPAGE pre-cast polyacrylamide gels using the Novex system 
(Invitrogen). The gel and wells were rinsed in dH2O and assembled in to the Novex 
tank according to the manufacturer’s instructions. 5 µL of All-Blue pre-stained 
marker (BioRad) was run as a protein size marker. Bis-Tris gels were run in either 1x 
MES buffer or 1x MOPS buffer (Life Technologies). 500 µL antioxidant (Life 
Technologies) was added to the inner chamber of the tank during electrophoresis, 
which was carried out at 200 V for 50 minutes, or until the running buffer reached 
the foot of the gel. 
2.6.4 Western blotting using LI-COR Odyssey 
Polyvinyldifluoride (PVDF) sheets (Millipore) were cut to size and dipped in 
methanol to wet, rinsed in H2O and equilibrated in transfer buffer (Appendix 2) for 
10 min. Protein was transferred to PVDF by semi-dry transfer between fibre blotting 
pads (Life Sciences, E-PAGE Blotting Pads) and filter paper (Whatman Grade 1, 150 
mM) at 30 V for 2 h, keeping the tank on ice. PVDF membrane was rinsed in Tris 
buffered saline (TBS) (pH 7.4). Transferred protein was visualised by reversible 
staining with 42 mM Ponceau red in 3 % (v/v) trichloroacetic acid, and washed off in 
dH2O.  
To block free protein-binding sites and minimise non-specific binding, membranes 
were incubated in Odyssey blocking buffer (LI-COR) diluted 1:1 (v/v) with TBS for 
1 hour at ambient temperature on an orbital shaker. Odyssey blocking buffer is also 
optimised to reduce autofluorescence of the membranes at detection wavelengths of 
the LI-COR scanner system. Membranes were probed with primary antibody diluted 
in blocking buffer and TBS-0.1% Tween 20 for 16 hours at 4 °C with shaking. 0.1% 
(w/v) NaN3 was included in the primary antibody solutions as a preservative. 
Membranes were washed four times with TBS-0.1% Tween 20 (Appendix 2) and 
were then probed with secondary antibody, diluted in blocking buffer and TBS-0.1% 
Tween 20, for one hour at ambient temperature with shaking. Membranes were 
washed four times for five minutes in TBS-0.1% Tween before one wash in TBS.  
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Membranes were scanned on the LI-COR Odyssey scanner (Odyssey CLx Scanner, 
LICOR). The LICOR uses laser excitation at 685 and 785 nm to stimulate emission 
from the Alexa-conjugated secondary antibodies and a scan-head with 700 and 800 
nm filters to detect their respective emissions. Scans were analysed using Odyssey 
v1.1 software (LI-COR). Band intensities were measured using the Odyssey software 
by drawing boxes around the protein band to calculate densitometry following 
background subtraction.  
2.6.5 Recycling western blot membranes 
Membranes were stripped to allow re-probing. Membranes were stripped by 
incubating in high pH Western Blot Recycling Kit reagent (Source Bioscience 
Autogen) for 30 minutes at ambient temperature on an orbital shaker. After stripping, 
secondary antibody was applied and membrane scanned as above to confirm removal 
of primary antibodies. Membranes were then washed in TBS, re-blocked and re-
probed as in section 2.6.4 above. 
2.7 Immunofluorescence labelling 
2.7.1 Slide Preparation 
12–well slides (CA Hendley) were wiped with 70% (v/v) ethanol, placed into a metal 
rack in a pipette box and autoclaved to sterilise. Slides were placed in to individual 
chambers of Heraeus boxes (Greiner) using sterile forceps. Cells were seeded in 50 
µL droplets at 1x105 cells mL-1 for proliferative studies or 3x105 cells mL-1 for 
differentiation studies. Cells were left to attach for four hours at 37 °C, before the 
chambers of the Heraeus box were flooded with 5 mL of medium. Cells were treated 
the following day (as indicated for each experiment) with medium replaced every 2-3 
days. At the desired time point cells were washed in PBS and fixed. Slides were 
fixed in methanol:acetone in a 1:1 mixture for 30 seconds before being air-dried and 
stored in cling film desiccated at -20 °C until use. 
2.7.2 Immunolabelling 
Primary antibodies were diluted in TBS containing 0.1% (w/v) BSA and 0.1% (w/v) 
NaN3, pH 7.6. In order to contain the antibodies within individual wells, wells were 
surrounded by liquid repellent grease (Dako Pen, Dako). 20 µL of primary antibody 
solution or TBS (negative control) was added to each well. Cells were incubated with 
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antibodies overnight at 4 °C and then slides were washed three times with PBS on an 
orbital shaker. From this point slides were protected from UV light using aluminium 
foil in order to protect the fluorophores. 20 µL of appropriate secondary antibody 
diluted in TBS containing 0.1% (w/v) BSA and 0.1% (w/v) NaN3, pH 7.6, was 
applied to each well for one hour at ambient temperature. Slides were then washed 
with PBS containing 0.25% (w/v) Tween 20 for 5 minutes on an orbital shaker.  
Nuclei were stained by incubation with Hoechst 33258, diluted to 0.1 µg/mL in PBS, 
for 5 minutes at ambient temperature. Slides were washed once in PBS and then 
rinsed in distilled water. Slides were mounted in antifade solution (appendix 2) and 
sealed under glass coverslips using nail varnish.   
2.7.3 Fluorescence microscopy 
Labelled immunofluorescence slides were viewed under epifluorescence illumination 
using an Olympus BX60 microscope with x20, x40 and x60 oil immersion 
objectives. The microscope was equipped with appropriate excitation and emission 
filters for bisbenzimide (blue), and dual and specific filters for FITC (green) and 
Texas Red (red). Images were captured using an Olympus DP50 digital camera and 
Image- Pro® Plus software. 
2.7.4 Quantification using TissueQuest 
TissueQuest (TissueGnostics) is analysis software for cells and stained areas in 
samples stained with immunofluorescent markers. TissueQuest software was used to 
quantify CK13, CK14 and CK20 protein expression from immunofluorescence 
microscopy images acquired as described in section 1.7.3. Samples were only 
comparable if labelled at the same time and if TissueQuest settings were unaltered 
after initial optimisation. 
Hoechst 33258 labelling of nuclei was used as a master marker for cell identification. 
Furthermore, the average nuclear size, discrimination area, discrimination grey value 
and background threshold for the master marker was specified. Immunolabelling 
intensity was quantified using the appropriate cellular mask parameter. Masks 
projecting from identified cell nuclei were adjusted using the scale settings until cell 
boundaries were clearly identified. Labelling within the masks was quantified and 
data was displayed as dot plot scattergrams indicating arbitrary fluorescence intensity 
values. In order to differentiate between positive and negative cells, cut-offs based on 
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visual assessment were set in the dot plots. The percentage of positively labelled 
cells was then determined. 
2.8 Histology 
2.8.1 Tissue embedding and sections 
Tissue samples were fixed overnight in 10% (v/v) formalin in PBS and transferred to 
70% (v/v) ethanol until required. Samples were encased in embedding cassettes and 
submerged in fresh 70% ethanol for 10 minutes on an orbital shaker. This was 
followed by three changes in absolute ethanol, two changes in propan-2-ol and four 
changes in xylene for 10 minutes each. Samples were transferred to molten paraffin 
wax (Thermo) at 60 °C for 15 minutes, followed by three further 15 minute 
incubations in fresh wax. Tissue samples were orientated within a metal mould, 
embedded in wax and allowed to solidify on a cold table (RA Lamb). 5 µm sections 
were cut using a Leica RM2135 rotary microtome and collected onto electrostatically 
charged Super Frost Plus™ microscope slides (BDH). Sections were allowed to dry 
and then baked on a hot plate (RA Lamb) at 50 °C for one hour then stored at 
ambient temperature until use. 
2.8.2 In vitro cell sheets 
Formalin fixed differentiated cell sheets lifted by dispase (II) (section 2.5.10) were 
submerged in fresh 70% (v/v) ethanol for 5 minutes on an orbital shaker. Samples 
were then sequentially submerged in absolute ethanol (x3), propan-2-ol (x2) for 5 
minutes each. The alcohol was removed from cell sheets with xylene (4 washes of 5 
minutes each). Cell sheets were then transferred to molten paraffin wax (Thermo) at 
60 °C for 10 minutes, followed by three further 10 minute incubations in fresh wax. 
Cell sheets were then orientated, embedded in wax and cut as previously described in 
section 2.8.1. 
2.8.3 Haematoxylin and eosin staining 
Sections were de-waxed with two 10 minute washes in xylene followed by two one 
minute washes in xylene then rehydrated by three one minute washes in absolute 
ethanol and one minute wash in 70% (v/v) ethanol. Sections were then washed for 
one minute under running tap water before staining in haematoxylin for two minutes. 
Slides were washed in running water for one minute before a one minute wash in 
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Scott’s tap water followed by another wash in running water for one minute. Sections 
were stained in eosin for 30 seconds before being washed in running water for one 
minute. Sections were dehydrated with a one minute wash in 70% (v/v) ethanol 
followed by three one minute washes in absolute ethanol and two one minute washes 
in xylene. Slides were mounted with DPX (Cell Path) and sealed under glass 
coverslips. 
2.9 Immunohistochemistry 
Immunolabelling was performed using an indirect streptavidin ‘ABC’ 
immunoperoxidase method. A CK7 positive control and negative control, where TBS 
was substituted for primary antibody, were used in every experiment.  
2.9.1 Dewaxing tissue sections 
Paraffin wax-embedded sections were de-waxed with two 10 minute washes in 
xylene, followed by two one minute xylene washes. Sections were rehydrated by 
three one minute washes in absolute ethanol, a one minute wash in 70% (v/v) ethanol 
and a one minute wash under running tap water. 
2.9.2 Antigen retrieval 
Antigen retrieval was performed to restore the immunoreactivity of antigens masked 
by tissue processing. The method of antigen retrieval used in this study was 
trypsinisation followed by citric acid heat retrieval. Trypsinisation was performed by 
incubating sections in 100 mL of 0.1% (w/v) trypsin (Sigma) in 0.1% (w/v) CaCl2. 
pH 7.8, for 1 minute at 37 °C. This was followed by citric acid heat retrieval where 
slides were microwaved in a Pyrex dish containing 10 mM citric acid buffer, pH 6.0 
(appendix 2). The dish was covered with punctured Clingfilm, microwaved on full 
power for 13 minutes and then rapidly cooled on ice. Following antigen retrieval 
slides were washed under running tap water. 
2.9.3 Blocking of endogenous sites 
Slides were placed in Shandon Sequenza units (Thermo) and washed once with TBS 
(appendix 2). Endogenous avidin sites were blocked with 100 µL of avidin followed 
by 100 µL biotin from the blocking kit (Vector Labs). Sections were incubated for 10 
minutes at ambient temperature for each blocking step with two TBS washes after 
each step. Non-specifc antibody binding was eliminated by blocking each section 
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with 100 µL of normal rabbit serum (10% (v/v) in TBS for 5 minutes at ambient 
temperature.  
2.9.4 Steptavidin ‘ABC’ Immunoperxidase method 
100 µL of CK13 primary antibody, or CK7 primary antibody (positive control) or 
TBS (negative control) was applied to the slides and incubated at 4 °C overnight. 
Primary antibody was washed off with three washes of TBS. 100 µL of biotinylated 
secondary antibody was applied to each slide for 30 minutes at ambient temperature, 
followed by two washes with TBS. 100 µL steptavidin-biotin HRP complex (Vector 
Labs), prepared according to the manufacturer’s instructions, was applied to each 
slide and incubated for 30 minutes at ambient temperature. Slides were then washed 
twice with TBS and once with distilled water. Bound antibody was visualised using a 
Diaminobenzidine (DAB) substrate prepared using Sigma Fast DAB tablets 
dissolved in 5ml dH2O. Slides were incubated with 200 µL DAB solution for a 
maximum of 15 minutes before being washed twice with distilled water.  
2.9.5 Dehydration and mounting of sections 
Slides were removed from the Shandon Sequenza units and placed into staining 
racks. Slides were counterstained for 5-10 seconds with haematoxylin and washed 
under running tap water. Sections were dehydrated through 70% and absolute 
ethanol and four changes of xylene. Slides were mounted in DPX (Cell Path) and 
sealed under glass coverslips.  
2.9.6 Quantification using HistoQuest 
Images of whole tissue sections were captured using an AxioScan.Z1 slide scanner 
(Zeiss) and Zen 2012 blue edition software (Zeiss). Images were stored as .czi files 
and opened using HistoQuest software (TissueGnostics) in order to quantify CK13 
expression on differentiated cell sheets treated with or without cadmium.  HistoQuest 
is brightfield image analysis software for the FACS-like analysis of samples stained 
with immunohistochemical or other stains. 
Haematoxylin staining was used as a master marker for cell identification on the 
basis of nuclear detection. Furthermore, the average nuclear size, discrimination area, 
discrimination grey value and background threshold for the master marker was 
specified. DAB intensity was quantified using the inside and outside cellular mask 
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parameter to produce scattergrams displaying arbitrary intensity values. In order to 
differentiate between positive and negative cells, cut-offs based on visual assessment 
were set. The percentage of positively labelled cells was then determined. 
2.10 Analysis of Gene Expression 
2.10.1 General 
For RNA work, all solutions were made with ultra pure dH2O treated with 0.1% (v/v) 
diethyl pyrocarbonate (DEPC) at ambient temperature overnight. 13 mL 
polypropylene tubes and caps (Starstedt) were also incubated overnight with 0.1% 
(v/v) DEPC to inhibit RNase activity. DEPC was then destroyed by autoclaving. 
RNase/DNase free microfuge tubes and pipette tips (Axygen) were used for all RNA 
experiments. RNase Zap  (Ambion) was used to clean the bench and pipettes before 
use.  
2.10.2 RNA Extraction 
Culture medium was aspirated from cell cultures. Trizol™ solution was added to 25 
cm2 flasks (2.5 mL) or Snapwell membranes (1 ml per Snapwell) and left to incubate 
on a rocking platform for 5 min before scrape-harvesting and transferring to a DEPC- 
treated 13 mL centrifuge tube. At this point samples can be stored at -80 °C until 
further processing. Lysates were thawed on ice then left at ambient temperature for 
five minutes to allow complete dissociation of nucleoprotein complexes. 0.2 mL 
chloroform was added per millilitre of Trizol reagent. Lysates were vortexed for 15 
seconds and incubated at ambient temperature for two minutes, followed by 
centrifugation at 12,000 g for 15 minutes at 4 °C. Centrifugation was performed in a 
Sorvall RC-5 using rotor SM-24. The upper aqueous phase, containing the mRNA, 
was collected and transferred to a fresh DEPC-treated centrifuge tube. RNA was 
precipitated by the addition of 0.5 mL propan-2-ol per millilitre of Trizol and 
incubated at ambient temperature for 10 minutes. RNA was centrifuged at 12,000 g 
for 20 minutes at 4 °C. Following centrifugation the supernatant was discarded. The 
RNA pellet was washed with 75% (v/v) ethanol and centrifuged at 7500 g for 10 
minutes at 4 °C. Ethanol was removed and pellets air-dried. Pellets were resuspended 
in 30 µL nuclease free DEPC treated ddH2O then stored at -80 °C. 
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2.10.3 DNase Treatment  
RNA samples were treated with the DNA-easy kit (Ambion) to remove any DNA 
contamination. 3 µL DNase 1 Buffer was added to RNA followed by 1 µL rDNase 1 
(2 U/µL). After mixing by pipetting the sample was incubated for 30 minutes at 37 
°C. DNase Inactivation Reagent was resuspended by vortexing to tube to form a 
slurry, 3.3 µL was then added to each sample to terminate the digestion. Samples 
were incubated at ambient temperature for two minutes then centrifuged for 90 
seconds at 10,000g. RNA contained in the aqueous phase was collected and placed 
into a new microfuge tube then 1 µL (40 U/µL) of RNaseOUT (Life Technologies) 
was mixed into samples to prevent degradation of RNA by RNases.  
2.10.4 Quantification of RNA 
RNA was quantified by UV spectrophotometry. Samples were measured directly 
using a Nanodrop ND-1000 Spectrophotometer. Optical densities (ODs) were 
measured at 260 and 280nm and concentration calculated from the Nanodrop 
software. Sample purity was derived from the OD260/OD280 ratio, which is 2.0 for 
pure preparations of RNA.  
2.10.5 cDNA synthesis with Random Hexamers 
DNA-free RNA was reverse transcribed using Invitrogen’s SuperScript® II First-
Strand Synthesis Kit and 50 ng random hexamers primers. 1 µg of DNase treated 
RNA was mixed with 1 µL (50 ng/µL) random hexamers and nuclease-free H2O in a 
final volume of 12 µL. Samples were incubated at 65°C to anneal primers to RNA. 
To each sample the following volumes of reagents from the kit were added: 4 µL 5x 
First-Strand Buffer, 2 µL 0.1 M DTT and 1 µL dNTP mix (10 mM each). Samples 
were incubated at 25°C for two minutes. As a control for the presence of 
contaminating DNA, two of each sample was prepared and at this stage one sample 
was mixed with 1 µL (50 U/µL) of Superscript II reverse transcriptase, and the other 
with 1 µL nuclease-free H2O. Samples were incubated at 25 °C for ten minutes 
followed by 42 °C for 50 minutes and then heated at 70 °C for 15 minutes in order to 
inactivate the enzyme. cDNA samples were then used neat for RT-PCR reactions or 
diluted 1in 5 for RTQPCR. 
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2.10.6 Primer Design 
Primers were designed against target regions using the NCBI primer-BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primers used for SYBR-green 
QPCR were designed using Primer express Software v.3 (Applied Biosystems) using 
recommended optimal parameters. The top ranked primers were checked for 
specificity using the NCBI primer-BLAST search facility. Primers were ordered 
from MWG Eurofins and stock made in nuclease free ddH2O. Primer sequences used 
in this thesis are detailed in Table 2.5. 
Table 2.5. Primers used for RTPCR and RTQPCR in this study. Primers for SYBR-green 
QPCR were designed to have an amplicon length between 50 and 125 bases.  
Gene Primer Sequence (5’-3’) Amplicon Length 
APC For – GGCTTCTTCTGGACAGATTGATTT 
Rev - ATCCTTCCCGGCTTCCATA 
125 
ELF3 For – GTTCATCCGGGACATCCTC 
Rev - GCTCAGCTTCTCGTAGGTC 
160 
FOXA1 For - CAAGAGTTGCTTGACCGAAAGTT 
Rev - TGTTCCCAGGGCCATCTGT 
75 
GAPDH For – ACCCAGAAGACTGTGGATGG 
Rev - TTCTAGACGGCAGGTCAGGT 
201 
GAPDH 
(QPCR) 
For - CAAGGTCATCCATGACAACTTTG 
Rev - GGGCCATCCACAGTCTTCTG 
90 
GATA3 For – TCCAGACACATGTCCTCCCT 
Rev - TGGTGTGGTCCAAAGGACAG 
113 
GRHL3 For – GTGACAAGGGAGCTGAGAGG Rev - CAGTCTCTGGCCGAAGGTAG 153 
IRF1 For – TGCATTTATTTATACAGTGCCTTGCT 
Rev - CCCTCCCTGGGCCTGTT 
79 
KDM3A For – CTGTCAAAGGTGTTCGAGAAATGT 
Rev - CACCCAGTGCAGGTTGAAGA 
65 
KDM3B For – CCCAACTTTCTTGACCACATCA 
Rev - CCCGCTTTGAAGCATCTGA 
70 
KDM4A For – CCCAGGAAGTGCTCAAAGCT 
Rev - GGGAAATCAGGGTCATCTTGTG 
59 
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Gene Primer Sequence (5’-3’) Amplicon Length 
KDM4B For – CCCTCCAAAAGCCGTCAGA 
Rev - GCCAGAGGTGAAGCACATCTC 
60 
KDM4C For – GGCTATGAGAAGCCCGAGAA 
Rev - CAGGTGACTTTGGCCATGAA 
58 
KDM4E For – GCCAACTGTTCAGCCTGCAT 
Rev - TTGAGCTCTACTCCTTGTACCCATT 
61 
KDM7A For – GTGATGGATGTGGAACGTTATGTAG 
Rev - TGCCTCGCCACATCAATG 
65 
KDM7B/PHF2 For – CAAGCGGGTCCTCAACGT 
Rev - CCACGAAGCTGGACATTCG 
62 
KDM7C/PHF8 For – GGCTCCATTCCCCTAACCA 
Rev - GACAGCCTGGACATGGACACT 
59 
KLF5 For – GACACCTCAGCTTCCTCCAG 
Rev - ACTCTGGTGGCTGAAAATGG 
232 
KRT13 For – CTGATGTCCGTAGGCCTTAAATCT 
Rev - GGGAACTGCCGGCTCTCT 
83 
KRT14 For - CGGCCTGCTGAGATCAAAGA 
Rev - ATCTGCAGAAGGACATTGGCA 
107 
KRT20 For – CAAAAAGGAGCATCAGGAGGAA 
Rev - CAACCTCCACATTGACAGTGTTG 
71 
NR3C1 For – GAGGAGGAGCTACTGTGAAGGTTT 
Rev - TTCGCTGCTTGGAGTCTGATT 
78 
P16INK4A For - GCGGAAGGTCCCTCAGACA  
Rev - TGATCTAAGTTTCCCGAGGTTTCTC 
73 
RASSF1A For - ACAAGGGCACGTGAAGTCATT 
Rev - GCTCAGCGCGCTCAAAG 
91 
SOX9 For – AGCGACGTCATCTCCAACATC 
Rev - GTTGGGCGGCAGGTACTG 
66 
UPK1A For – CATTCTTGCTGAACCGTTTGTG 
Rev - GTGACCGTGACAGAACTCTCATG 
77 
UPK2 For - CAGTGCCTCACCTTCCAACA 
Rev - TGGTAAAATGGGAGGAAAGTCAA 
77 
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2.10.7 Polymerase Chain Reaction 
PCR was performed using a T100 thermal cycler (BioRad) and the GoTaq® reagent 
kit (Promega).  PCR reactions were made to total volumes of 20 µL, with 8.5 µL 
ddH2O, 4 µL GoTaq® buffer, 0.4 µL dNTPs (10 mM), 2 µL MgCl2 (25 mM), 2 µL 
forward primer (10 µM), 2 µL reverse primer (10 µM). 0.1 µL GoTaq® polymerase 
and 1 µL test cDNA or ddH2O (negative control) or genomic DNA (positive 
control). DNA underwent a two minute initial denaturation step at 95° C, followed 
by 25-35 cycles of denaturation for 30 seconds at 95 °C, annealing for 30 seconds at 
50-65 °C (depending on optimal temperature for primers) and 1 min/Kb DNA at 72 
°C for extension. A final extension stage of five minutes at 72 °C was followed by 
incubation at 4 °C. 
2.10.8 Gel Electrophoresis 
DNA was visualised under UV light after separation by gel electrophoresis. 
Electrophoresis grade agarose was boiled in 1x Tris-Borate-EDTA (TBE) buffer 
(Appendix 2) and cooled to 50 °C before adding 1/10,000 (v/v) GelRed (Cambridge 
Bioscience), which fluoresces under UV light when it intercalates with double 
stranded DNA. Gels were cast and then allowed to set before PCR products and 
Hyperladder I or IV (Bioline) were electrophoresed on the gel submerged in 1x TBE 
at 80V for 30 minutes. Gel images were captured digitally using a Gene Genius Gel 
Imaging System (Syngene) with GeneSnap software.  
2.10.9 SYBR® Green Quantitative PCR 
Quantitative polymerase chain reaction (QPCR) is a powerful method that enables 
the accumulation of PCR products to be measured over time. The binding of SYBR® 
Green I Dye to double-stranded DNA emits a fluorescent signal. The increase in 
fluorescence over time is proportional to the accumulation of PCR products. Fast 
SYBR® Green Master Mix (Applied Biosystems) containing the SYBR® Green I 
Dye, AmpliTaq® Fast DNA Polymerase, dNTPs, Uracil-DNA Glycosylase and a 
passive internal reference (ROX) was used.  5 µL of cDNA was mixed with 10 µL of 
the 2x Fast SYBR® Green Master Mix, 3.8 µL ddH2O and 0.6 µL each of the 
forward and reverse primers (10 mM) in the wells of a optical 96-well plate (Applied 
Biosystems). Each cDNA sample was amplified by QPCR in triplicate wells and 
negative control samples (where the reverse transcriptase was omitted during cDNA 
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synthesis) were included. The plates were sealed with optical adhesive covers 
(Applied Biosystems) and briefly centrifuged. Plates were run on a StepOnePlus™ 
Real-Time PCR System (Applied Biosystems) and analysed with StepOne™ 
Software. The thermal profile used was: incubation at 95 °C for 20 seconds, followed 
by 40 cycles of denaturation at 95 °C for 3 seconds and elongation at 60 °C for 30 
seconds. 
During each cycle the fluorescence of the SYBR® Green I Dye was detected for 
every well. This fluorescence signal was normalised against the fluorophore ROX 
(yielding the normalised reporter value) to account for any changes in plate 
fluorescence that were unrelated to product amplification.  
A final stage was included to establish the melting profiles of the products and give 
dissociation curves. This involved incubation for 15 seconds at 95 °C, 60 °C and 
finally 95 °C to ensure only one product was produced. Dissociation curves 
confirmed both the presence of a single amplification product and the absence of 
primer dimers for each primer set (example shown in Figure 2.1). 
Amplification plots were generated by the StepOne™ Software. Threshold values 
were set in the region of exponential amplification across all of the plots. Threshold 
cycle (Ct) values were obtained as the cycle at which the fluorescence generated 
within a reaction crosses the threshold value. QPCR results were expressed as 
relative quantification (RQ) (relative expression/fold change). This is calculated 
using the following calculations: 
Sample values were calculated relative to GAPDH to give ∆Ct: 
  ∆Ct = Ct target – Ct GAPDH 
This was then calibrated to the control/calibrator sample to give ∆∆Ct: 
 ∆∆Ct = Ct test sample – Ct control/calibrator samples 
Relative quantification was then calculated using: 
 RQ = 2∆∆Ct 
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Figure 2.1. An example dissociation curve. Dissociation plot showing the change in fluorescence 
against temperature. Replicate cDNA samples are shown in purple and the corresponding 
negative control sample is shown in red. Note the presence of one peak, representing the 
dissociation curve of a product in each of the cDNA samples and the absence of product in the 
negative control. Also note the absence of primer dimers. 
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2.10.10 Microarrays 
Two independent NHU cell lines (Y1441 and Y1451) were treated ± TZPD  ± 10 µM 
CdCl2 ± 400 nM TSA for 3 days. RNA was extracted from the 8 treated NHU cell 
cultures as described in section 2.10.2, followed by DNase treatment (section 2.10.3). 
RNA was quantified using a ND-1000 Spectrophotometer (section 2.10.4) and 1 ug 
of RNA was synthesised into cDNA using random hexamers (section 2.10.5) in order 
to perform RTQPCR (section 2.10.9) to determine that the cadmium and TSA 
treatment had been successful prior to microarrays being perfomed. 
Gene expression analysis was performed using Agilent SurePrint G3 Human 
Microarrays. Microarrays were carried out by the Genomics Department of the 
Bioscience Technology Facility at the University of York. Normalisation and fold 
change calculations were carried out by the Bioscience Technology Facility’s 
Bioinformatics Laboratory using GeneSpring software (Agilent). Normalised 
intensity values and fold change data was supplied in the form of Excel spreadsheets. 
2.10.11 Gene ontology and promoter analysis 
Gene ontology enrichment analysis was performed using the PANTHER 
Classification System (http://pantherdb.org/) as described by Mi et al. (2013). 
Enrichment analysis finds which GO terms are over-represented (or under-
represented) using annotations for that gene set. 
Promoter analysis for the four differentiation genes (UPK1A, UPK2, KRT13 and 
KRT20) was carried out using the PSCAN promoter analysis tool, which was run 
against the JASPAR database of transcription factor binding profiles 
(http://159.149.160.51/pscan/) as described by Zambelli et al. (2009). 
2.11 Chromatin Immunoprecipitation-(Q)PCR 
Chromatin Immunoprecipitation (ChIP-QPCR) involves immunoprecipitation of 
formaldehyde fixed chromatin-DNA complexes followed by quantitative PCR 
(Figure 2.2).  Cross-linked cell samples were subjected to hypotonic lysis and 
sonication to fragment chromatin. DNA-histone complexes were incubated with 
antibody:bead complexes, using antibodies raised against specific histone 
modifications. Protein:DNA complexes were then eluted from beads, cross-links 
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were reversed and ChIP-DNA was purified by phenol:chloroform extraction. ChIP-
DNA was then analysed by PCR. 
 
Figure 2.2. Cross-linking chromatin immunoprecipitation overview. 
2.11.1 Blocking of Dynabeads® 
Magnetic protein-G conjugated Dynabeads® (Novex) were used for 
immunoprecipitations (IP). Before beads were used for IP, beads were pre-blocked to 
reduce non-specific binding. Every 100 µL of bead suspension was mixed with 1 mL 
of RIPA buffer (Appendix 2), beads were then recovered on a magnet and mixed 
with another 1 mL RIPA buffer for a total of three washes. Beads were then mixed 
with 1 mL blocking buffer (0.2 mg/mL glycogen, 0.2 mg/ml BSA and 0.2 mg/mL 
yeast tRNA in RIPA buffer). Beads were incubated with blocking buffer overnight at 
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4 °C. Beads were recovered on a magnet and washed twice with RIPA buffer before 
diluted to starting volume in RIPA buffer. 
2.11.2 Preparation of chromatin from formaldehyde fixed cell pellets 
Cell pellets which had been fixed in formaldehyde (section 2.5.7) were thawed and 
resuspended in 1 mL of cold Swelling Buffer (Appendix 2) with freshly added 0.5% 
NP-40 and 1:500 protease inhibitors. Samples were transferred to a 1.5 mL micro-
centrifuge tube and incubated for 20 minutes on ice on an orbital shaker. Samples 
were then centrifuged at 800 g for 5 minutes at 4 °C. Pellet was resuspended in 1 mL 
RIPA buffer containing protease inhibitors. Chromatin was sonicated on ice with a 
probe sonicator (50% power output, MSE Soniprep 150).  
For initial optimisation, samples were sonicated for 10 cycles of 15 seconds with 30 
second breaks between bursts. After each cycle a 50 µL aliquot was taken from the 
sample; the sample was then topped up with equal volume RIPA buffer. Aliquots 
were topped up to 250 µL with RIPA buffer, and then incubated at 65°C overnight to 
reverse cross-links. Samples were cooled to ambient temperature and 250 µL TE 
buffer (Appendix 2) and 10 µL of 10 mg/mL proteinase K was added to each aliquot 
before incubation at 37 °C for two hours. Fragmented DNA was purified by 
phenol:chloroform phase separation. To each aliquot, 500 µL of a 1:1 mixture of 
phenol:chloroform was added before vortexing for 30 seconds followed by 
centrifugation for 15 minutes at 14,000 g at ambient temperature. The upper phase 
was collected into a new 1.5 mL centrifuge tube. 50 µL of 3M sodium acetate was 
added along with 1 mL 100% ethanol before incubating the samples at -80 °C for 
one hour. Samples were centrifuged at 18,000g for 15 minutes at 4 °C, supernatant 
was removed then the pellet was washed in 1 mL 70% (v/v) ethanol before 
centrifugation for 15 minutes at 18,0000g at 4  °C.  Ethanol was removed and the 
pellets were air-dried. Pellets were resuspended in 25 µL TE buffer. DNA was then 
electrophoretically separated on a 0.75% agarose gel. The number of cycles where 
the DNA was fragmented to 100-600 bp was chosen as the optimum number of 
cycles for sonication (8 cycles).  
For all sonication performed, 50 µL aliquots were always taken after the final 
sonication cycle and subjected to purification, and fragmentation of DNA assessed 
by electrophoresis through agarose gels as above.  
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2.11.3 Quantification of DNA 
DNA was quantified by UV spectrophotometry. Samples were measured directly 
using a Nanodrop ND-1000 Spectrophotometer (Thermo Scientific). Optical 
densities (ODs) were measured at 260 and 280nm and concentration calculated from 
the Nanodrop™ software.  
2.11.4 Preparation of Antibody-Bead complexes 
10 µL blocked Dynabeads® were used for each IP. Beads were washed twice with 
RIPA buffer.  Beads were recovered using a magnetic rack. 2.4 µg antibody (H3 or 
H3K9me3) was added to each 10 µL beads, diluted to 100 µl using RIPA buffer then 
incubated for two hours on a rotator at 4 °C.  For negative control samples Rabbit 
IgG was used.   
2.11.5 Immunoprecipitation and Washes 
2 µg chromatin was diluted with RIPA-ChIP Buffer (Appendix 2) to 100 µL. To pre-
clear chromatin which binds non-specifically to Dynabeads®, blocked Dynabeads® 
that had been washed twice in RIPA-ChIP buffer were added to chromatin samples 
(10 µL beads per 100 µL chromatin) and then incubated with rotation at 4 °C for 90 
minutes. Samples were placed on a magnetic rack and cleaned chromatin recovered. 
100 µL pre-cleared chromatin was added into each 0.2 mL PCR tube containing 
antibody-beads complexes held to the wall in a magnetic rack on ice, and from which 
the RIPA buffer had been pipetted out. At this point 100 µL pre-cleared chromatin 
from each treatment sample was added to 1.5 mL centrifuge tubes to be used as the 
input chromatin. Samples were removed from the magnetic rack to release the 
antibody-bead complexes into the chromatin suspension and samples were then 
incubated on a rotator for two hours at 4 °C. Tubes were centrifuged for one second 
to bring down any solution trapped in the lid during incubation then immune 
complexes were captured by placing tubes in a chilled magnetic rack.  
Supernatant was discarded, 100 µL ice cold RIPA buffer was added and the tubes 
were then removed from the magnetic rack to release the immune complexes into the 
buffer. The complexes were resuspended by gentle manual agitation and tubes were 
then placed on a rotator for four minutes at 4 °C. This step was repeated for a total of 
three washes in RIPA buffer. Tubes were briefly centrifuged, supernatant removed, 
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100 µL TE buffer added then incubated for four minutes on a rotator at 4 °C. Tubes 
were briefly centrifuged, placed on ice and then contents were transferred to separate 
clean 0.2 mL tubes on ice. The complexes were captured in the magnetic rack and 
TE buffer removed. 
2.11.6 DNA Recovery by Phenol-Chloroform Extraction 
150 µL complete elution buffer (Appendix 2) was added to each tube then incubated 
for two hours on a Thermomixer at 68 °C, 1300 rpm. Tubes were removed from the 
Thermomixer and briefly centrifuged before beads where captured on the magnetic 
rack. Supernatant was collected and placed in a clean 1.5 mL centrifuge tube. 150 µL 
complete elution buffer was added to the remaining ChIP material and incubated on 
the Thermomixer for five minutes at 68 °C, 1300 rpm. Tubes were removed from the 
Thermomixer, beads captured using the magnetic rack, supernatant collected and 
then combined with the first supernatant, 200 µL elution buffer was then to the 
combined supernatants.  
Input chromatin samples were prepared by the addition of 200 µL elution buffer 
(Appendix 2) and 7.5 µL proteinase K (2 mg/mL). Samples were vortexed and then 
incubated for two hours on a heating block at 68 °C. Samples were removed from the 
heating block and 200 µL elution buffer was added. 
DNA was extracted once with 500 µL phenol:chloroform. Samples were centrifuged 
at 14,000g for five minutes to separate the phases then 460 µL of the aqueous phase 
was transferred to a clean 1.5 mL centrifuge tube. DNA was then extracted with 460 
µL chloroform. Samples were centrifuged at 14,000g for five minutes and 400 µL of 
the aqueous phase was then transferred to a clean 1.5 mL centrifuge tube. 44 µL 3M 
sodium acetate (pH 7.0) and 1 mL 100% ethanol was added to the aqueous phase, 
mixed thoroughly and then incubated for at least one hour at -80 °C. Samples were 
thawed and centrifuged at 18,000g for 15 minutes at 4 °C. Supernatant was removed, 
1 mL 70% ethanol was added and then vortexed briefly to wash the DNA pellet then 
centrifuged at 18,000g for ten minutes at 4 °C. This step was repeated to give two 
ethanol washes. Ethanol was removed and DNA dissolved in 60 µL TE buffer. 
Samples were stored at -80 °C until use. 
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2.11.7 Analysis using PCR and QPCR  
Chromatin Immunoprecipitation success was ascertained by ChIP-PCR. The 
Ensemble genome browser (www.ensemble.org) was used to identify the sequences 
for KRT13, KRT20, UPK1A and UPK2. These sequences were inputted into primer 
design software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The software was 
instructed to design a PCR product of 50-150 bp (Table 2.6). The search target was 
the human reference genome (hg19) and all other settings were left as default. The 
highest ranked primer pair with no other hits in the genome was chosen.  
Table 2.6. Primers for ChIP(Q)PCR. 
Gene Primer Sequence Amplicon Length 
KRT13 For - GAGCTCCTCTGCCAGCTATG 
Rev - CACCAAAACCACAGCTCACG 
146 
KRT20 For – TCAGTACAGTGGGCATGCAG 
Rev – TCACCGTGTGTCTGGAGTTG 
99 
UPK1A For – TGCGGCAGCAGCGGA 
Rev – AATGATATTGCCCACAACTAGCAG 
70 
UPK2 For – CACCCCTGCTGCCCATC 
Rev – GCAGCCCCTGGGGACA 
70 
 
1 µL of purified ChIP-DNA and chromatin IP input were prepared for PCR using the 
GoTaq (Promega) PCR kit as described in section 2.10.7. PCR was performed using 
the conditions outlined in Table 2.7. 10 µL of PCR reactions were separated by 
electrophoresis on a 4 % agarose gel and gels photographed under UV light using a 
Gene Genius Gel Imaging System (Syngene) with GeneSnap software to visualise 
DNA bands.  
Table 2.7. ChIP-PCR amplification settings. 
Step Temperature Time 
1 95 °C 2 min 
2 95 °C 30 s 
3 60 °C 30 s 
4 72 °C 15 s 
5 Go to 2 35 cycles 
6 72 °C 5 min 
  Chapter 2 
 
74 
 
SYBR® Green QPCR (as described in section 2.10.9) was then utilised to quantify 
the changes observed for four known differentiation genes KRT13, KRT14, UPK1A 
and UPK2. ChIP-DNA was diluted 1:2.5 with 5 µL DNA added to each reaction. 
Data was represented as % of input where % of input = (2-Ct IP/2-Ct input) x 100. 
2.12 Quantification of post-translational histone modifications using mass 
spectrometry 
Quantification of global post-translational histone changes using mass spectrometry 
was performed in collaboration with Dr Mark Dickman and Tom Minshull from the 
Department of Chemical and Biological Engineering at the University of Sheffield.  
Quantification of post-translational histone changes was performed following the 
procedures in Figure 2.3. Cell culture treatments and preparation of histones was 
performed in York; RP-HPLC, LCMS/MS and MS analyses were performed by Tom 
Minshull in Sheffield. 
 
Figure 2.3. Work flow for the quantification of post-translational histone modifications by mass 
spectrometry. 
2.12.1 Acid extraction of histones 
Culture medium was aspirated from cell cultures in 75 cm2 flasks. Cell monolayers 
were incubated in 0.1% (w/v) EDTA in PBS for 5 minutes at 37 °C, until the cells 
began to round up and dissociated from each other. Cells were then incubated in 1 
mL of 0.25 % (w/v) trypsin (Sigma Aldrich) and 0.02% (w/v) EDTA in Hank’s 
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balanced salt solution (Invitrogen) for 2 minutes at 37 °C. Cells were harvested into 
5 mL KSFMc containing 1.5 mg/mL soybean trypsin inhibitor (Sigma). Cells were 
collected by centrifugation (10 min, 300g), supernatant was discarded and cell pellets 
were washed in PBS and centrifuged again at 300g for ten minutes. Supernatant was 
discarded; cell pellets were resuspended in 1 mL hypotonic lysis buffer (Appendix 2) 
and transferred to a 1.5 mL centrifuge tube. Samples were incubated for 30 minutes 
on a rotator at 4 °C to promote hypotonic swelling of cells and lysis by mechanical 
shearing during rotation. Intact nuclei were pelleted by centrifugation at 10,000g for 
ten minutes at 4 °C. Supernatant was discarded and nuclei were resuspended in 400 
µL 0.4 N H2SO4 then incubated on a rotator for four hours at 4 °C. Samples were 
centrifuged at 16,000g for ten minutes at 4 °C to remove nuclear debris. Supernatant 
containing histones was transferred in to a clean 1.5 mL centrifuge tube. 132 µL 
trichloroacetic acid (Sigma) was added drop-wise to the histone solution (to give a 
final concentration of 33% TCA) after which the tube was inverted several times to 
mix the solutions. The samples were incubated overnight at 4 °C. Histones were 
pelleted by centrifugation at 16,000g for ten minutes at 4 °C. Supernatant was 
removed and the histones where then washed with ice-cold acetone to remove the 
acid from the solution without dissolving the protein pellet. Samples were 
centrifuged for ten minutes at 16,000g at 4 °C. The acetone washing step was 
performed twice before histones were left to air-dry at ambient temperature for 20 
minutes before being dissolved in 100 µL ddH20. 
2.12.2 Quantification and purity testing of histones 
The histone protein concentration of each sample was determined using a 
Coomassie® protein assay reagent kit (Pierce), which is based on the Bradford 
colorimetric assay. Samples were diluted 1:5 in dH2O. 10 µL of each sample was 
aliquoted in duplicate into a 96-well plate with 200 µL Coomassie reagent. The 
absorbance of samples was measured at test and reference wavelengths of 570 and 
630nm, respectively using a MRX II 96-well plate spectrophotometer (Dynex). 
Samples were measured alongside bovine serum albumin (BSA) (Pierce) diluted to 
concentrations ranging from 0 to 1000 µg/mL in dH2O. The Revelation software 
package (Dynex) was used to plot the BSA standard curve and calculate the R2 value. 
The average of duplicate absorbance readings from each sample was used to estimate 
the protein concentration by comparison with the BSA standard curve.  
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Histone purity was tested by SDS-Polyacrylamide gel electrophoresis. 2.5 µg 
histones samples were mixed with 4x LDS (Life Technologies) and 10x reducing 
agent (Life Technologies). Reagents were diluted to a final concentration of 1x with 
dH2O into a total volume of 10 µL and then heated at 70 °C for ten minutes. Histones 
were resolved by electrophoresis through 1 mm thick 10 well 4-12% Bis-Tris 
NuPAGE pre-cast polyacrylamide gels using the Novex system (Invitrogen). The gel 
and wells were rinsed in dH2O and assembled in to the Novex tank according to the 
manufacturer’s instructions. 5 µL of All-Blue pre-stained marker (BioRad) was run 
as a protein size marker. Bis-Tris gels were run in 1x MES buffer (Life 
Technologies). 500 µL antioxidant (Life Technologies) was added to the inner 
chamber of the tank during electrophoresis, which was carried out at 200 V for 50 
minutes. Gels were washed in dH2O, stained with Coomassie Brilliant Blue solution 
(Appendix 2) for one hour and then rinsed in dH2O for at least 30 minutes. 
2.12.3 Chemical derivatization and tryptic digestion 
In these procedures extracted histones were first derivatized using propionic 
anhydride to neutralise charge and block lysine residues before digestion using 
trypsin, which cleaved only the arginine residues as all lysine residues were blocked 
by endogenous modifications or chemically by conversion to propionyl amides, to 
give reproducible histone peptides. 
10 µg histones were diluted with 5 µL 100 mM ammonium bicarbonate (pH 8) 
before 2 µL concentrated ammonium hydroxide was added to the sample. Fresh 
propionylation reagent was prepared by adding 75 µL propionic anhydride to 25 µL 
isopropanol. 10 µL propionylation reagent was added to histone samples followed by 
vortexing and then a short spin down in a mini-centrifuge. pH was then checked 
using pH indicator strips; if pH was less than 8, ammonium hydroxide was added 
dropwise until pH was approximately 8. Samples were incubated for 20 minutes at 
51 °C. Samples were dried down to approximately 5 µL in a SpeedVac concentrator 
(Thermo Scientific) at ambient temperature for 20 minutes. Samples were diluted 
with 5 µL 100 mM ammonium bicarbonate (pH 8) before the propionylation reaction 
was performed a second time to ensure maximum conversion. 2 µL concentrated 
ammonium hydroxide was added followed by 10 µL propionylation reagent, pH was 
tested and then samples were incubated for 20 minutes at 51 °C. 
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50 µL 100 mM ammonium bicarbonate (pH 8) was added to the propionylated 
histones. Trypsin was added to the samples to make a 20:1 (w/w) protein:trypsin 
ratio and samples were then incubated overnight at 37 °C. The trypsin digestion was 
quenched by adding glacial acetic acid and pH was measured to make sure pH had 
dropped to about 3. Samples were then incubated at -80 °C for 10 minutes in order to 
inactivate the trypsin. Samples were dried down to approximately 5 µL in a 
SpeedVac concentrator before chemical derivatization with propionic anhydride was 
performed in order to convert the newly trypsin-generated N-termini on peptides to 
propionyl amides. 2 µL concentrated ammonium hydroxide was added followed by 
10 µL propionylation reagent, pH was tested and then samples were incubated for 20 
minutes at 51 °C. Samples were diluted with 5 µL 100 mM ammonium bicarbonate 
(pH 8) before the propionylation reaction was performed a second time to ensure 
maximum conversion. Samples were then dried down in a SpeedVac concentrator. 
2.12.4 HPLC fractionation 
Digested, propionylated histone samples were resuspended in 10 µL 0.1% 
trifluoroacetic acid (TFA) and were fractionated on the U3000 HPLC (Thermo 
Scientific) with a Hypercarb™ Column (50 x 2.1 mm, 5 µm particle size) (Thermo 
Scientific) running Chromleon software. Buffers used for HPLC: Buffer A contained 
3% Acetonitrile (ACN) and 0.1% TFA and Buffer B contained 97 % ACN and 0.1% 
TFA. Parameters used: column temperature was 30 °C, UV was 214 mm (50 Hz) and 
flow rate was 0.2 mL/min. Gradient used is outlined in Table 2.8. Fractions were 
collected every 60 seconds (18 in total) in a 384 lo-bind deep well plate, starting at 
eight minutes. Following collection samples were transferred to lo-bind micro 
centrifuge tubes (Eppendorf), vacuum centrifuged to dryness and then stored at -80 
°C. 
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Table 2.8. HPLC gradient for fractionation of histone samples. 
% Buffer B Time (min) Flow rate (µL/min) 
0 0 0.3 
0 1 0.3 
70 25 0.3 
90 26 0.3 
90 30 0.3 
5 31 0.3 
0 35 0.3 
	
2.12.5 Mass spectrometry 
All samples were re-suspended in 10 µL 0.1% TFA (LC-MS grade), and a proportion 
of this was used for LC/MS analysis. Peptides were separated on an Ultimate 3000 
RSLC nano liquid chromatography system (Dionex), using a 150 mm x 75 µm i.d. 
PepMap reversed phase column (Dionex) online with the mass spectrometer. Elution 
of peptides occurred over 61 minutes with the following gradient (see Table 2.9). 
Buffers used: Buffer A contained 0.1% Formic acid (FA) and 3% ACN (LC-MS 
grade) and Buffer B contained 0.1% FA and 97% ACN (LC-MS grade). 
Table 2.9. RP-HPLC gradient. 
% Buffer B Time (min) Flow rate (µL/min) 
3 0 0.3 
3 2 0.3 
25 30 0.3 
50 40.1 0.3 
90 41 0.3 
90 47 0.3 
3 48 0.3 
3 55 0.3 
 
MS/MS data was acquired using the MaXis Ultra high resolution quadrupole time-
of-flight (Q-ToF) system (Bruker Daltonics) using a data dependent acquisition 
approach. A captive spray ESI was used to introduce the sample into the mass 
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spectrometer. MS and MS/MS scans (m/z 100-1800) were acquired in positive ion 
mode. Automatic internal calibration was performed using HP 1221.990364. 
 
2.12.6 Analysis 
Mass spectrometry analsysis (Figure 2.4) was performed as described by Dickman er 
al. (2013). Line spectra data was analysed in Data Analysis 4.1 software (Bruker 
Daltonics) and used to create .mgf files. The sum peak finder algorithm was used for 
peak detection using a signal to noise (S/N) ratio of 100 and an absolute intensity 
threshold of 3000. The .mgf files were then searched in MASCOT v2.5.1 using 
Mascot Daemon (Matrix science). MS and MS/MS tolerance were set at 0.15 Da, 
and searched against the SwissProt database with the Homo sapiens Taxonomy 
selected. Fixed modifications were set as propionylation (K & N-term) Variable 
modification selected were Methylpropionylation (K), Dimethylation (K), 
Trimethylation (K), Phosphorylation (S,T) and Acetylation (K) Enzyme selected was 
Arg-C (due to the propionylation reaction altering the specificity), with 2 missed 
cleavages allowed. Charge states searched were 2+, 3+ and 4+. All post-translational 
modifications were manually verified via manual assignments of MS/MS peaks. The 
relative abundance of histone peptides was determined by the integration of 
smoothed (gauss algorithm, 1 cycle) extracted ion chromatograms. This process was 
automated using Hist-o-matic VBscript. Finally, correction factor as detailed by Lin 
et al. (2014) were applied, to compensate for differences in ionisation efficiency 
between differently modified peptides. 
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Figure 2.4. Mass spectrometry analysis for quantification of post-translational histone 
modifications. 
 
 
Line	spectra	data	was	processed	into	peak	list	by	DataAnalysis	so5ware	(Bruker)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Example above shows total ion chromatogram and extracted ion chromatograms for various modified peptides ([M+2H]2+ ions) 
spanning the 9–17 residues KSTGGKAPR. Labels indicate the particular modified form eluting in that peak. 
	
	
All MS-MS spectra from modified peptides were manually inspected for accurate mass and correct fragmentation 
assignment (example below shows K23ac) 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
MS/MS spectrum of the [M+2H]2+ precursor ion from the digest of propionylated histone H3. This peptide span residues 18–26 
and was found to contain an acetylation (ac) modification on K23. b and y type ions are labeled.	
	
 
Relative abundance of each modified peptide determined by integration of smoothed extracted ion chromatograms 
	
	
Correction factor applied to compensate for differences in ionisation efficiency 
Predicted mass for b and 
y ions for acetylated 
18-26 (KQLATKAAR) 
peptide at K23 
Mass spectrum of the 
precursor parent ion 
differentiates this peptide 
as being acetylated as the 
experimental mass is 
consistent with an 
acetylation mark 
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2.13 Statistical Analysis 
Data is represented graphically using Microsoft Excel and GraphPad. Data is 
represented as the mean of all replicates with error bars representing ± one standard 
deviation. Statistical tests were performed using GraphPad Prism 6 software. One-
way analysis of variance (ANOVA) tests were used to compare three or more sample 
means along with the appropriate post-test. Dunnett’s post-test was performed to 
compare whether each treatment was significantly different to the control treatment. 
Tukey’s post-test was performed to test which treatments were significantly different 
from each other. Details of statistical tests used are cited in the figure legends. 
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3 Effect of Cadmium on Proliferation and Differentiation of NHU 
Cell Cultures 
3.1 Aim & Objectives 
The aim of this chapter was to determine the effect that cadmium treatment had on 
proliferative and differentiated NHU cells in culture. 
The working hypothesis is that exposure of the urothelium to cadmium leads to 
epigenetic dysregulation of gene expression, causing field changes within the 
urothelium characteristic of dysplasia/carcinoma in situ, which is the most common 
precursor of invasive carcinomas. 
The specific objectives of this chapter were to assess the effect of cadmium on: 
a) proliferative NHU cell cultures. 
b) the differentiation potential of NHU cell cultures 
- ABS/Ca2+ and TZ/PD differentiating NHU cell cultures. 
- ABS/Ca2+ differentiated NHU cell cultures. 
- the expression of transcription factors involved in urothelial differentiation.  
c) tumour suppressor gene expression in NHU cell cultures. 
 
3.2 Experimental Approach 
3.2.1 Proliferative NHU cell cultures 
To investigate the effect that cadmium exposure had on proliferative NHU cell 
cultures, urothelial cell cultures were established in KSFMc, (Keratinocyte serum-
free medium supplemented with 50 µg/mL bovine pituitary extract, 5 ng/mL 
epidermal growth factor and 30 ng/mL cholera toxin) then left to adhere overnight 
before addition of cadmium chloride.  
alamarBlue® assays and population doubling calculations were used to assess the 
effect of cadmium on the proliferation of NHU cells. An alamarBlue® assay uses a 
mitochondrial enzyme assay in order to measure proliferation by using the 
assumption that mitochondrial activity is proportional to cell number. Number of 
population doublings equals log2 (CMF), where CMF (cell multiplication factor) 
equals the final cell number divided by the initial cell number.   
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3.2.2 Differentiated NHU cell cultures 
In order to look at the effect cadmium had on differentiation, NHU cell cultures were 
established in KSFMc medium until cultures reached at least 80% confluence, at this 
point two methods to induce NHU cell differentiation were used as described in 
sections 2.5.3.1 and 2.5.3.2, with medium replaced every 2/3 days:  
(1) 5% serum and 2 mM Ca2+ (Biomimetic)  
 
 
(2) Troglitazone and PD153035 (Pharmacological) 
 
Using the ABS/Ca2+ method NHU cell cultures were exposed to cadmium before, 
during and after differentiation (Figure 3.1).  
Cadmium treatments were applied to proliferative NHU cell cultures before the 
induction of differentiation in order to investigate whether cadmium exposure 
affected the potential of NHU cell cultures to differentiate. Immunoblotting was used 
to examine protein expression of differentiation markers, ie. claudins and 
cytokeratins. 
ABS/Ca2+ differentiating cell cultures were treated with cadmium to test whether 
cadmium would affect the ability of cultures to form a functional barrier. 
Transepithelial electrical resistance (TER) measurements were used to monitor 
barrier formation.  
ABS/Ca2+ differentiated cell sheets were exposed to cadmium once a stable barrier 
was formed to investigate whether NHU cell cultures were able to maintain a tight 
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barrier upon cadmium insult. Additionally, differentiated cell sheets were wounded 
in order to see if the presence of cadmium would affect their ability to recover. TER 
measurements were used to monitor barrier function. 
 
Figure 3.1. Experimental approach for cadmium chloride treatments using the ABS/Ca2+ 
method of differentiation induction. 
Using the TZPD method, NHU cell cultures were exposed to cadmium before and 
during the induction of differentiation in order to investigate whether cadmium 
affected their ability to differentiate (Figure 3.2). Immunoblotting along with 
immunofluorescence microscopy was used to examine protein expression of 
differentiation markers.  
 
Figure 3.2. Experimental approach for cadmium chloride treatments using the TZPD method of 
differentiation induction. 
RT(Q)PCR was used to assess transcript levels of differentiation-associated genes 
and transcription factors known to be involved in urothelial differentiation. 
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3.2.3 Tumour suppressor genes 
RTQPCR was used to assess transcript levels of the tumour suppressor gene p16 in 
proliferative and TZPD-induced differentiated NHU cell cultures.  
Immunoblotting was used to examine protein expression of p16 in proliferative NHU 
cell cultures exposed to cadmium for up to 22 days. 
RTPCR was used to assess transcript levels of three tumour suppressor genes, (p16, 
RASSF1A and APC) in ABS/Ca2+ differentiated NHU cell cultures. 
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3.3 Results 
3.3.1 Proliferation 
NHU cells cultured in concentrations up to 10 µM CdCl2 showed no differences in 
their proliferative ability to reach confluence over a 96 hour treatment period, 
however 100 µM CdCl2 proved toxic to the cells within 48 hours (Figure 3.3).  From 
further study it was found that constant exposure to 10 µM CdCl2 was tolerated by 
the cultures, but more than 5 days treatment with 25 µM CdCl2 was toxic, as at day 5 
the cells had started to round up, indicative of cell death (Figure 3.4).  
 
Figure 3.3. Phase contrast microscopy of proliferating NHU cell cultures. NHU cell cultures 
(Y1054) were treated with a range of cadmium chloride concentrations for 96 hours with images 
taken at time points 0, 48 and 96 hours.  
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Figure 3.4. Phase contrast microscopy of proliferating NHU cell cultures. NHU cell cultures   
(Y1160) were maintained in  KSFMc medium or treated with 10 µM or 25 µM cadmium 
chloride for 120 hours. Images taken at 0 hours and 120 hours. 
An alamarBlue® assay showed that NHU cells treated with 1 and 5 µM CdCl2 
proliferated at the same rate as the KSFMc control whereas cultures treated with 10 
µM CdCl2 showed a reduced rate of proliferation but were still able to reach full 
confluence. Concentrations above 10 µM CdCl2 proved toxic, with cultures failing to 
thrive (Figure 3.5 A). 
Statistically significant differences in culture biomass were observed between 
KSFMc control and cultures in 10, 15, 20, and 25 µM CdCl2 at day 3 (Figure 3.5 B). 
At days 5 and 7 there was still a statistically significant difference in biomass 
between cultures maintained in control medium and those treated with 10 µM CdCl2; 
however, by day 9 there were no significant differences between cell cultures 
maintained in KSFMc or those treated with 1, 5 and 10 µM CdCl2 (Figure 3.5 C).  
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Figure 3.5. Effect of cadmium chloride on NHU cell growth. A) Y1237 NHU cells were seeded at 
a concentration of 2x104 cells mL-1 in 96-well plates, treated with cadmium chloride 
concentrations and underwent alamarBlue® assays at 1, 3, 5, 7 and 9 days post cadmium 
treatment. Results were normalised against no cell controls and the percentage reduction in 
alamarBlue calculated. Each data point is the average of 6 replicates with standard deviations 
shown by error bars. B) alamarBlue® assays performed after 3 days of culture in KSFMc ± 
CdCl2.  (***p<0.001, ANOVA then Dunnett’s post test). C) alamarBlue® assays performed after 
5, 7, 9 days of culture in KSFMc ± CdCl2.  (***p<0.001, ANOVA then Dunnett’s post test). 
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Population doubling calculations were used to assess the cumulative effect that 
cadmium exposure had upon proliferating NHU cells over several generations. 
Proliferating NHU cell cultures were exposed to 1, 10 and 25 µM CdCl2. Cumulative 
population doublings of continuous exposure in two cell lines (Figure 3.6) showed 
that NHU cell cultures exposed to 10 µM CdCl2 showed growth attenuation; 25 µM 
CdCl2 caused cell death; and no difference was seen in 1 µM CdCl2 when compared 
to the medium only control.  
 
 
Figure 3.6. Growth curves showing cumulative population doublings of NHU cells as a function 
of time during continuous cadmium chloride exposure. Cells were counted with a 
haemocytometer then seeded into Primaria® flasks. Media were replaced after 48-72 hours. 
Once cultures reached 80% confluence cells were harvested, counted and then seeded into new 
Primaria® flasks. Number of population doublings equals log2 (CMF), where CMF (cell 
multiplication factor) equals the final cell number divided by the initial cell number. Points on 
the graph mark where cultures were subcultured.  
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As occupational or environmental exposure to cadmium is not constant, the ability 
for NHU cells to recover once exposed to cadmium was examined. NHU cells from 
two cell lines were transiently exposed to 1, 10 and 25 µM CdCl2 for 5 days after 
which the cadmium was removed. At all concentrations used, including 25 µM 
CdCl2, the cells recovered (Figure 3.7), although a lag phase occurred in cultures 
treated with 10 and 25 µM CdCl2. 
 
 
 
Figure 3.7. Growth curves showing cumulative population doublings of NHU cells as a function 
of time following transient exposure. Cells were counted with a haemocytometer then seeded 
into Primaria® flasks. Cultures were treated with cadmium for 5 days. Once cultures reached 
80% confluence cells were harvested, counted and then seeded into new Primaria® flasks. 
Number of population doublings equals log2 (CMF), where CMF (cell multiplication factor) 
equals the final cell number divided by the initial cell number. Points on the graph mark where 
cultures were subcultured.  
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3.3.2 The effect of cadmium on differentiating NHU cells 
The most common precursor to invasive urothelial cancer, carcinoma in situ (CIS), is 
associated with dysregulation of differentiation; therefore the potential of NHU cells 
to differentiate in the presence of cadmium was assessed.  
Before cadmium treatments were performed, successful induction of differentiation 
using the ABS/Ca2+ and TZPD methods was confirmed.  
Two markers of NHU cell differentiation, CK13 and claudin 5, were unregulated in 
whole cell lysates of ABS/Ca2+ treated NHU cell cultures (Figure 3.8A). The ability 
of ABS/Ca2+ treated cell cultures to form a functional barrier was demonstrated by 
cell sheets being able to form barriers greater than 2000 ohms.cm2, an epithelium is 
considered tight and impermeable if it has a TER > 500 ohms.cm2.  Cell sheets were 
lifted off the permeable membranes they were cultured on, then fixed and processed 
into paraffin. The embedded cell sheets were sectioned and then stained with 
hematoxylin and eosin to show a stratified urothelia consisting of basal, intermediate 
and superficial cell layers (Figure 3.8B). 
Upregulation of the terminal differentiation-associated gene UPK2 and the 
transitional differentiation marker, CK13, along side downregulation of CK14, a 
marker of proliferative NHU cells in culture, was demonstrated in TZPD induced 
differentiated NHU cell cultures (Figure 3.9). 
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Figure 3.8. Confirmation of ABS/Ca2+ induced differentiation. A) Western blot showing 
upregulation of CK13 and claudin 5 in response to ABS/Ca2+ induced differentiation. Cells were 
lysed using SDS lysis buffer and then sonicated. Protein concentration was measured using a 
Bradford assay. 4-12% bis-Tris gels were loaded with 20 µg of protein and run at 200 V in MES 
running buffer. Protein was blotted on to PVDF membranes using the Novex apparatus for 2 
hours at 30 V. Membranes were blocked in Odyssey blocking buffer, incubated with primary 
antibodies overnight at 4°c, and secondary immunoconjugates for one hour at ambient 
temperature then scanned on the Li-Cor imaging system. B) Hematoxylin and eosin stained cell 
sheet, showing stratified urothelia.  
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Figure 3.9. UPK2 and CK13 upregulation and CK14 downregulation in response in TZPD 
induced differentiation. A) Cells were lysed using SDS lysis buffer and then sonicated. Protein 
concentration was measured using a Bradford assay. 4-12% Bis-Tris gels were loaded with 20 
µg of protein and run at 200 V in MES running buffer. Protein was blotted on to PVDF 
membranes using the Novex apparatus for 2 hours at 30 V. Membranes were blocked in 
Odyssey blocking buffer, incubated with primary antibodies overnight at 4°c, and secondary 
antibodies for one hour at ambient temperature then scanned on the Li-Cor imaging system. B) 
UPK2 RTQPCR results. mRNA was harvested from the cultures at day 3, with RTQPCR 
performed to quantify the relative expression of UPK2. Each value is the average of 3 replicates 
with standard deviations shown by error bars. C) Immunofluorescence microscopy images of 
CK13 and CK14. NHU cells were seeded at a concentration of 1x105 cells mL-1 on to 12-well 
slides. Cells were cultured for 6 days ± TZ/PD before being fixed in methanol:acetone. Scale bar, 
10 µM. 
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3.3.2.1 Differentiated NHU cells – ABS/Ca2+ method 
Cadmium pre-treatment of NHU cell cultures before ABS/Ca2+ differentiation 
To investigate whether pre-treatment of proliferative NHU cell cultures with 
cadmium affected their ability to differentiate, two NHU cell lines were treated with 
1 and 10 µM CdCl2 for 4 days. The cadmium was removed prior to pre-treatment of 
the cells with 5% ABS for 5 days then cultured in the presence of 5% ABS and 2mM 
calcium. Cells were lysed and western blots performed to look at markers of 
differentiation (Figure 3.10).  Claudin 4, a tight junction protein upregulated in NHU 
cell differentiation, was shown to decrease slightly when cells were pre-treated with 
cadmium whereas claudin 5, another tight junction protein, was shown to increase 
slightly in both cell lines. In both cell lines CK13, a transitional differentiation 
marker was shown to decrease in cadmium pre-treated cells. By contrast CK14, a 
marker of squamous metaplasia, which is down regulated in differentiation, showed 
increases in one cell line but decreases in the other upon cadmium pre-treatment. 
Taken together these results indicate that cadmium pre-treatment of NHU cell 
cultures before ABS/Ca differentiation has a negligible effect upon differentiation. 
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Figure 3.10. Western blot analysis of NHU cells maintained with KSFMc only (Control), 1 µM 
CdCl2 and 10 µM CdCl2 before undergoing ABS/Ca2+ differentiation. Cells were lysed using 
SDS lysis buffer and then sonicated. Protein concentration was measured using a Bradford 
assay. 4-12% Bis-Tris gels were loaded with 20 µg of protein and run at 200 V using MES 
running buffer. Protein was blotted on to PVDF membranes using the Novex apparatus for 2 
hours at 30 V. Membranes were blocked in Odyssey blocking buffer, incubated with primary 
antibodies overnight at 4°C, and secondary antibodies for one hour at ambient temperature 
then scanned on the Li-Cor imaging system. The fluorescence of each band was quantified and 
normalised to the loading control β-actin using the Odyssey software. A) Treatment timelines. 
B) NHU cell line Y1019. C) NHU cell line Y1183. 
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Cadmium treatment during ABS/Ca2+ differentiation 
To see if the presence of cadmium affected the ability of NHU cells to form a 
functional barrier urothelium, Y1183 NHU cells were exposed continually to either 1 
or 10 µM CdCl2 during ABS/Ca2+ differentiation. Transepithelial electrical resistance 
(TER) was used to monitor differentiation, with readings taken every day.  Neither 1 
nor 10 µM CdCl2 produced any significant differences compared to the control 
(Figure 3.11B). Further cadmium treatments with an additional NHU cell line 
(Y1279) supported the initial observations with 1 and 10 µM CdCl2, however a 
concentration of 20 µM CdCl2 was shown to lead to a tightening of the barrier 
compared to the control, which was statistically significant at day 5 (Figure 3.11C).  
At the end of the cadmium treatment time course mRNA was extracted from the 
differentiated cell sheets (Figure 3.11B) and RTQPCR was performed to quantify 
uroplakin 2 (UPK2) transcript expression as a measure of differentiation. It was 
found that UPK2 gene expression decreased with increasing concentration of 
cadmium chloride (Figure 3.12).  
To follow up these observations, NHU cell cultures were maintained in either control 
5% ABS KSFMc medium or treated with 5% ABS medium containing 10 µM CdCl2 
for 3, 6 and 9 days. At each time point the cells were harvested for mRNA with 
RTQPCR performed to measure the expression of differentiation markers. When 
NHU cell cultures were differentiated with ABS/Ca in the presence of cadmium, the 
expression of terminal differentiation-associated genes was suppressed by cadmium 
exposure (Figure 3.13).   
Immunohistochemistry for CK13 was performed on paraffin embedded ABS/Ca2+ 
differentiated cell sheets that had been treated with 10 or 20 µM CdCl2. Labelled cell 
sheets were imaged using a Zeiss AxioScan.Z1 slide scanner with representative 
images for each treatment shown in Figure 3.14A. When CK13 expression was 
quantified using HistoQuest software (TissueGnostics), cadmium exposure was 
shown to reduce expression of CK13 (Figure 3.14B). 
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Figure 3.11. TER readings of NHU cells  differentiating in the presence of cadmium. A) 
Treatment timeline: NHU cell cultures were pre-treated with 5% ABS for 5 days before 500,000 
cells were seeded on to Snapwell or Griener membranes. Calcium concentration was increased 
to 2 mM 24 hours later at which point cadmium treatments started. B) NHU cell line Y1183. 
TER readings at day 4 and day 8 dip due to media changes having taken place. C) NHU cell line 
Y1279. Each data point is the average of at least 3 replicates with standard deviations shown by 
error bars. 
Passage&
5%&ABS&
5&days&
Ca2+&
&(2&mM)&
5%&ABS&+&Ca2+&
Cd2+&
8610&days&
0	
1000	
2000	
3000	
4000	
0	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	
Ω
.c
m
²	
	
Day	
TER readings of differentiating NHU cells 
	
ABS/Ca	
1	uM	CdCl₂	
10	uM	CdCl₂	
0	
500	
1000	
1500	
2000	
2500	
3000	
3500	
4000	
0	 1	 2	 3	 4	 5	 6	 7	 8	 9	
Ω
.c
m
²	
Day	
TER readings of differentiating NHU cells 
Control	
1	µM	CdCl₂	
10	µM	CdCl₂	
20	µM	CdCl₂	
A 
B 
C 
  Chapter 3 
 
98 
 
 
Figure 3.12. UPK2 expression in ABS/Ca2+ differentiated NHU cell cultures ± cadmium.  Y1183 
NHU cells were seeded on Snapwell™ membranes and then differentiated in the absence or 
presence of cadmium for 10 days at which point mRNA was harvested and UPK2 transcript 
expression quantified using RT-QPCR. Each value is the average of 3 replicates with standard 
deviations shown. One-way ANOVA with Tukey post testing was performed; where there are 
statistical differences between the treatments these are indicated on the graph. * p<0.05, **** 
p<0.0001 
 
 
Figure 3.13. RT-QPCR results of mRNA expression for three archetypal differentiation-
associated genes in ABS/Ca2+ differentiated cell cultures at day 3, 6 and 9. Each value is the 
average of 3 technical replicates with standard deviation shown. One-way ANOVAs with 
Turkey post testing was performed; where there are statistical differences between the 
treatments these are indicated on the graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001 
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Figure 3.14. CK13 expression in cadmium exposed ABS/Ca2+ differentiated NHU cell cultures. 
A) NHU cells pre-treated with 5% ABS were seeded on to Snapwell™ inserts. Cells were 
cultured for 9 days ± 10 or 20 µM CdCl2 before cell sheets were fixed in 10% (v/v) formalin. Cell 
sheets were embedded in paraffin wax before immunolabelling was performed using an indirect 
streptavidin ‘ABC’ immunoperoxidase method and then counterstained in haematoxylin. Cell 
sheets were imaged using a Zeiss AxioScan.Z1 slide scanner. Scale bar, 25 µM. B) Image 
analysis (HistoQuest by TissueGnostics) was used to quantify the percentage of CK13 labelled 
cells. 
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Cadmium treatment after ABS/Ca2+ differentiation 
To study the effect cadmium had on already differentiated cells, ABS/Ca2+ 
differentiation was performed on NHU cell cultures to form cell sheets on Snapwell 
membranes. Once a stable barrier was formed (>2500 Ω.cm²), the differentiated cell 
sheets were exposed to 1, 10 or 20 µM CdCl2 for 7 days in triplicate. The TER 
readings taken from cultures exposed to cadmium did not differ significantly from 
controls (Figure 3.15). At all cadmium concentrations the barrier was able to be 
maintained including at 20 µM CdCl2 which was toxic to the proliferative NHU cells. 
  
 
Figure 3.15. TER readings of differentiated cell sheets in the presence of cadmium. A) 
Treatment timeline: NHU cell cultures were pre-treated with 5% ABS for 5 days before 500,000 
cells were seeded on to each Griener membrane, 24 hours later calcium was added. When all 
barriers exceeded 2500 Ω.cm² the cadmium was added. B) NHU cell line Y1237. Three 
replicates were performed for each concentration. Standard deviations are shown by error bars. 
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Wounding and recovery of differentiated cell sheets in the presence of cadmium 
Differentiated cell sheets can be wounded and their ability to recover monitored by 
measuring TER. To see if the presence of cadmium affected this ability to recover, 
differentiated cell sheets were scratch wounded and then allowed to recover in 
presence of 1, 10 and 20 µM CdCl2. TER readings were taken every 3 hours to 
monitor the recovery of the barrier (Figure 3.16 A). Although the barrier fully 
recovered at each cadmium concentration there was a delayed recovery after 
wounding in the presence of cadmium compared to the control. This was statistically 
significant at 6 and 9 hours for 10 µM CdCl2 (Figure 3.16 B) and 6, 9 and 12 hours 
for 20 µM CdCl2 (Figure 3.16 C). Repetitive wounding (3x) performed on cell sheets 
still led to barrier reformation with TER readings recovering to at least 4500 Ω.cm² 
after each wounding (Table 3.1). 
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Figure 3.16. A) TER readings of barrier recovery in the presence of cadmium (Y1244). Graphs 
show TER readings of barrier recovery after wounding, in the presence of 10 (B) or 20 (C) µM 
cadmium chloride. Error bars represent the standard deviation of 4 experimental replicates. 
*p<0.05, **p<0.01 Unpaired t test with Welch’s correction applied. 
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Table 3.1. TER readings of barrier reformation after repetitive wounding (Y1244). All values in 
Ω.cm² ± standard deviations. 
 After 1st  
Wounding 
After 2nd 
Wounding 
After 3rd 
Wounding 
ABS/Ca Control 5390 ± 496 4643 ± 448 4956 ± 806 
1 µM CdCl2 5643 ± 752 5252 ± 234 4735 ± 752 
10 µM CdCl2 5628 ± 416 4678 ± 1354 4660 ± 416 
20 µM CdCl2 5694 ± 292 4635 ± 926 4958 ± 292 
 
3.3.2.2 Differentiated NHU cells – TZPD method 
Cadmium pre-treatment of NHU cell cultures before TZPD differentiation 
Proliferative NHU cell cultures were maintained in control KSFMc medium or 
treated with 1 or 10 µM CdCl2 before undergoing TZPD differentiation. The cultures 
that were treated with 1 and 10 µM CdCl2 were split in to two groups; one group had 
the cadmium removed before TZPD differentiation while the other group remained 
in cadmium while undergoing TZPD differentiation.  
Cultures pre-treated with cadmium showed non-significant differences in the 
expression of differentiation-associated proteins (Figure 3.17). By contrast, cultures 
maintained in cadmium showed a decrease in the three differentiation markers 
Claudin 4 and 5 and CK13. CK14 a marker of proliferative NHU cells in culture 
remained high when cadmium was present. 
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Figure 3.17. Western blot analysis of NHU cells pre-treated with KSFMc only , 1 µM CdCl2 and 
10 µM CdCl2  before TZPD induced differentiation in the absence (-) or presence (+) of 
cadmium. A) Treatment timelines.  B) Cells were lysed using SDS lysis buffer and then 
sonicated. Protein concentration was measured using a Bradford assay. 4-12% Bis-Tris gels 
were loaded with 20 µg of protein and run at 200 V in MES running buffer. Protein was blotted 
on to PVDF membranes using the Novex apparatus for 2 hours at 30 V. Membranes were 
blocked in Odyssey blocking buffer, incubated with primary antibodies overnight at 4°c, and 
secondary antibodies for one hour at ambient temperature then scanned on the Li-Cor imaging 
system. The fluorescence of each band was quantified and normalised to the loading control β-
actin using Odyssey software.  
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Cadmium treatment during TZPD differentiation 
Proliferative NHU cells were treated with or without TZPD in the absence or 
presence of cadmium for up to 7 days. At day 3 and day 7 time points the cells were 
harvested for mRNA with RTQPCR performed to measure the transcript expression 
of known differentiation markers. 
It was found that exposure to cadmium resulted in a failure to upregulate KRT13 
(Figure 3.18 C), a marker of transitional (or urothelial)-type differentiation, as well 
as the late archetypical differentiation-associated genes UPK1a (Figure 3.18 A), 
UPK2 (Figure 3.18 B) and KRT20 (Figure 3.18 D) at both day 3 and day 7. 
There were statistically significant differences for all four differentiation-associated 
genes when comparing untreated with TZPD cell cultures and TZPD with TZPD 
Cd2+ treated cell cultures at day 3. 
Further treatments with two independent NHU cell lines (Figure 3.19) confirmed the 
initial observation that cadmium exposure during TZPD differentiation led to a 
failure of NHU cell cultures to fully differentiate, as the four differentiation-
associated genes UPK1a, UPK2, KRT13 and KRT20 all showed reduced expression 
when cadmium was present. 
There were statistically significant differences for all four differentiation-associated 
genes when comparing untreated with TZPD cell cultures and TZPD with TZPD 
Cd2+ treated cell cultures.  
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Figure 3.18. RT-QPCR data for four differentiation genes. Y1226 NHU cell cultures were 
treated ± TZPD ± 10 µM CdCl2 for 7 days (A). mRNA was harvested from the cultures at day 3 
and 7, with RTQPCR performed to quantify the relative expression of four differentiation-
associated genes B) UPK1a, C) UPK2, D) KRT13 and E) KRT20. Each value is the average of 3 
replicates with standard deviations shown by error bars. One-way ANOVAs with Tukey post 
testing was performed; where there are statistical differences between the TZPD treatments 
these are indicated on the graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 3.19. RT-QPCR data of four differentiation genes in two independent NHU cell lines. 
Y1197 and Y1233 NHU cell lines were cultured ± TZPD ± 10 µM CdCl2 for 3 days before 
mRNA was harvested (A). RTQPCR was performed to quantify the relative expression of B) 
UPK1a, C) UPK2, D) KRT13 and E) KRT20.  Each value is the average of 3 replicates with 
standard deviation shown as error bars. One-way ANOVAs with Tukey post testing was 
performed; where there are statistical differences between the treatments these are indicated on 
the graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001. 
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Immunofluorescence for CK20 was performed on NHU cell cultures which had been 
treated with or without TZ/PD and cadmium for 6 days (Figure 3.20A). TissueQuest 
software was then used to determine the percentage of CK20 labelled cells from the 
IF images (Figure 3.20B). These results support the RT-QPCR data shown above 
which show that CK20 expression was decreased in the presence of cadmium. 
 
 
 
Figure 3.20. Cytokeratin 20 expression in cadmium exposed TZPD differentiating NHU cell 
cultures. A) Representative images of CK20 immunolabelled cells. NHU cells were seeded at a 
concentration of 1x105 cells mL-1 on to 12-well slides. Cells were cultured for 6 days ± TZ/PD ± 
10 µM CdCl2 before being fixed in methanol:acetone. Cells were immunolabelled using mouse 
primary antibodies and goat anti-mouse secondary antibodies. Nuclei were stained with Hoechst 
33258. Scale bar, 10 µM. B) Image analysis (TissueQuest by TissueGnostics) was used to 
quantify the percentage of CK20 labelled cells. 
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CK13/14 Switch and Cadmium 
A switch in expression occurs between KRT14 and KRT13 in NHU cell cultures 
upon differentiation. KRT14 is a marker of squamous metaplasia and is expressed in 
proliferative, but not differentiated NHU cells, whereas KRT13 is only expressed in 
differentiated NHU cells. KRT14 transcript was not down regulated in the TZ/PD-
differentiated cells in the presence of cadmium in two independent cell lines Y1226 
(Figure 3.21 A) and Y1236 (Figure 3.21 B), suggesting the cells may have remained 
in a more squamous phenotype. 
Immunofluorescence for CK14 was performed on NHU cell cultures that had been 
treated with or without TZ/PD and cadmium for 6 days (Figure 3.22 A). TissueQuest 
software was then used to determine the percentage of CK14 labelled cells from the 
IF images (Figure 3.22 B). These results support the RT-QPCR and western blot data 
(Figure 3.23), showing that in the presence of cadmium TZ/PD-induced 
differentiated cells continue to express CK14 while CK13 expression remained low. 
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Figure 3.21. RTQPCR results of KRT14 mRNA expression in two independent NHU cell lines ± 
TZ/PD ± Cd. A) Y1226 NHU cell cultures were treated ± TZPD ± 10 µM CdCl2 for 7 days. 
mRNA was harvested from the cultures at day 3 and 7, with RTQPCR performed to quantify 
the relative expression of KRT14. B) Y1197 NHU cell lines were cultured  ± TZPD ± 10 µM 
CdCl2 for 3 days before mRNA was harvested and RTQPCR performed to quantify the relative 
expression of KRT14. Each value is the average of 3 replicates with standard deviation shown. 
One-way ANOVAs with Tukey post testing was performed; where there are statistical 
differences between the treatments these are indicated on the graphs. * p<0.05 ** p<0.01, *** 
p<0.001, **** p<0.0001. 
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Figure 3.22. Effect of cadmium on CK14 protein expression. A) CK14 labelled 
immunofluorescence images of NHU cell cultures ± TZ/PD ± Cd. NHU cells were seeded at a 
concentration of 1x105 cells mL-1 on to 12-well slides. Cells were cultured for 6 days before being 
fixed in methanol:acetone. Cells were immunolabelled using mouse primary antibodies and goat 
anti-mouse secondary antibodies. Nuclei were stained with Hoechst 33258. Scale bar, 10 µM. B) 
Quantification results from TissueQuest software, used to determine the percentage of labelled 
CK14 cells in the NHU cells cultures ± TZ/PD ± Cd. 
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Figure 3.23. Western blot analysis for cytokeratin 13 and 14 in NHU cell cultures ±TZ/PD ± 
cadmium. Cells were lysed using SDS lysis buffer and then sonicated. Protein concentration was 
measured using a Bradford assay. 4-12% Bis-Tris gels were loaded with 20 µg of protein and 
run at 200 V using MES running buffer. Protein was blotted on to PVDF membranes using the 
Novex apparatus for 2 hours at 30 V. Membranes were blocked in Odyssey blocking buffer, 
incubated with primary antibodies overnight at 4°c, and secondary antibodies for one hour at 
ambient temperature then scanned on the Li-Cor imaging system. The fluorescence of each 
band was quantified and normalised to the loading control β-actin using the Odyssey software. 
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3.3.3 Transcription factors involved in urothelial differentiation 
The expression of six transcription factors known to act downstream of PPARγ in 
urothelial differentiation (FOXA1, IRF1, GATA3, ELF3, KLF5 and GRHL3) was 
investigated using RT-PCR (Figure 3.24). An up regulation of all six transcription 
factors was seen between the proliferative DMSO treated control and TZPD induced 
differentiated cells. By contrast, no differences were seen between TZPD and TZPD 
Cd2+ treated NHU cell cultures. 
Quantitative PCR looking at two known intermediary transcription factors, FOXA1 
and IRF-1 showed that there was no statistical difference between transcript 
expression levels at day 1 and 3 in TZPD induced NHU cell cultures when cadmium 
was present or not (Figure 3.25). 
 
Figure 3.24. RTPCR of known transcription factors involved in urothelial differentiation. Y1236 
NHU cell cultures were treated ± TZPD ± 10 µM CdCl2 for 3 days before mRNA was harvested 
and RTPCR was performed to look at expression of known transcription factors involved in 
urothelial differentiation. 
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Figure 3.25. RT-QPCR data for two intermediary transcription genes involved in urothelial 
differentiation. Y1226 NHU cell cultures were treated ± TZPD ± 10 µM CdCl2 for 3 days. 
mRNA was harvested from the cultures at day 1 and 3, with QPCR performed to quantify the 
relative expression of the two transcription factors A) FOXA1 and B) IRF-1. Each value is the 
average of 3 replicates with standard deviation shown. One-way ANOVAs with Tukey post 
testing was performed; where there are statistical differences between the TZPD treatments 
these are indicated on the graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001, ns not 
significant. Attention is drawn to the observation that there is no significant difference between 
TZPD and TZPD Cd at day 1 and day 3. 
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3.3.4 Tumour suppressor gene expression 
The tumour suppressor, p16, was shown to be downregulated in cadmium exposed 
proliferative NHU cells, at transcript level (Figure 3.26) and at a protein level (Figure 
3.27) and in TZ/PD-induced differentiated NHU cells (Figure 3.28).  
NHU cell cultures were differentiated and seeded on to Snapwell™ membranes 
using the standard ABS/Ca2+ differentiation protocol. The NHU cell cultures were 
then treated with (1 or 10 µM) or without cadmium for ten days. Gene expression for 
tumour suppressor genes (p16, RASSF1A and APC) was then assessed by RTQPCR.  
Transcript expression for p16 and APC was significantly inhibited by cadmium 
treatment (Figure 3.29). 
 
 
Figure 3.26. RT-QPCR for p16 transcript expression in proliferative NHU cell cultures. 
Proliferative NHU cell cultures (Y1233) were treated for ± 10 µM CdCl2 22 days. mRNA was 
harvested from the cultures at day 4, 7 , 14 and 22, with RTQPCR performed to quantify p16 
transcript expression. Each value is the average of 3 technical replicates with standard deviation 
shown. One-way ANOVA with Tukey post testing was performed; where there are statistical 
differences between the treatments these are indicated on the graphs. * p<0.05 ** p<0.01, *** 
p<0.001, **** p<0.0001. 
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Figure 3.27. Western blot analysis for p16 expression in proliferative NHU cell cultures. Cells 
were lysed using SDS lysis buffer and then sonicated. Protein concentration was measured using 
a Bradford assay. 4-12% Bis-Tris gels were loaded with 20 µg of protein and run at 200 V using 
MES running buffer. Protein was blotted on to PVDF membranes using the Novex apparatus 
for 2 hours at 30 V. Membranes were blocked in Odyssey blocking buffer, incubated with 
primary antibodies overnight at 4°c, and secondary antibodies for one hour at ambient 
temperature then scanned on the Li-Cor imaging system. The fluorescence of each band was 
quantified and normalised to the loading control β-actin using the Odyssey software. Numbers 
quantifying the percentage intensity of the bands are displayed below the corresponding bands. 
 
 
Figure 3.28. RT-QPCR for p16 transcript expression in TZPD-induced differentiated NHU cell 
cultures. Y1226 NHU cell cultures were treated ± TZPD ± 10 µM CdCl2 for 7 days. mRNA was 
harvested from the cultures at day 1, 3 and 7, with RTQPCR performed to quantify transcript 
expression of p16. Each value is the average of 3 technical replicates with standard deviation 
shown. 
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Figure 3.29. RT-QPCR for p16, RASSF1A and APC transcript expression in ABS/Ca2+ 
differentiated NHU cell cultures. Y1183 NHU cells were seeded on Snapwell™ membranes and 
differentiated in the absence or presence of cadmium for 10 days at which point mRNA was 
harvested and quantified using RT-QPCR. Each value is the average of 3 technical replicates 
with standard deviation shown. One-way ANOVAs with Tukey post testing were performed; 
where there are statistical differences between the treatments these are indicated on the graphs. 
* p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001. 
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3.4 Summary 
• Proliferation 
Proliferative NHU cell cultures could be exposed to cadmium concentrations up to 
10 µM CdCl2 before cytotoxicity occurred; cultures exposed to 10 µM CdCl2 showed 
a reduced proliferation rate, but this was reversible upon withdrawal of cadmium 
from the medium. 
• ABS/Ca2+ differentiation 
Pre-treatment of NHU cell cultures with cadmium before ABS/Ca2+ differentiation 
had no significant effect upon differentiation. 
The presence of cadmium during differentiation had no effect on barrier formation as 
measured by TER, but it did affect the rate of barrier recovery following wounding. 
At the transcript expression level, three terminal markers of differentiation (UPK1a, 
UPK2 and KRT20) were shown to be downregulated as a consequence of cadmium 
exposure. The transitional differentiation marker CK13 was also downregulated by 
cadmium exposure during ABS/Ca2+ differentiation.  
• TZPD differentiation 
Exposure of NHU cell cultures to cadmium during TZ/PD-induced differentiation 
compromised their ability to undergo urothelial differentiation as shown by a 
decrease in transcript of four differentiation-associated genes (UPK1a, UPK2, 
KRT13 and KRT20). There was also a failure to downregulate KRT14, a maker of 
squamous metaplasia. 
• Transcription factors 
Cadmium exposure during TZ/PD-induced differentiation did not affect transcript 
expression of the PPARγ-induced intermediary transcription factors IRF-1 and 
FOXA1 or on four other transcription factors known to be involved in urothelial 
differentiation. These results suggest that cadmium affects urothelial differentiation 
downstream of the initial PPARγ -induced effects. 
• Tumour suppressor genes 
Expression of the tumour suppressor gene p16 was downregulated during cadmium 
treatment in proliferative and differentiating NHU cell cultures. Transcript 
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expression of two further tumour suppressor genes RASSF1A and APC was 
downregulated by cadmium exposure in ABS/Ca2+ differentiated cultures. 
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4 Epigenetic mechanisms in cadmium exposure 
4.1 Aims 
Trichostatin A (TSA), a HDAC inhibitor and 5-azacytidine, a DNA 
methyltransferase inhibitor are often used in studies to examine whether epigenetic 
mechanisms are involved (Vallot et al., 2010; Scholpa et al., 2014; Chen et al., 
2015).  
The aims of this chapter were to determine whether epigenetic mechanisms were 
involved in the ability of cadmium to silence differentiation-associated genes as 
reported in Chapter 3 and to identify gene expression changes that occur when NHU 
cell cultures were differentiated in the presence of cadmium and TSA. 
The specific objectives of this chapter were to: 
• Treat cadmium exposed differentiating NHU cell cultures with TSA or 5-
azacytidine.  
• Perform promoter analysis on differentiation-associated genes that responded 
differentially to TSA in order to identify transcription factor binding motifs 
that differ between them. 
• Identify genes that were up/downregulated by cadmium and TSA in TZPD-
differentiating NHU cell cultures using Agilent microarrays. 
• Relate the changes determined from the microarrays to: 
1. Known markers of differentiation. 
2. Transcription factors involved in urothelial differentiation. 
3. Chromatin remodelling enzymes. 
4.2 Experimental Approach 
4.2.1 Cell culture 
NHU cells were cultured until 80-90% confluent and then induced to differentiate 
using TZPD as described in section 2.5.3.1. Cadmium chloride (10 µM), TSA (400 
nM) and 5-azacytidine (5aza) (1 µM) were applied to NHU cell cultures at the same 
time as TZPD.  The concentrations used for the epigenetic modifiers were in line 
with those described in the literature and in particular those used by Vallot et al. 
(2010) when treating NHU cell cultures. 
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4.2.2 RTQPCR  
RTQPCR was utilised in order to quantify changes in expression of known urothelial 
differentiation-associated genes following cadmium exposure and TSA or 5aza 
treatment. Genes examined included UPK1A, UPK2, KRT13, and KRT20. KRT14 
expression was also examined as a marker of squamous metaplasia expressed in 
proliferative but not differentiated NHU cell cultures.  Expression of all genes was 
calculated relative to the housekeeping gene, GAPDH. 
4.2.3 Immunoblotting 
Western blotting was performed to examine changes in CK13 protein expression 
following cadmium exposure and TSA treatment. Two independent NHU cell 
cultures, Y1197 and Y1223 were treated for 7 days ± TZPD ± 10 µM CdCl2 ± 400 
nM TSA. Upon completion of treatments, NHU cell cultures were lysed in situ with 
SDS lysis buffer to give whole cell lysates. 
4.2.4 Immunofluorescence microscopy 
Immunofluorescence microscopy was performed to examine protein expression and 
localisation of CK13 and CK14. NHU cells were seeded on to 12-well slides. Once 
cultures were 80-90% confluent, cells were treated ± TZPD  ± 10 µM CdCl2 ± 400 
nM TSA for 3 days before being fixed in methanol:acetone. Following air-drying, 
cells were immunolabelled using CK13 or CK14 antibodies. Positive and negative 
controls for immunofluorescence microscopy were performed as described in section 
2.7. 
4.2.5 Promoter analysis 
Promoter analysis for the four differentiation genes (UPK1A, UPK2, KRT13 and 
KRT20) was carried out using the PSCAN promoter analysis tool, which was run 
against the JASPAR database of transcription factor binding profiles 
(http://159.149.160.51/pscan/).  
Following identification of transcription factor motifs that differed in the promoters, 
RTPCR was performed to see how the expression of these transcription factors 
changed following cadmium and TSA treatment. In order to examine protein 
expression and localization of the candidate transcription factors 
immunofluorescence microscopy was performed.  
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4.2.6 Gene expression analysis 
Gene expression analysis was performed using Agilent SurePrint G3 Human 
Microarrays on two independent NHU cell lines (Y1441 and Y1451) which had been 
treated ± TZPD  ± 10 µM CdCl2 ± 400 nM TSA for 3 days. Microarrays were carried 
out by the Genomics Department of the Technology Facility at the University of 
York. Normalisation and fold change calculations were carried out by the Bioscience 
Technology Facility’s Bioinformatics Laboratory. Normalised intensity values and 
fold change data was supplied in the form of Excel spreadsheets. 
Gene ontology enrichment analysis was performed using the PANTHER 
Classification System (http://pantherdb.org/). 
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4.3 Results 
4.3.1 Ability of cadmium to silence differentiation markers is associated with 
histone modifications 
In order to determine if epigenetic mechanisms were involved in the process by 
which cadmium silenced differentiation genes as reported in Chapter 3, 
differentiating NHU cell cultures exposed to cadmium were treated with either TSA 
or 5aza for 3 days. 
RTQPCR results showed that TSA was able to reverse the inhibitory effects of 
cadmium on the expression of UPK2 and KRT20 genes, but not for UPK1A and 
KRT13; KRT13 showed a further reduction upon TSA treatment (Figure 4.1). These 
results were statistically significant, whereas TSA alone had no affect on TZ/PD-
induced differentiation on three of four differentiation-associated genes (UPK1A, 
UPK2 and KRT20).  
RTQPCR results for 5-azacytidine treatments showed that 5aza was not able to 
reverse the inhibitory effects of cadmium (Figure 4.2). 5aza affected TZ/PD-induced 
differentiation in two of the four differentiation genes (UPK1A and KRT20). 
Overall the results from the TSA and 5aza experiments indicated that histone 
modifications rather than DNA methylation may be responsible for the silencing of 
differentiation genes by cadmium. 
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Figure 4.1. RTQPCR data for four differentiation genes from NHU cell cultures treated with 
TSA.  Y1233 NHU cell cultures were treated ± TZPD ±  400 nM TSA ± 10 µM CdCl2 for 3 days. 
mRNA was harvested from the cultures, cDNA was synthesised using random hexamers and 
then RTQPCR was performed to quantify the relative expression of four differentiation-
associated genes UPK1A, UPK2, KRT13 and KRT20. Each value is the average of 3 technical 
replicates with standard deviations shown by error bars. One-way ANOVAs with Tukey post 
testing was performed (see Table 4.1) * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001, ns not 
significant. Note that TSA had no effect on the expression of the three terminal differentiation 
markers (UPK1A, UPK2 and KRT20), but TSA did reverse the inhibitory effects of cadmium 
for UPK2 and KRT20. 
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Table 4.1. Results of ANOVAs with Tukey post testing for the four differentiation genes in TSA 
treated NHU cell cultures. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001, ns –not significant. 
UPK1A Control TZPD TZPD TSA TZPD Cd TZPD TSA Cd 
Untreated - **** **** ** ** 
TZPD  - ns **** **** 
TZPD TSA   - **** **** 
TZPD Cd    - ns 
TZPD TSA Cd     - 
 
UPK2 Control TZPD TZPD TSA TZPD Cd TZPD TSA Cd 
Untreated - **** **** **** **** 
TZPD  - ns *** ns 
TZPD TSA   - **** * 
TZPD Cd    - * 
TZPD TSA Cd     - 
 
KRT13 Control TZPD TZPD TSA TZPD Cd TZPD TSA Cd 
Untreated - **** **** *** * 
TZPD  - ** **** **** 
TZPD TSA   - *** **** 
TZPD Cd    - * 
TZPD TSA Cd     - 
 
KRT20 Control TZPD TZPD TSA TZPD Cd TZPD TSA Cd 
Untreated - **** **** ns **** 
TZPD  - ns **** ** 
TZPD TSA   - **** ** 
TZPD Cd    - *** 
TZPD TSA Cd     - 
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Figure 4.2. RTQPCR data for four differentiation genes from NHU cell cultures treated with 5-
azacytidine.  Y1236 NHU cell cultures were treated ± TZPD ± 1 µM 5aza ± 10 µM CdCl2 for 3 
days. mRNA was harvested from the cultures, cDNA was synthesised using random hexamers 
and then RTQPCR was performed to quantify the relative expression of four differentiation-
associated genes UPK1A, UPK2, KRT13 and KRT20. Each value is the average of 3 technical 
replicates with standard deviations shown by error bars. One-way ANOVAs with Tukey post 
testing was performed (see Table 4.2) * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001, ns not 
significant. Note that 5-azacytidine did not reverse the inhibitory effects of cadmium but 5aza 
did affect the expression of two terminal differentiation markers in opposite directions (UPK1A 
and KRT20). 
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Table 4.2. Results of ANOVAs with Tukey post testing for the four differentiation genes in 5-
azacytidine treated NHU cell cultures. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001, ns –not 
significant. 
UPK1A Control TZPD TZPD 5aza  TZPD Cd TZPD Cd 5aza 
Untreated - **** *** ns ns 
TZPD  - * **** **** 
TZPD 5aza   - ** ** 
TZPD Cd    - ns 
TZPD Cd 5aza     - 
 
UPK2 Control TZPD TZPD 5aza  TZPD Cd TZPD Cd 5aza 
Untreated - **** **** **** **** 
TZPD  - ns **** **** 
TZPD 5aza   - **** **** 
TZPD Cd    - ns 
TZPD Cd 5aza     - 
 
KRT13 Control TZPD TZPD 5aza  TZPD Cd TZPD Cd 5aza 
Untreated - **** **** ** *** 
TZPD  - ns **** **** 
TZPD 5aza   - **** **** 
TZPD Cd    - ns 
TZPD Cd 5aza     - 
 
KRT20 Control TZPD TZPD 5aza  TZPD Cd TZPD Cd 5aza 
Untreated - **** **** ns ns 
TZPD  - **** *** *** 
TZPD 5aza   - **** **** 
TZPD Cd    - ns 
TZPD Cd 5aza     - 
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4.3.2 TSA treatments on two further independent NHU cell lines 
Two further independent NHU cell lines (Y1197 and Y1357) were treated with 
TZPD, cadmium and TSA for 3 days. RTQPCR results for Y1197 (Figure 4.3) and 
Y1357 (Figure 4.4) confirmed the initial findings that TSA was able to reverse the 
cadmium reduced expression of UPK2 and KRT20 but was not able to reverse the 
cadmium-reduced expression UPK1A and KRT13.  
 
 
Figure 4.3. RTQPCR data for four differentiation genes from Y1197 NHU cultures. NHU cell 
cultures were treated ± TZPD ±  400 nM TSA ± 10 µM CdCl2 for 3 days. mRNA was harvested 
from the cultures, cDNA was synthesised using random hexamers and then RTQPCR was 
performed to quantify the relative expression of four differentiation-associated genes UPK1A, 
UPK2, KRT13 and KRT20. Each value is the average of 3 technical replicates with standard 
deviations shown by error bars. One-way ANOVAs with Tukey post testing was performed; 
where there are statistical differences between the TZPD treatments these are indicated on the 
graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 4.4. RTQPCR data for four differentiation genes from Y1357 NHU cultures. NHU cell 
cultures were treated ± TZPD ±  400 nM TSA ± 10 µM CdCl2 for 3 days. mRNA was harvested 
from the cultures, cDNA was synthesised using random hexamers and then RTQPCR was 
performed to quantify the relative expression of four differentiation-associated genes UPK1A, 
UPK2, KRT13 and KRT20. Each value is the average of 3 technical replicates with standard 
deviations shown by error bars. One-way ANOVAs with Tukey post testing was performed; 
where there are statistical differences between the TZPD treatments these are indicated on the 
graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001. 
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4.3.3 CK13 protein expression  
Immunoblotting for CK13, a transitional marker of urothelial differentiation, was 
performed using whole cell lysates from two independent NHU cell lines (Figure 
4.5). CK13 was upregulated upon TZPD-induced differentiation in both cell lines. 
TSA alone led to slight increases in CK13. Upon exposure to cadmium CK13 
expression was reduced in both cell lines with TSA leading to a slight rescue in the 
protein expression amounts in one cell line, while a reduction was observed in the 
other cell line. These results were consistent with transcript data for KRT13 reported 
above.  
Immunofluorescence microscopy for CK13 (Figure 4.6) showed an upregulation of 
CK13 upon differentiation that was inhibited by cadmium exposure. TSA did not 
prevent the downregulation of CK13 caused by cadmium. 
Overall these results showed that TSA did not affect the cadmium-reduced 
expression of CK13 protein in differentiated NHU cell cultures in two of out three 
independent cell lines. 
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Figure 4.5. Western blot analysis of CK13 protein expression from two independent NHU cell 
lines. NHU cultures, Y1197 (A) and Y1223 (B), were treated for 7 days ± TZPD ± 10 µM CdCl2 
± 400 nM TSA. Cultures were lysed in situ with SDS lysis buffer and then sonicated. Protein 
concentration was measured using a Bradford assay. 4-12% Bis-Tris gels were loaded with 20 
µg of protein and run at 200 V in MES running buffer. Protein was blotted on to PVDF 
membranes using the Novex apparatus for 2 hours at 30 V. Membranes were blocked in 
Odyssey blocking buffer, incubated with primary antibodies overnight at 4°C, and secondary 
antibodies for one hour at ambient temperature then scanned on the Li-Cor imaging system. 
The fluorescence of each band was quantified and normalised to the loading control β-actin 
using the Odyssey software. Numbers quantifying the percentage intensity of the bands are 
displayed below the corresponding bands. Differentiation induced expression of CK13, which 
was further de-repressed by TSA. Cadmium inhibited differentiation-associated CK13 
expression, which was partially alleviated by TSA in one cell line only.  
 
 
 
U
nt
re
at
ed
 
TZ
PD
 
TZ
PD
	T
SA
 
TZ
PD
	C
d 
TZ
PD
	T
SA
	C
d 
CK13 
			0									100							127										46										68				 
β-actin	 
U
nt
re
at
ed
 
TZ
PD
 
TZ
PD
	T
SA
 
TZ
PD
	C
d 
TZ
PD
	T
SA
	C
d 
CK13 
			0										100							107									85									78				 
β-actin	 
A 
B 
  Chapter 4 
 
134 
 
 
 
Figure 4.6. Immunofluorescence microscopy images for CK13. NHU cells (Y1357) were seeded  
at a concentration of 3x105 cells mL-1 on to 12-well slides. Once cultures were 80-90% confluent 
cells were treated for 3 days ± TZPD ± 10 µM CdCl2 ± 400 nM TSA before fixation in 
methanol:acetone. Following air-drying, cells were immunolabelled using anti-CK13 mouse 
primary antibodies and a goat anti-mouse secondary immunoconjugate. Nuclei were stained 
with Hoechst 33258. Scale bar, 10 µM. 
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4.3.4 CK14 transcript and protein expression 
When differentiating NHU cell cultures were exposed to cadmium, there was a 
failure to downregulate KRT14, as reported in Chapter 3. TSA alone was shown to 
have no effect on the downregulation of KRT14 upon TZ/PD-induced differentiation 
(Figure 1.7A). TSA treatment enabled KRT14 to be downregulated when cadmium 
was present in Y1236 NHU cell cultures (p<0.001) (Figure 4.7B) but not in Y1197 
NHU cell cultures (Figure 4.7A). 
CK14 protein expression was examined by immunofluorescence microscopy (Figure 
4.8). These results showed that upon differentiation CK14 was downregulated, 
however when cadmium was present downregulation of CK14 was inhibited. The 
addition of TSA to differentiating NHU cultures annulled the effect of cadmium and 
resulted in downregulation of CK14. 
Together these results showed that the inhibition of cytokeratin 14 downregulation 
due to cadmium exposure could be prevented by TSA treatment in two out of three 
independent differentiating NHU cell cultures. 
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Figure 4.7. RTQPCR results for KRT14 transcript expression from two independent NHU cell 
lines treated with TSA. Y1197 (A) and Y1236 (B) NHU cell cultures were treated ± TZPD ±  400 
nM TSA ± 10 µM CdCl2 for 3 days. mRNA was harvested from the cultures, cDNA was 
synthesised using random hexamers and then RTQPCR was performed to quantify the relative 
expression of KRT14. Each value is the average of 3 technical replicates with standard 
deviations shown by error bars. One-way ANOVAs with Tukey post testing was performed; 
where there are statistical differences between the TZPD treatments these are indicated on the 
graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 4.8. Immunofluorescence microscopy images for CK14. NHU cells (Y1357) were seeded 
at a concentration of 3x105 cells mL-1 on to 12-well slides. Once cultures were 80-90% confluent 
cells were treated for 3 days ± TZPD ± 10 µM CdCl2 ± 400 nM TSA before fixation in 
methanol:acetone. Following air-drying, cells were immunolabelled using anti-CK14 mouse 
primary antibodies and a goat anti-mouse secondary imunnoconjugate. Nuclei were stained 
with Hoechst 33258. Scale bar, 10 µM. 
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4.3.5 Promoter analysis for UPK1A, KRT13, UPK2 and KRT20 
As UPK2 and KRT20 responded differently to TSA treatment compared to UPK1A 
and KRT13, a bioinformatics promoter analysis was performed for these genes. 
Promoter analysis was performed using the PSCAN promoter analysis tool applied to 
the JASPAR database of transcription factor binding motifs.  When promoter regions 
for UPK1A and KRT13 were compared against UPK2 and KRT20, PSCAN results 
identified some potential candidates that differed between the two groups and many 
which did not (Figure 4.9).  
 
Figure 4.9. PSCAN promoter analysis performed using the JASPAR database of transcription 
factor binding site motifs. The ‘heatmap’ image shows the contribution of each input gene to the 
z-score of each transcription factor matrix; red spots correspond to scores higher than the 
genome-wide mean, green spots are scores lower than the genome-wide mean and black spots 
are around the average genome score. Therefore the motifs which are enriched in the promoter 
region of these genes will show as red. The following RefSeq mRNA IDs were input: 
NM_001281443, NM_002274, NM_019010 and NM_006760 representing UPK1A, KRT13, 
KRT20 and UPK2 respectively. Shown is a subset of the complete PSCAN analysis. SOX9 and 
NR3C1 motifs are shown enriched in UPK2 and KRT20. 
Two motifs that were enriched in the promoter region for UPK2 and KRT20 but not 
UPK1A and KRT13 were SOX9 and NR3C1. RT-PCR was performed to see if 
cadmium exposure affected the transcript expression of these candidates. Results 
showed that SOX9 failed to downregulate upon differentiation when cadmium was 
present (Figure 4.10), whereas NR3C1 showed no change. 
In order to examine SOX9 protein expression, immunofluorescence microscopy was 
performed. Results showed slight differences in SOX9 protein expression between 
cultures differentiated with or without cadmium. SOX9 labelling in TSA treated cells 
was more akin to the DMSO control cell cultures with labelling appearing greater in 
the nuclei compared to TZPD and TZPD Cd treated NHU cell cultures (Figure 4.11). 
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Figure 4.10. RTPCR results for NR3C1 and SOX9. Y1236 NHU cell cultures were treated ± 
TZPD ± 10 µM CdCl2 ± 400 nM TSA for 3 days. mRNA was harvested from the cultures, cDNA 
was synthesised using random hexamers and RTPCR was performed to examine expression of 
NR3C1 and SOX9. 
 
Figure 4.11. Immunofluorescence microscopy images for SOX9. NHU cells (Y1357) were seeded 
at a concentration of 3x105 cells mL-1 on to 12-well slides. Once cultures were 80-90% confluent 
cells were treated for 3 days ± TZPD ± 10 µM CdCl2 ± 400 nM TSA before fixation in 
methanol:acetone. Following air-drying, cells were immunolabelled using an anti-SOX9 goat 
primary antibody and a donkey anti-goat secondary immunoconjugate. Scale bar, 5 µM. 
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4.3.6 Gene expression analysis using Agilent microarrays 
Agilent microarrays were used to identify genes that changed in expression when 
two independent NHU cell cultures were differentiated in the presence of cadmium 
and TSA.  
Before microarrays were performed, confirmation that cadmium and TSA treatments 
had been successful was determined. A fraction of extracted RNA for each of the 
four treatments from the two NHU cell lines was synthesised into cDNA and 
RTQPCR was performed to examine the expression of the four urothelial 
differentiation-associated genes that were inhibited by cadmium exposure as reported 
in Chapter 3. Results showed that cadmium inhibited the expression of all four genes 
in both cell lines, with TSA reversing the inhibitory effects of cadmium for three 
terminal differentiation genes UPK1A, UPK2 and KRT20 (Figures 4.12 and 4.13). 
The reversal of the inhibitory effect of cadmium on UPK1A expression was in 
contrast to the results from three different NHU cell lines previously reported in this 
chapter. 
Data obtained from microarray analysis revealed a number of genes that were 
differentially expressed due to cadmium exposure and TSA treatment  (Figure 4.14). 
TZPD-induced differentiation of NHU cell cultures led to an upregulation of 1784 
genes and a downregulation of 1503 genes when data was filtered for >2-fold 
up/down changes, p<0.05. 
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Figure 4.12. Confirmation of cadmium and TSA treatment in Y1441 NHU cell cultures. NHU 
cell cultures were treated ± TZPD ±  400 nM TSA ± 10 µM CdCl2 for 72 hours. mRNA was 
harvested from the cultures, cDNA was synthesised using random hexamers and then RTQPCR 
was performed to quantify the relative expression of four differentiation-associated genes 
UPK1a, UPK2, KRT13 and KRT20. Each value is the average of 3 technical replicates with 
standard deviations shown by error bars. One-way ANOVAs with Tukey post testing was 
performed; where there are statistical differences between the TZPD treatments these are 
indicated on the graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001.  
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Figure 4.13. Confirmation of cadmium and TSA treatment in Y1451 NHU cell cultures. NHU 
cell cultures were treated ± TZPD ±  400 nM TSA ± 10 µM CdCl2 for 72 hours. mRNA was 
harvested from the cultures, cDNA was synthesised using random hexamers and then RTQPCR 
was performed to quantify the relative expression of four differentiation-associated genes 
UPK1a, UPK2, KRT13 and KRT20. Each value is the average of 3 technical replicates with 
standard deviations shown by error bars. One-way ANOVAs with Tukey post testing was 
performed; where there are statistical differences between the TZPD treatments these are 
indicated on the graphs. * p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001.  
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Figure 4.14. Section of a dendrogram heat map produced using GeneSpring GX software. Heat 
map shows genes with high expression levels (red), low expression levels (blue) or average 
expression values (yellow). Showed that changes in gene expression occurred when 
differentiating NHU cultures were treated with cadmium and TSA. 
 
 
 
 
  DMSO Control               TZPD                 TZPD Cd           TZPD Cd TSA 
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4.3.6.1 Confirmation of known differentiation-associated markers 
The expression of known urothelial differentiation markers was analysed using fold 
change expression profiles. Fold changes were calculated using the combined 
microarray data of the two independent NHU cell lines (Y1441 and Y1451). Where 
more than one probe was present for a single gene the data was combined and 
standard deviations shown.  
Uroplakin gene expression fold changes are shown in Figure 4.15. When TZPD-
induced differentiated cell cultures were compared with DMSO control cultures all 
five uroplakin genes were shown to be upregulated. Cadmium exposure led to a 
decrease in expression of UPK1A, UPK2, UPK3A and UPK3B but not UPK1B. TSA 
reversed the inhibitory effect of cadmium by a 2 fold increase or more in three out of 
the four uroplakin transcripts (UPK1A, UPK3A and UPK3B) that were 
downregulated by cadmium.  
Cytokeratin transcript fold changes are shown in Figure 4.16. KRT13, a transitional 
differentiation-associated gene, and KRT20 a terminal differentiation-associated 
gene were both upregulated in TZPD treated cell cultures. Cadmium exposure led to 
a 2.7 fold decrease in KRT20 expression with TSA shown to reverse this 
downregulation.  
KRT14, KRT16, KRT17 and the KRT6 family all showed a marked reduction of 
transcript expression upon TZPD-induced differentiation. Cadmium treatment led to 
an increase of expression for all the transcripts when compared to TZPD only treated 
cultures. TSA alleviated the effects of cadmium exposure for two genes, KRT16 and 
KRT6C, by a 2 fold decrease or more.  
Tight junction genes were also analysed and are shown in Figure 4.17. Tight 
junctions are built from 40 different proteins including claudins, occludin and zona 
occludens. Claudin 3 and 4 were shown to be upregulated upon differentiation. 
Cadmium exposure led to a very slight increase in expression of claudin 3 and 4, 
TSA was shown to reverse this increase. Occludin was shown to be upregulated upon 
differentiation of NHU cell cultures, with cadmium exposure leading to a slight 
decrease in occludin transcript expression, further treatment with TSA did not affect 
occludin expression. ZO-2 and ZO-3 were upregulated in differentiated NHU cell 
cultures, with cadmium and TSA only having a minimal effect on expression levels.  
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Figure 4.15. Agilent microarray analysis for uroplakin targets during urothelial differentiation, 
cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures were treated ± 
TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was collected at 72 hours and gene expression 
analysed using Agilent SurePrint G3 Human Microarrays. 
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Figure 4.16. Agilent microarray analysis for cytokeratin targets during urothelial 
differentiation, cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures 
were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was collected at 72 hours and gene 
expression analysed using Agilent SurePrint G3 Human Microarrays. 
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Figure 4.17. Agilent microarray analysis for tight junction targets during urothelial 
differentiation, cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures 
were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA.  mRNA was collected at 72 hours and gene 
expression analysed using Agilent SurePrint G3 Human Microarrays. 
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4.3.6.2 Expression of urothelial transcription factors 
The expression of six transcription factors known to be involved in urothelial 
differentiation was analysed (Figure 4.18). All six transcription factors were shown 
to be upregulated in differentiation by at least 2-fold with ELF3 shown to be the most 
upregulated by 35-fold. Transcription factor expression was not affected by cadmium 
exposure or TSA, except for ELF3, which showed minor changes, however these 
changes in expression were both less than 1.5 fold changes. 
These results were in agreement with the RTPCR and RTQPCR results reported in 
Chapter 3. Additionally they showed that TSA did not affect their expression. 
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Figure 4.18. Agilent microarray analysis for transcription factors targets during urothelial 
differentiation, cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures 
were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was collected at 72 hours and gene 
expression analysed using Agilent SurePrint G3 Human Microarrays. 
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4.3.6.3 Expression of chromatin modifying enzymes 
As the results from the TSA experiments reported above indicated that histone 
modifications may be responsible for the silencing of differentiation genes by 
cadmium, the expression of chromatin modifying enzymes was analysed using the 
microarray data in order to investigate if histone modification changes were 
occurring during to a change in expression of these enzymes. In total six classses of 
chromatin modifying proteins were analysed. 
Expression of polycomb group proteins which create and maintain repressive 
chromatin environments by forming two polycomb repressive complexes, PRC1 and 
PRC2 was analysed (Figure 4.19). Although differences were apparent upon 
differentiation, no differences greater than 1.5 fold change were noted during 
cadmium expoure.   
Expression of herterochromatin protein (HP1) whch is a family of three proteins that 
are vital for the formation of transcriptionally inactive heterochromatin was analysed 
(Figure 4.20). No differences in their expression were found upon differentiation or 
cadmium and TSA treatment.  
Three families of histone acetyltransferases (HATs) were analysed (Figure 4.21).  
The only change seen in expression amongst the HATs was for KAT2B upon 
differentiation. Cadmium exposure and TSA treatment did not affect HAT 
expression. 
Expression of histone deacetylases (HDACs) was analysed (Figure 4.22). A few 
HDACs showed differential expression upon differentiation, but cadmium and TSA 
did not affect their expression.  
Lysine methyltransferase (KMT) gene expression was analysed (Figure 4.23). 
Neither differentiation or cadmium and TSA treamtment affected the expression of 
KMTs.  
Lysine demethylase (KDM) gene expression was analysed (Figure 4.24). 
Differentiation led to the uprgualtion of KDM1A, KDM3B and KDM7C by 2-fold 
change or greater and the downregualtion of KDM7A. Cadmium had no significant 
effect on expression of KDMs except for KDM1B which showed a 2-fold decrease in 
expression which was recovered by TSA. 
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Figure 4.19. Agilent microarray analysis for the polycomb repressive complexes (PRC1 and 
PRC2) during urothelial differentiation, cadmium exposure and TSA treatment. Y1441 and 
Y1451 NHU cell cultures were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was 
collected at 72 hours and gene expression analysed using Agilent SurePrint G3 Human 
Microarrays. 
 
 
 
Figure 4.20. Agilent microarray analysis for herterochromatin protein (HP1) during urothelial 
differentiation, cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures 
were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was collected at 72 hours and gene 
expression analysed using Agilent SurePrint G3 Human Microarrays. 
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Figure 4.21. Agilent microarray analysis for histone acetyltransferases during urothelial 
differentiation, cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures 
were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was collected at 72 hours and gene 
expression analysed using Agilent SurePrint G3 Human Microarrays 
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Figure 4.22. Agilent microarray analysis for histone deacetylases during urothelial 
differentiation, cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures 
were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was collected at 72 hours and gene 
expression analysed using Agilent SurePrint G3 Human Microarrays. 
  
 
Figure 4.23. Agilent microarray analysis for lysine methltransferase (KMT) during urothelial 
differentiation, cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures 
were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was collected at 72 hours and gene 
expression analysed using Agilent SurePrint G3 Human Microarrays. 
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Figure 4.24. Agilent microarray analysis for lysine demethylases (KDM) during urothelial 
differentiation, cadmium exposure and TSA treatment. Y1441 and Y1451 NHU cell cultures 
were treated ± TZPD ± 10 µM CdCl2 ± 400 nM TSA. mRNA was collected at 72 hours and gene 
expression analysed using Agilent SurePrint G3 Human Microarrays. 
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4.3.6.4 Identification of genes up/downregulated by cadmium and TSA 
In order to identify genes that were affected by cadmium exposure, genes that had p 
values less than 0.05 were filtered for 2-fold up or down changes. Filtering of the 
upregulated genes selected 118 gene targets. The most upregulated genes are shown 
in Table 4.3. Filtering of the downregulated genes selected 588 gene targets, with the 
most downregulated genes shown in Table 4.4. Complete gene lists are shown in 
Appendix 4. 
As expected, gene ontology enrichment analysis of the 118 genes upregulated in 
cadmium exposure (Figure 4.25) showed enrichment in GO biological process terms 
for a response to cadmium and zinc ions. This was due to the upregulation in 
metallothionein genes. 
Other genes of note that were shown upregulated in response to cadmium included 
three zinc transporters (Figure 4.26). 
When TSA was included in the treatment of NHU cell cultures, filtering produced 
245 gene targets that were upregulated and 78 gene targets that were downregulated 
when compared to differentiating cultures exposed to cadmium (Appendix 4).  
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Table 4.3. Most upregulated genes by cadmium in TZPD-differentiating NHU cell cultures. 
Pairwise comparisons were performed between the two relevant treatment groups (TZPD and 
TZPD Cd) to identify genes that were differentially expressed, p<0.05. 
Gene 
Symbol 
Gene Name Fold 
change log2 
GO biological process term 
MT1G Metallothionein 1G 14.5 Cellular response to 
cadmium/zinc ion 
MT1H Metallothionein 1H 11.8 Cellular response to 
cadmium/zinc ion 
MT1M Metallothionein 1M 8.4 Cellular response to zinc ion 
MT1B Metallothionein 1B 6.4 Cellular response to zinc ion 
MT1L Metallothionein 1L 6.4 Cellular response to zinc ion 
MT1E Metallothionein 1E 6.1 Cellular response to 
cadmium/zinc ion 
MT1F Metallothionein 1F 5.9 Cellular response to 
cadmium/zinc ion 
MT1X Metallothionein 1X 5.3 Cellular response to 
cadmium/zinc ion 
MT1A Metallothionein 1A 4.8 Cellular response to 
cadmium/zinc ion 
MT2A Metallothionein 2A 4.7 Cellular response to zinc ion 
ALDH3A1 Aldehyde dehydrogenase 3 
family, member A1 
3.4 Response to hypoxia // positive 
regulation of cell proliferation // 
oxidation-reduction process 
UCHL1 Ubiquitin carboxyl-terminal 
esterase L1 (ubiquitin 
thiolesterase) 
3.1 Response to ischemia // protein 
deubiquitination // cell 
proliferation 
HMOX1 Heme oxygenase 
(decycling) 1 
2.8 Heme oxidation // angiogenesis 
// cellular response to cadmium 
ion 
KRT16 Keratin 16 2.7 Cytoskeleton development // 
Keratinization // cell 
proliferation 
TMEM71 Transmembrane protein 71 2.4 --- 
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Table 4.4. Most downregulated genes by cadmium in TZPD-differentiating NHU cell cultures. 
Pairwise comparisons were performed between the two relevant treatment groups (TZPD and 
TZPD Cd) to identify genes that were differentially expressed, p<0.05. 
Gene 
Symbol 
Gene Name Fold 
change log2 
GO biological process term 
KRT8 Keratin 8 -4.1 Structural molecule activity 
GPR179 G protein-coupled receptor 
179 
-3.2 Visual perception 
BRIP1 BRCA1 interacting protein 
C-terminal helicase 1 
-2.8 DNA duplex unwinding // DNA 
damage checkpoint // double-
strand break repair 
TDGF1 Teratocarcinoma-derived 
growth factor 1 
-2.7 Cell differentiation // canonical 
Wnt signalling pathway 
FCN2 Ficolin 2 -2.5 Complement activation // innate 
immune respnse 
DTX1 Deltex 1, E3 ubiquitin 
ligase 
-2.5 Notch signalling pathway 
//transcription  
C4BPB Complement component 4 
binding protein, beta 
-2.4 Complement activation, 
classical pathway 
GRAMD1B GRAM domain containing 
1B 
-2.4 --- 
CD200R1 CD200 receptor 1 -2.4 Regulation of immune response 
FAM159B Family with sequence 
similarity 159, member B 
-2.3 --- 
TEX11 Testis expressed 11 -2.3 Negative regulation of 
apoptotic process 
ZC3H12D Zinc finger CCCH-type 
containing 12D 
-2.3 Negative regulation of cell 
growth 
FCAMR Fc receptor, IgA, IgM, high 
affinity 
-2.3 Immune system process 
CD4 T-cell surface glycoprotein 
CD4 
-2.3 Regulation of T cell activation 
// cell surface receptor 
signalling pathway 
OR5J2 Olfactory receptor, family 
5, subfamily J, member 2 
-2.3 G-protein coupled receptor 
signalling pathway 
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Figure 4.25. GO enrichment analysis for genes upregulated by cadmium exposure. T-tests were 
performed and genes were then filtered by 2-fold increase resulting in a list of 118 genes 
upregulated by cadmium exposure. This list was inputted in to the PANTHER Classification 
System; a PANTHER Overrepresentation Test was then performed using the annotation data 
set ‘GO biological process experimental only’. The second column represents background 
frequency while the third column is sample frequency. Background frequency is the number of 
genes annotated to a GO term in the entire background set, while sample frequency is the 
number of genes annotated to that GO term in the input list. The symbols + and - indicate over 
or underrepresentation of a GO term. 
 
Figure 4.26. Upregulation of zinc transporters in TZPD-differentiating NHU cell cultures 
exposed to cadmium. Y1441 and Y1451 NHU cell cultures were treated with TZPD ± 10 µM 
CdCl2. mRNA was collected at 72 hours and gene expression analysed using Agilent SurePrint 
G3 Human Microarrays.  
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4.4 Summary 
• TSA treatment was able to reverse the inhibitory effects of cadmium for 
UPK2 and KRT20 (5/5), UPK1A (2/5) but not for KRT13 in five independent 
NHU cell lines. However, 5-azacytidine was not able to do the same. Overall 
the results from the TSA and 5aza experiments indicate that histone 
modifications rather than DNA methylation may be responsible for the 
silencing of differentiation-associated genes by cadmium. 
• TSA did not affect the downregulation of CK13 protein by cadmium 
exposure in two out of three independent NHU cell lines. 
• The inhibition of KRT14 downregulation at both transcript and protein level 
due to cadmium exposure reported in Chapter 3, could be prevented by TSA 
treatment. 
• The SOX9 motif was shown to be enriched in the promoter regions for UPK2 
and KRT20. SOX9 transcript was not downregulated upon differentiation 
when cadmium was present, although protein levels, assessed subjectively by 
immunofluorescence microscopy, remained unchanged. 
• Results from Agilent microarrays showed: 
o Changes in uroplakin and cytokeratin gene expression following 
combined cadmium and TSA treatment 
o No significant changes in urothelial transcription factors or chromatin 
remodelling enzymes following cadmium and TSA treatment, with 
exception of KDM1B. 
o High induction of metallothionein genes upon cadmium exposure. 
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5 Cadmium Induced Post-translational Histone Modification 
Changes  
5.1 Aims 
Many metals, including arsenic, nickel and cobalt have been shown to induce post-
translational histone modification changes in cell cultures. Histone modification 
changes implicated in arsenic exposure include alterations in global histone H3 
methylation, with decreases in H3K27 trimethylation and increases in di- and 
trimethylated H3K4 (Zhou et al, 2008). Nickel exposure has been shown to lead to 
decreased histone acetylation of H2A, H2B, H3 and H4 (Broday et al., 2000; 
Golebiowski & Kasprzak, 2005; Ke et al., 2006), and increases in histone H3 lysine 
9 dimethylation (Chen et al., 2006). Finally histone changes implicated with cobalt 
exposure include increases in H3K4me3, H3K9me2, H3K9me3, H3K27me3 and 
H3K36me3 and a decrease in acetylation of H4 (Li et al., 2009). 
Reports of post-translational histone modification changes due to cadmium exposure 
are rather limited. However, one study reporting the epigenetic and genotoxic effects 
of cadmium telluride quantum dots in human breast carcinoma cells, found that free 
cadmium ions released in the cells led to chromatin condensation and global histone 
hypoacetylation (Choi et al., 2008).  
The aims of this chapter were to: 
• examine cadmium treated proliferative and differentiating NHU cell cultures 
for changes in global levels of post-translational histone modifications. 
• determine if any of these changes correlate with the transcript expression 
decreases reported in Chapter 3 with the differentiation genes (KRT13, 
KRT20, UPK1A, UPK2) upon cadmium exposure. 
5.2 Experimental Approach 
5.2.1 Proliferative NHU cell cultures 
Proliferative NHU cell cultures were treated with cadmium chloride concentrations 
ranging from 10 nM to 20 µM; medium was replaced every 48 hours. Control NHU 
cell cultures were maintained in KSFMc. Upon completion of cadmium treatment 
cultures was lysed using SDS lysis buffer to give whole cell lysates. Western blotting 
was performed to examine changes in known acetylation and methylation marks 
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present on the histone tails of H2A, H3 and H4. Equal quantities of protein were 
loaded per track and for quantification, final adjustments for loading were made 
using ß-actin as the housekeeping control protein. Densitometry was performed using 
LiCOR Odyssey software, and values were normalised to those obtained in the 
control (KSMFc) samples. 
Antibodies used for histone acetylation marks included anti-H2AK5ac, anti-
H3K9/14ac and anti-H4K5ac. Acetylation of histone tails by acetyltransferases 
induces chromatin decondensation, whereas the removal of acetyl groups by 
deacetylases promotes a tighter binding of the histones to the DNA. 
Antibodies used for histone methylation marks included anti-H3K4me3, anti-
H3K27me3 and anti-H4K20me3. Methylation of histones can be associated with 
either euchromatin or heterochromatin depending on the target histone residue. The 
tri-methylation of histone H3 lysine 27 (H3K27me3) is implicated in gene repression 
by promoting a compact chromatin structure (Ringrose et al., 2004). Tri-methylation 
of histone H4 lysine 30 (H4K20me3) is also associated with gene repression when 
present at promoters (Wang et al., 2008), whereas di/tri-methylated histone H3 lysine 
4 (H3K4me2/me3) is associated with transcriptional activation, with the highest 
levels of this modification being observed near transcriptional start sites of highly 
expressed genes (Shi et al., 2004). 
Immunofluorescence microscopy was performed to examine cellular localisations 
and confirm observations seen from the western blotting. NHU cells were seeded at a 
concentration of 1x105 cells mL-1 on to 12-well slides. Cells were cultured for 5 days 
in the presence of 1 and 10 µM CdCl2 before being fixed in methanol:acetone. 
Following air-drying, cells were immunolabelled using the H3K9/14ac and H4K5ac 
antibodies.  
5.2.2 Differentiating NHU cell cultures 
NHU cells were cultured until 80-90% confluent and then induced to differentiate 
using TZPD as described in Chapter 2. Cadmium chloride (concentration range 10 
nM - 20 µM) and TSA (400 nM) were applied to NHU cell cultures at the same time 
as TZPD.   
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5.2.2.1 Quantification of histone changes using mass spectrometry 
Quantification of global post-translational histone changes using mass spectrometry 
was performed in collaboration with Dr Mark Dickman and Tom Minshull from the 
Department of Chemical and Biological Engineering at the University of Sheffield. 
Cell culture treatments and preparation of histones was performed in York; RP-
HPLC, MS/MS and MS analyses were performed in Sheffield. 
NHU cell cultures were treated with TZPD ± 10 µM CdCl2 for 72 hours. Histones 
were acid-extracted from cell cultures as described in Chapter 2, following the 
technique of Shechter et al (2007). Histones were quantified using a Bradford assay 
and purity tested via SDS/PAGE gel and staining with Coomassie Brilliant Blue 
solution. 10 µg of histone proteins were derivatized using propionic anhydride to 
neutralize charge and block lysine residues as described by Garcia et al (2007). 
Histones were digested by trypsin, which cleaved only at the arginine residues as all 
lysine residues were blocked by endogenous modifications or chemically by 
conversion to propionyl amides, to give reproducible histone H3 fragments (Figure 
5.1). 
 
Figure 5.1. Peptides generated from the trypsin digestion of propionylated histone H3.  
The histone peptides then underwent offline fractionation by reversed phase high 
performance liquid chromatography using a porous graphitic carbon (Hypercarb™) 
column before MS/MS analysis. Relative quantification of histone post-translational 
modifications was determined using the area under the extracted ion chromatogram 
peak corresponding to a specific modified peptide, normalized to the sum of the peak 
areas corresponding to all observed modified forms of such peptide. 
5.2.2.2 Immunofluorescence microscopy 
Immunofluorescence microscopy was performed to confirm the results seen from the 
MS analysis. NHU cells were seeded on to 12-well slides. Once cultures were 80-
  Chapter 5 
 
163 
 
90% confluent cells were treated ± TZPD  ± CdCl2 for 3 days before being fixed in 
methanol:acetone. Following air-drying, cells were immunolabelled using the 
H3K9me2 and H3K9me3 antibodies.  
5.2.2.3 ChIP-(Q)PCR 
In order to investigate if the silencing of differentiation genes brought about by 
cadmium exposure was associated with the H3K9me3 mark, ChIP-QPCR was 
performed.  
ChIP-QPCR was performed using Dynabeads® as described by Collas (2011). 
Sonicated chromatin (100 bp-600bp) from formaldehyde-fixed cells, that had been 
treated ±TZPD  ±CdCl2 ±TSA for 3 days, was diluted in RIPA ChIP buffer and 
subjected to ChIP using antibodies targeted to either histone H3 trimethylated lysine 
9 (H3K9me3), total histone H3 (positive control) or anti-rabbit IgG (negative 
control). 
To confirm the success of the ChIP, PCR was performed with QPCR then utilised to 
quantify the changes observed for four known differentiation genes (KRT13, 
KRT20, UPK1A, UPK2). 
5.2.2.4 Western blotting  
Upon completion of cadmium treatment, cell cultures were either lysed in SDS lysis 
buffer to give whole cell lysates or underwent acid-extraction by 0.2 M H2SO4 to 
give histone proteins before western blotting was performed to examine changes in 
histone post-translational modifications in differentiating NHU cell cultures treated 
with cadmium.  
Antibodies used for acetylation and methylation marks included anti-H3K9ac, anti-
H3K18ac, anti-H3K23ac, anti-H3K9me2 and anti-H3K9me3. Total histone H3 was 
used as the loading control. 
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5.3 Results 
5.3.1 Proliferative NHU cell cultures 
To study whether cadmium exposure alters epigenetic marks on histones, 
proliferative NHU cell cultures (Y1054) were treated with 10 nM, 100 nM, 1 µM and 
10 µM CdCl2 for 96 hours. Global levels of commonly studied histone 
modifications, including histone acetylation and methylation were assessed by 
western blot analysis. The results showed that global acetylation levels on histones 
H2A, H3 and H4 were reduced by cadmium treatment in a dose-dependent manner 
(Figure 5.2).  However results for histone methylation marks differed across the 
cadmium chloride concentrations (Figure 5.3). Amounts of tri-methylation on H3 
lysine 4 (H3K4me3) and tri-methylation on H3 lysine 27 (H3K27 me3) increased 
with lower doses (≤100 nM) of CdCl2, but decreased with the highest dose (10 µM), 
while levels of tri-methylation on H4 lysine 20 (H4K20me3) decreased with doses 
above 100 nM CdCl2. 
Two further proliferative NHU cell lines, Y1141 and Y1220 were treated with 1 µM, 
10 and 20 µM CdCl2 for 72 and 96 hours respectively to assess global amounts of 
acetylation on histone H2A, H3 and H4. Both cell lines showed decreased global 
amounts of H2AK5ac, H3K9/14ac and H4K8ac with increasing concentrations of 
CdCl2 (Figure 5.4, Figure 5.5). 
Additionally, immunofluorescence microscopy was used to examine global amounts 
of histone acetylation. NHU cell cultures (Y1183) were treated with 1 and 10 µM 
CdCl2 for 5 days before fixation with methanol:acetone, followed by 
immunolabelling using antibodies against H4K8ac and H3K9/14ac. All fluorescence 
images were taken at the same exposure and showed that H4K8ac and H3K9/14ac 
labelling was nuclear and appeared less bright in the cadmium exposed cell cultures 
(Figure 5.6). 
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Figure 5.2. Western blot analysis for acetylation marks on histone H2A, H3 and H4 in 
proliferative NHU cell cultures (Y1054) treated with cadmium for 96 hours. Cells were lysed 
using SDS lysis buffer and then sonicated. Protein concentration was measured using a 
Bradford assay. 4-12% Bis-Tris gels were loaded with 20 µg of protein and run at 200 V in MES 
running buffer. Protein was blotted on to PVDF membranes using the Novex apparatus for 2 
hours at 30 V. Membranes were blocked in Odyssey blocking buffer, incubated with primary 
antibodies overnight at 4°C, and secondary antibodies for one hour at ambient temperature 
then scanned on the Li-Cor imaging system. The fluorescence of each band was quantified and 
normalised to the loading control β-actin using the Odyssey software. Numbers quantifying the 
percentage intensity of the bands are displayed below the corresponding bands.  
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Figure 5.3. Western blot analysis for methylation marks on histone H3 and H4 in proliferative 
NHU cell cultures (Y1054) treated with cadmium for 96 hours. Cultures were lysed in situ with 
SDS lysis buffer and then sonicated. Protein concentration was measured using a Bradford 
assay. 4-12% Bis-Tris gels were loaded with 20 µg of protein and run at 200 V in MES running 
buffer. Protein was blotted on to PVDF membranes using the Novex apparatus for 2 hours at 30 
V. Membranes were blocked in Odyssey blocking buffer, incubated with primary antibodies 
overnight at 4°C, and secondary antibodies for one hour at ambient temperature then scanned 
on the Li-Cor imaging system. The fluorescence of each band was quantified and normalised to 
the loading control β-actin using the Odyssey software. Numbers quantifying the percentage 
intensity of the bands are displayed below the corresponding bands. 
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Figure 5.4. Western blot analysis for acetylation marks on histone H2A, H3 and H4 in NHU cell 
cultures (Y1141) treated with cadmium for 72 hours. Cultures were lysed in situ with SDS lysis 
buffer and then sonicated. Protein concentration was measured using a Bradford assay. 4-12% 
Bis-Tris gels were loaded with 20 µg of protein and run at 200 V in MES running buffer. Protein 
was blotted on to PVDF membranes using the Novex apparatus for 2 hours at 30 V. Membranes 
were blocked in Odyssey blocking buffer, incubated with primary antibodies overnight at 4°C, 
and secondary antibodies for one hour at ambient temperature then scanned on the Li-Cor 
imaging system. The fluorescence of each band was quantified and normalised to the loading 
control β-actin using the Odyssey software. Numbers quantifying the percentage intensity of the 
bands are displayed below the corresponding bands. 
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Figure 5.5. Western blot analysis for acetylation marks on histone H2A, H3 and H4 in NHU cell 
cultures (Y1202) treated with cadmium for 96 hours. Cultures were lysed in situ with SDS lysis 
buffer and then sonicated. Protein concentration was measured using a Bradford assay. 4-12% 
Bis-Tris gels were loaded with 20 µg of protein and run at 200 V in MES running buffer. Protein 
was blotted on to PVDF membranes using the Novex apparatus for 2 hours at 30 V. Membranes 
were blocked in Odyssey blocking buffer, incubated with primary antibodies overnight at 4°C, 
and secondary antibodies for one hour at ambient temperature then scanned on the Li-Cor 
imaging system. The fluorescence of each band was quantified and normalised to the loading 
control β-actin using the Odyssey software. Numbers quantifying the percentage intensity of the 
bands are displayed below the corresponding bands. 
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5.3.2 Differentiating NHU cell cultures 
5.3.2.1 Mass spectrometry quantification of epigenetic marks on histone H3 
Post-translational histone modifications of histone H3 were quantified using a mass 
spectrometry approach using histones isolated from differentiating NHU cell cultures 
(Y1202) that had been treated with or without 10 µM CdCl2 for 72 hours.  
Three peptides, K9-17, K18-26 and K27-40 of the H3 tail gave reliable 
identifications across all samples to allow quantification. In total 22 different 
combinations of histone modifications on 6 different lysine residues were manually 
verified and identified along the H3 tail. These modifications were quantified to give 
relative abundances per peptide (Figure 5.7). Due to overlapping retention times for 
acetylation on different positions of the same peptide (ie. K9ac v K14ac and K18ac v 
K23ac) an accurate percentage for each individual mark could not be ascertained, 
therefore in these cases relative abundance is given as the sum of both the individual 
marks.  
The most profound change seen when cadmium was present was the change in 
methylation state of lysine 9 (K9). Mono and di-methylation (K9me1 and K9me2) 
were reduced with cadmium treatment whereas tri-methylation (K9me3), a 
repressive mark, was increased. Relative abundance reduced from 9.1% to 5.8% for 
K9me1 and 39.6% to 28.9% for K9me2 whereas K9me3 increased from 25.4% to 
36% upon cadmium treatment. 
Other changes of note include decreases in activating marks including K18/23ac and 
K9me1K14ac, although K9/14ac was increased, alongside increases in repressive 
marks including K27me2 and K27me3. Also the combinatorial mark 
K27me1K36me3 appears absent in cadmium treated cultures. Overall this indicated 
that cadmium treatment resulted in a more repressive chromatin state. 
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Figure 5.7. Mass spectrometry analysis of histone modification changes on histone H3 isolated 
from TZPD-induced differentiating NHU cell cultures (Y1202) treated with or without 10 µM 
CdCl2 for 72 hours. Bar charts represent the relative abundance of the histone modifications for 
peptides covering residues 9-17 (KSTGGKAPR), 18-26 (KQLATKAAR) and 27-40 
(KSAPATGGVKKPHR). MS data provided by Tom Minshull under the supervision of Dr 
Mark Dickman (University of Sheffield). 
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5.3.2.2 Immunofluorescence microscopy for H3K9me2 and H3K9me3 
Immunofluorescence microscopy was used to further examine the H3K9me2 and 
H3K9me3 marks. NHU cell cultures (Y1357) were treated with TZPD or TZPD and 
10 µM CdCl2 alongside a DMSO control for 3 days. Immunofluorescence for 
H3K9me2 showed a change in shape and size of H3K9me2 foci between 
differentiated and non-differentiated (DMSO) cultures with H3K9me2 labelling 
appearing more punctate in TZPD and TZPD Cd treated cultures (Figure 5.8).  
 
Figure 5.8. Immunofluorescence microscopy images for H3K9me2. NHU cells (Y1357) were 
seeded at a concentration of 3x105 cells mL-1 on to 12-well slides. Once cultures were 80-90% 
confluent cells were treated for 3 days ± TZPD ± 10 µM CdCl2 before being fixed in 
methanol:acetone. Cells were immunolabelled using anti-H3K9me2 rabbit primary antibodies 
and goat anti-rabbit secondary antibodies. Scale bar, 5 µM. 
DMSO
TZPD
TZPD	Cd
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Immunofluorescence for H3K9me3 showed qualitative increases with differentiation 
and cadmium treatment compared to control cultures treated with DMSO only 
(Figure 5.9). Additionally, cadmium treatment showed increases in H3K9me3 at the 
nuclear periphery. 
 
Figure 5.9. Immunofluorescence microscopy images for H3K9me3. NHU cells (Y1357) were 
seeded at a concentration of 3x105 cells mL-1 on to 12-well slides. Once cultures were 80-90% 
confluent cells were treated for 3 days ± TZPD ± 10 µM CdCl2 before being fixed in 
methanol:acetone. Cells were immunolabelled using anti-H3K9me3 rabbit primary antibodies 
and goat anti-rabbit secondary antibodies. Arrows indicate H3K9me3 labelling at the nuclear 
periphery. Scale bar, 5 µM. 
DMSO
TZPD
TZPD	Cd
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5.3.2.3 Chromatin Immunoprecipitation 
As the results from the MS analysis showed that the greatest change seen was with 
the H3K9me3 mark, ChIP-QPCR was performed using antibodies to this mark to see 
how H3K9me3 associated with four urothelial differentiation genes known to be 
downregulated due to cadmium exposure (KRT13, KRT20, UPK1A and UPK2). 
Fragmented chromatin from NHU cell cultures (Y1141) that had been treated with 
either DSMO only, TZPD, TZPD CdCl2 or TZPD CdCl2 TSA for 72 hours was 
incubated with antibodies against H3K9me3, as well as H3 (positive control) and 
rabbit IgG (negative control). Anti-IgG Dynabeads were used to capture antibody-
chromatin complexes; DNA was recovered by phenol-chloroform extraction.  
In order to determine if ChIP had been successful, ChIP-isolated DNA was subjected 
to PCR using primers designed against the four differentiation genes. ChIP-PCR for 
H3K9me3 (Figure 5.10) showed that eluates from the positive control, H3, were 
positive in all samples and eluates from anti-rabbit IgG were negative in all samples. 
Differing amounts of PCR product for all four differentiation genes was present in 
each of the treated cell cultures; QPCR was used to quantify these changes. 
ChIP-QPCR for H3K9me3 (Figure 5.11) showed that H3K9me3 occupancy at all 
four differentiation-associated genes was highest in the TZPD Cd samples.
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Figure 5.11. ChIP-QPCR analysis for H3K9me3. Data is represented as % of input where % of 
input = (2-Ct IP/2-Ct input) x 100. Error bars indicate standard deviation of three technical 
replicates. 
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5.3.2.4 Mass spectrometry quantification of epigenetic marks on histone H3 for 
a biological repeat 
Post-translational histone modifications of histone H3 were quantified using a mass 
spectrometry approach using histones isolated from differentiating NHU cell cultures 
(Y1456) that had been treated with or without 10 µM CdCl2 for 72 hours.  
Overall the changes seen in histone modifications in the biological repeat Y1456 
cultures (Figure 5.12) were not as profound as those seen in the Y1202 cultures, with 
only minor changes seen in the methylation states of K9.  The greatest change seen 
due to cadmium treatment was the decrease in acetylation on K18 and K23 
(K18/K23ac); relative abundance decreased from 34.9% in TZPD cultures to 22.8% 
in TZPD Cd cultures. Other notable changes include increases in the combinatorial 
marks K27me1K36me2, K27me2K36me2 and K27me2K36me3. 
The two data sets for the biological replicates were combined to show the combined 
relative abundances and standard deviations against a DMSO treated non-
differentiated culture (Figure 5.13). When comparing differentiating cultures (TZPD) 
with undifferentiated (DMSO) cultures, epigenetic marks that showed differences 
outside of the standard deviation of the measurements included decreases in all three 
of the unmodified peptides (K9-17, K18-26 and K27-40), decreases in K36me2, 
K27me1K36me1 and K27me1K36me2 and increases in K9me2, K18/23ac, K27me3, 
K27me2K36me3 and K27me3K36me1. When comparing TZPD Cd with TZPD 
treated cultures, changes in epigenetic marks that were outside of the standard 
deviation of the two biological replicates included increases in K27me3, 
K27me1K36me2 and unmodified K9-17 and K18-26 peptides along with a decrease 
in K18/23ac.  
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Figure 5.12. Mass spectrometry analysis of histone modification changes on histone H3 isolated 
from TZPD-induced differentiating NHU cell cultures (Y1456) treated with or without 10 µM 
CdCl2 for 72 hours. Bar charts represent the relative abundance of the histone modifications for 
peptides covering residues 9-17 (KSTGGKAPR), 18-26 (KQLATKAAR) and 27-40 
(KSAPATGGVKKPHR). MS data provided by Tom Minshull under the supervision of Dr 
Mark Dickman (University of Sheffield). 
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Figure 5.13. Mass spectrometry analysis of histone modification changes on histone H3 isolated 
from two NHU cell lines treated ± TZPD ± 10 µM CdCl2 for 72 hours. Bar charts represent the 
relative abundance of the histone modifications for peptides covering residues 9-17 
(KSTGGKAPR), 18-26 (KQLATKAAR) and 27-40 (KSAPATGGVKKPHR). Error bars 
indicate the SD of two independent biological replicates (Y1202 and Y1456) except for those for 
DMSO, which indicate the SD of two technical replicates (Y1456). MS data provided by Tom 
Minshull under the supervision of Dr Mark Dickman (University of Sheffield). 
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5.3.2.5 Immunoblotting for histone H3 epigenetic marks 
To further explore changes in epigenetic marks on histone H3, immunoblotting 
against methylation on histone H3 lysine 9 and acetylation on histone H3 lysine 9, 18 
and 23 was performed.   
Western blots, carried out using whole cell lysates from two independent NHU cell 
lines treated with DMSO (control), TZPD or TZPD Cd, for H3K9me2, H3K18ac and 
H3K23ac showed that upon differentiation there was an increase in all three 
epigenetic marks (Figure 5.14). This was in agreement with the MS analysis. 
However cadmium treatment led to differing effects between the two cell lines. 
When TZPD and TZPD Cd treated cultures were compared, H3K9me2 was 
decreased in one cell line (Y1197) but slightly increased in the other (Y1223) and 
H3K23ac was increased in one (Y1197) and stayed the same in the other (Y1223). 
However, changes in H3K18ac were shown to be the same for both cell lines with 
expression of H3K18ac being decreased upon cadmium exposure. 
Immunoblotting was performed on whole cell lysates from TZPD-differentiating cell 
cultures, treated with either 1 or 10 µM CdCl2, in order to investigate changes in 
epigenetic marks caused by differing concentrations of cadmium. Cadmium 
treatments of 1 µM had a different effect compared to 10 µM treatments (Figure 
5.15). 1 µM treatments led to increases in all four of the epigenetic marks 
(H3K9me2, H3K9me3, H3K18ac and H3K23ac). However, 10 µM treatments led to 
decreases in methylation marks (H3K9me2 and H3K9me3) but increases in the 
acetylation marks (H3K18ac and H3K23 ac).  
Western blots were also performed on histones extracted from two independent NHU 
cell lines that had been treated with or without TZPD and CdCl2. Results for 
acetylation marks on histone H3 (Figure 5.16), showed that upon differentiation 
(Cont v TZPD), acetylation at lysine 9, 18 and 23 increased in both cell lines. When 
differentiating cultures where treated with cadmium (TZPD Cd), acetylation was 
shown to increase for all three marks in one cell line (Y1335). However, the other 
cell line (Y1445) showed decreases in two of the acetylation marks (H3K18ac and 
H3K23ac) alongside an increase in H3K9ac which was in agreement with the MS 
results. Results for methylation at lysine 9 (Figure 5.17), showed a decrease for 
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H3K9me3 for both cell lines, whereas, H3K9me2 increased in one cell line and 
decrease in the other upon cadmium exposure. 
 
 
Figure 5.14. Western blot analysis of methylation and acetylation marks on histone H3 in whole 
cell lysates from two independent NHU cell lines. Cultures were treated ± TZPD ± 10 µM CdCl2 
for 6 days.  Cultures were lysed in situ with SDS lysis buffer and then sonicated. Protein 
concentration was measured using a Bradford assay. 4-12% Bis-Tris gels were loaded with 20 
µg of protein and run at 200 V in MES running buffer. Protein was blotted on to PVDF 
membranes using the Novex apparatus for 2 hours at 30 V. Membranes were blocked in 
Odyssey blocking buffer, incubated with primary antibodies overnight at 4°C, and secondary 
antibodies for one hour at ambient temperature then scanned on the Li-Cor imaging system. 
The fluorescence of each band was quantified and normalised to the loading control histone H3 
using the Odyssey software. Numbers quantifying the percentage intensity of the bands are 
displayed below the corresponding bands.  
H3K9me2 
Total	H3 
H3K18ac 
H3K23ac 
		100															137																116																100														136																144				 
			100															171															169															100																182															170 
			100															131															146															100																101															100 
		Cont												TZPD											TZPD	Cd				 				Cont												TZPD												TZPD	Cd			 
													Y1197	 																								Y1223	  
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Figure 5.15. Western blot analysis of methylation and acetylation marks on histone H3 in whole 
cell lysates. Y1529 NHU cell cultures were treated with TZPD and either 1 or 10 µM CdCl2 for 6 
days. Cultures were lysed in situ with SDS lysis buffer and then sonicated. Protein concentration 
was measured using a Bradford assay. 4-12% Bis-Tris gels were loaded with 20 µg of protein 
and run at 200 V in MES running buffer. Protein was blotted on to PVDF membranes using the 
Novex apparatus for 2 hours at 30 V. Membranes were blocked in Odyssey blocking buffer, 
incubated with primary antibodies overnight at 4°C, and secondary antibodies for one hour at 
ambient temperature then scanned on the Li-Cor imaging system. The fluorescence of each 
band was quantified and normalised to the loading control histone H3 using the Odyssey 
software. Numbers quantifying the percentage intensity of the bands are displayed below the 
corresponding bands. 
 
 
 
 
 
 
				100															180																70 
H3K9me2 
Total	H3 
H3K18ac 
H3K23ac 
H3K9me3 
				100															134																90 
				100															125														103 
				100															124													146 
														Y1529	  
				TZPD												TZPD													TZPD			
							1	µM	Cd						10	µM	Cd					
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Figure 5.16. Western blot analysis for acetylation marks on histone H3 in acid extracted 
histones from two independent NHU cell lines. Cultures were treated ± TZPD ± 10 µM CdCl2 
for 72 hours. 4-12% Bis-Tris gels were loaded with 2.5 µg of isolated histones and run at 200 V 
in MES running buffer. Histone protein was blotted on to PVDF membranes using the Novex 
apparatus for 2 hours at 30 V. Membranes were blocked in Odyssey blocking buffer, incubated 
with primary antibodies overnight at 4°C, and secondary antibodies for one hour at ambient 
temperature then scanned on the Li-Cor imaging system. The fluorescence of each band was 
quantified and normalised to the loading control histone H3 using the Odyssey software. 
Numbers quantifying the percentage intensity of the bands are displayed below the 
corresponding bands. 
  
						Cont																Cd																				TZPD															TZPD	Cd 
Y1335 
						100																		132																					206																		291 
						100																		116																					112																		138 
							100																	106																				122																			129																																												
H3K23ac 
H3K18ac 
Total	H3 
H3K9ac 
H3K23ac 
H3K18ac 
Total	H3 
				Cont																			Cd																		TZPD													TZPD	Cd 
Y1445 
					100																			176																					243																233 
					100																			149																					151																148 
H3K9ac 
					100																			148																		160																		216																																												
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Figure 5.17. Western blot analysis for H3K9me2 and H3K9me3 marks in acid extracted histones 
from two independent NHU cell lines. Cultures were treated ± TZPD ± 10 µM CdCl2 for 72 
hours. 4-12% Bis-Tris gels were loaded with 2.5 µg of isolated histones and run at 200 V in MES 
running buffer. Histone protein was blotted on to PVDF membranes using the Novex apparatus 
for 2 hours at 30 V. Membranes were blocked in Odyssey blocking buffer, incubated with 
primary antibodies overnight at 4°C, and secondary antibodies for one hour at ambient 
temperature then scanned on the Li-Cor imaging system. The fluorescence of each band was 
quantified and normalised to the loading control histone H3 using the Odyssey software. 
Numbers quantifying the percentage intensity of the bands are displayed below the 
corresponding bands. 
 
 
 
 
 
 
 
 
 
 
Total	H3 
			Cont									TZPD					TZPD	Cd							Cont									TZPD							TZPD	Cd			 
									Y1335		 				 			Y1445		  
H3K9me2 
H3K9me3 
				100												91														68													100													98											107			 
				100											88														59														100												96													76						 
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5.4 Summary 
• Proliferative NHU cultures 
Proliferative NHU cultures showed a decrease in global levels of histone acetylation 
on H2A lysine 5, H3 lysine 9 and 14 and H4 lysine 8 upon cadmium treatment. 
However histone methylation varied depending on cadmium concentration; 
H3K4me3 increased at low doses of cadmium, as did H3K27me3 but both marks 
showed a slight decrease when treated with 10 µM CdCl2. Global H4K20me3 was 
shown to decrease with increasing concentrations of cadmium. 
• Differentiated NHU Cultures 
Mass spectrometry quantification of epigenetic marks on the tail of histone H3 in 
differentiating NHU cultures showed that upon cadmium exposure the relative 
abundance of H3K9me3 increased. ChIP-QPCR results showed that H3K9me3 
occupancy for KRT13, KRT20, UPK1A and UPK2 was highest in TZPD-
differentiating cultures exposed to cadmium. 
MS data from two biological replicates showed that upon differentiation (TZPD v 
DMSO treated cultures) levels of H3K9me2, H3K18/23ac and H3K27me3 were all 
increased. The increase seen in H3K9me2 was supported by western blot analysis of 
whole cell lysates from two independent NHU cell lines. The increase in 
H3K18/23ac was supported by western blot analysis from four independent cell 
lines, two carried out using whole cell lysates and two performed on isolated 
histones.  
Upon cadmium exposure, changes in epigenetic marks that were outside of the 
standard deviation of the two biological replicates included an increase in 
H3K27me3 and a decrease in H3K18/23ac. The decrease in amounts of H3K18/23ac 
was supported by western blots analysis carried out using whole cell lysates from 
two independent NHU cell lines and histones extracted from a further independent 
cell line.  
When different concentrations of cadmium were used to treat the differentiating 
NHU cell cultures this led to differing effects on H3K9 methylation, as 1 µM CdCl2 
led to an increase in H3K9me2 and H3K9me3 whereas, 10 µM CdCl2 led to a 
decrease in these marks. 
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6 Discussion 
Mechanisms reported to be involved in cadmium carcinogenesis include induction of 
oxidative stress, aberrant gene regulation, repression of DNA repair, deregulation of 
cell proliferation and inhibition of apoptosis (reviewed by Joseph, 2009). However, 
the exact mechanism responsible for cadmium-induced carcinogenesis has not been 
identified. As cadmium is a weak mutagen, it has been proposed that epigenetic 
mechanisms could be involved in cadmium-induced carcinogenesis (Waalkes, 2003, 
Arita & Costa, 2009). Therefore cadmium carcinogenesis of human urothelial cells 
was investigated, with a focus on whether epigenetic modifications such as histone 
modifications were involved.  
Experimental results support the initial hypothesis that exposure of urothelial cells to 
cadmium leads to downregulation of tumour suppressor genes and inhibition of 
differentiation via epigenetic dysregulation of gene expression.  
The most important experimental findings were that: 
• Cadmium exposure inhibits differentiation of NHU cell cultures in vitro. 
• TSA reversed the inhibitory effect of cadmium on differentiation-associated 
genes. 
• H3K9me3 may play a role in the silencing of differentiation-associated genes 
during cadmium exposure. 
• Cadmium exposure downregulates expression of tumour suppressor genes 
p16, APC and RASSF1A. 
• Cadmium alters histone modifications leading to a more repressive chromatin 
environment.  
6.1 Exposure of urothelial cells to cadmium 
Non-toxic cadmium chloride doses were determined by the use of an alamarBlue® 
assay and observations of NHU cell cultures. Cadmium chloride was cytotoxic to 
proliferative NHU cell cultures when concentrations exceeded 10 µM. However, 
ABS/Ca2+-differentiated NHU cell cultures could still be maintained when exposed 
to 20 µM CdCl2. After initial treatments of proliferative NHU cell cultures, cultures 
in all following experiments were exposed to non-toxic cadmium chloride 
concentrations. These doses were consistent with those used in other reported studies 
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including cadmium treatments on an immortalised human urothelial cell line that was 
exposed to 1, 5 and 9 µM CdCl2 for 16 days (Sens et al., 2003).  Other epithelial cell 
lines have also been exposed to similar cadmium chloride treatment doses including 
normal human bronchial epithelial (BEAS-2B) cells (Jing et al., 2012; Person et al., 
2013). A study by Xiao et al. (2015) showed no significant change in the number of 
colonies formed by BEAS-2B cells treated with up to 10 µM cadmium compared to 
untreated cells. Additionally Chen at al. (2014) showed that there was no significant 
cytotoxicity in BEAS-2B cells after treatment with 10 µM CdCl2 for 36 hours but 20 
µM CdCl2 significantly induced cytotoxicity after 36 hours of exposure. 
It was observed that cadmium concentrations up to 20 µM did not adversely affect 
barrier function in ABS/Ca2+ differentiated cell cultures. This is consistent with a 
study examining tight junction permeability in differentiated human intestinal cells 
that found cadmium concentrations of 1 and 50 µM had no effect on TER values, 
whereas the very high concentrations (100 and 300 µM) caused time and 
concentration dependent decreases in TER (Rusanov et al., 2015).  This may be due 
to these concentrations starting to become cytotoxic to the cells.  The highest 
concentration of cadmium that ABS/Ca2+-differentiated NHU cell cultures were 
exposed to was 20 µM and although this was shown to be cytotoxic for proliferative 
NHU cell cultures this was not the case for differentiated cultures.  
Tight junctions regulate paracellular permeability (barrier function) and maintain cell 
polarity (Balda & Matter, 2008). Microarray results showed that cadmium exposure 
only had very minimal effects on gene expression of tight junction proteins. Claudin 
3 knockdown in NHU cells has been shown to inhibit the formation of a tight barrier 
in three independent cell lines (Smith et al., 2015), therefore the slight increase in 
expression of claudin 3 and 4 upon cadmium exposure may explain the observation 
from Chapter 3 where 20 µM CdCl2 treatment led to a tightening of the barrier 
compared to the control. By contrast, Schulzke et al. (2005) showed that occludin is 
not essential for barrier function in the urothelium. This may explain why even 
though occludin expression is reduced by cadmium exposure no reduction in barrier 
function was observed.  
Rusanov et al. (2015) have recently studied the effects of cadmium on the functional 
state of human intestinal cells. Differentiated human intestinal epithelial Caco-2 cells 
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were treated with cadmium chloride concentrations ranging from 1 to 300 µM. They 
observed dose-dependent changes in mRNA expression levels of proteins involved in 
the formation of TJs (claudin 4 and ZO1) and adherens junctions (E-cadherin and 
p120-catenin). Claudin 4 expression was increased with increasing doses of cadmium 
while ZO1 expression was increased by 1 and 50  µM CdCl2 but showed decreased 
expression when treated with 100 µM CdCl2. In this thesis claudin 4 was shown to be 
slightly increased upon 10 µM cadmium exposure whereas ZO1 showed minimal 
changes in expression. E-cadherin and p120-catenin expression was shown to be the 
most sensitive to cadmium in Caco-2 cells, with the greatest induction in expression 
seen with 1 µM cadmium (Rusanov et al., 2015). Cadmium has been shown to 
specifically displace calcium from E-cadherin binding sites (Prozialeck & Lamar, 
1999) and impair cell-cell adhesion in kidney epithelial cells (Prozialeck et al., 
2003). This is because Cd2+ ions have ionic radii very similar to those of Ca2+ and 
therefore can substitute for Ca2+ in protein binding sites and interfere with the 
functions of numerous Ca2+-transport and Ca2+-dependent signalling proteins 
(Beyerssmann & Hartwig, 2008). However, in this thesis no indication of 
dysregulation of gene expression of E-cadherin was observed in cadmium exposed 
differentiating NHU cell cultures as gene expression analysis performed using 
Agilent microarrays showed no changes in the expression of E-cadherin or p120-
catenin upon cadmium exposure. 
It was also observed that barrier recovery was delayed in the presence of cadmium. 
Therefore in cases where urothelial injury has occurred, the lack of a fully functional 
permeability barrier and leaky tight junctions will allow intermediate and basal 
urothelial cells and underling tissue to be exposed to cadmium and other potential 
carcinogens that may be present in urine. 
6.2 Induction of Metallothioneins 
Metallothioneins (MTs) are low molecular weight proteins containing approximately 
30% cysteine that bind transition metals with high affinity (Hamer, 1986; Andrews, 
2000). They play an important role in cellular detoxification of inorganic species by 
sequestering metal ions that are present at elevated concentrations. Each MT protein 
molecule can bind up to seven cadmium atoms where Cd2+ is tetrahedrally 
coordinated to cysteine residues (Kagi & Valle, 1960; Otvos & Armitage, 1980; 
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Boulanger et al., 1982). Transcriptional activation of MT genes is mediated by 
MTF1, a metal-responsive transcription factor which binds to metal response 
elements (MREs) located upstream of the MT gene coding sequences (Stuart et al., 
1984; Searle et al., 1985; Westin & Schaffner, 1988; Seguin & Prevost, 1988). The 
pattern of MT1/2 expression is distinct from that of MT3. MT1 and MT2 isoforms 
show a ubiquitous pattern of tissue expression and play a critical role in the 
homeostasis of essential metals ions such as Zn2+ and Cu2+ as well as in the 
detoxification of heavy metals such as cadmium. By contrast, MT3 expression is 
normally limited to neural tissues and is not metal responsive (Palmiter el al., 1992), 
but it does posses a neuronal cell growth inhibitory activity that the other MT genes 
do not (Uchida et al., 1991; Amoureux et al., 1995). Exposure to low concentrations 
of cadmium has been shown to result in a significant induction of MT genes in 
numerous cell lines and animal tissues including COS-7 (African green monkey 
kidney) cell lines (Lee et al., 2002) and adult male Wistar rats and adult male C57 
and DBA mice tissues (Misra et al., 1997). 
Metallothionein isoforms MT1 and MT2 were highly induced in NHU cell cultures 
upon cadmium exposure. This is consistent with a recent gene expression analysis of 
human hepatocarcinoma cells, performed using Affymetrix Human Gene 1.0 arrays, 
which showed that acute cadmium exposure (0.5 µM CdCl2 for 24 hours) altered the 
expression of 333 genes, with the most upregulated being MT1G, MT1F, MT1M, 
MT1B, MT1X and MT1H (Cartularo et al., 2015). 
Metallothioneins have been reported to be upregulated in bladder cancer. Sens et al. 
(2000) demonstrated that MT3 was upregulated in human bladder cancer and that 
levels of MT3 increased with increasing tumour grade as MT3 immunostaining was 
found to be high in both CIS and high-grade cancer with low to moderate staining 
observed in low-grade bladder cancer. MT3 was shown to be undetectable using 
immunohistochemical, western and RTPCR techniques in normal urothelium (Sens 
et al., 2000), this is consistent with experimental results for MT3 expression in NHU 
cell cultures. Somji et al. (2001) showed that MT1X was overexpressed in bladder 
cancer tissue compared to normal bladder tissue. Further investigation by Zhou et al. 
(2006), using an antibody that recognises both MT1 and MT2, found that there was 
no protein expression of MT1/2 in benign lesions and low-grade cancers, low 
expression in dysplastic lesions and high-grade cancers with no evidence of muscle 
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invasion, and significantly increased expression in high-grade cancers that had 
invaded the underlying matrix. Expression of MT1/2 was also determined in 
immortalised urothelial cells that had been malignantly transformed by Cd2+ and 
shown to be capable of tumour formation in nude mice. Expression of MT1/2 protein 
in the tumour heterotransplants was found to be similar to that found in high-grade 
bladder cancers.  
6.3 Epigenetic dysregulation of differentiation 
Normal human urothelium is commonly represented in vitro as immortalised cell 
lines. However, immortalised urothelial cells, such as those immortalised by the 
overexpression of human telomerase reverse transcriptase lose the potential to 
differentiate and form a functional barrier urothelium (Chapman et al., 2006; 
Georgopoulos et al., 2011). NHU cells can be induced to differentiate using two 
published methods (Cross et al., 2005; Varley et al., 2004); therefore NHU cells 
provide a relevant cell culture system to study the effect of cadmium on urothelial 
cytodifferentiation.  
The potential of NHU cells to differentiate in the presence of cadmium was assessed, 
as exposure of the urothelium to cadmium was hypothesised to cause invasive 
urothelial cancer via epigenetic dysregulation of gene expression leading to field 
changes within the urothelium characteristic of dysplasia/carcinoma in situ (loss of 
differentiation). The observation that the urothelial differentiation markers KRT13 
and KRT20 where downregulated upon cadmium exposure, whereas KRT6, KRT14, 
KRT16 and KRT17 where upregulated was consistent with previous studies 
examining cadmium transformed cell lines. Transformation of immortalised human 
urothelial cells (UROtsa) by cadmium or arsenic was shown to induce the expression 
of KRT6A mRNA and protein compared to non-transformed UROtsa cells (Somji et 
al., 2008). Immunostaining of keratin 6A in tumour heterotransplants showed focal 
staining of the tumour cells that was localised to the cytoplasm. Focal 
immunostaining was also found in some archival patient specimens of high-grade 
bladder cancer, confirming translation of the results to human bladder cancer. 
Microarray analysis on Cd2+ transformed cell lines and their respective transplants all 
had overexpression of KRT 6A, 16 and 17 mRNA and protein, which correlated with 
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the areas of urothelial tumours cells that had undergone squamous differentiation 
(Somji et al, 2011). 
The cytokeratin expression profile of differentiating NHU cell cultures exposed to 
cadmium is similar to the recently described basal subtype of muscle invasive 
bladder cancer (MIBC; Sjodahl et al., 2012; 2013; Choi et al., 2014), where basal 
MIBCs characteristically express KRT5, KRT6, KRT14 and lack KRT20 expression. 
This indicates a link between cadmium exposure and invasive urothelial carcinoma. 
Differentiation of NHU cells in vitro is known to occur via PPARγ activation (Varley 
et al., 2006) leading to the upregulation of transcription factors that play a role in 
inducing the expression of differentiation markers. FOXA1, IRF1, ELF3, GATA3, 
GRHL3 and KLF5 are known transcription factors involved in urothelial 
differentiation (Varley et al., 2009; Yu et al., 2009; Bell et al., 2011; Bock et al., 
2014). It was observed that cadmium exposure did not affect the expression of these 
transcription factors. As the transcription factors include the pioneer factor FOXA1, 
whose differential binding to chromatin sites is dependent on the distribution of H3 
lysine 4 dimethylation (Lupien et al., 2008), it was hypothesised that cadmium 
inhibits chromatin modifications associated with expression of terminal 
differentiation.  
Differentiating NHU cell cultures were treated with two epigenetic modifiers to test 
this hypothesis. The epigenetic modifier, TSA was able to reverse the cadmium-
induced down-regulation of three terminal differentiation markers whereas 5-
azacytidine, a DNA-methylation inhibitor was not. This suggests that exposure to 
cadmium affects histone modifications required for the expression of these 
differentiation-associated genes. TSA has previously been used in the treatment of 
the human bladder cancer cell line CL1207 to show that epigenetic silencing of 
chromosomal regions was due to histone modifications, as TSA treatment was 
associated with the re-expression of most genes in the silenced regions (Vallot et al., 
2010). It was found that the promoters of most genes in the silenced regions had high 
levels of the repressive marks H3K9me3 and H3K27me3. MS analysis of histone H3 
modifications in NHU cell cultures exposed to cadmium showed increased levels of 
these two marks. H3K9me3 and H3K27me3 are characteristic of silent and 
heterochromatic regions of the genome (Greer & Shi, 2012). The observation that 
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H3K9me3 was increased at the nuclear periphery in cadmium exposed NHU cell 
cultures is consistent with a report that shows H3K9me3 associates with repressed 
genes at the nuclear periphery  (Towbin et al., 2012). ChIP-QPCR results showed 
that H3K9me3 occupancy was highest in TZPD-differentiating cultures exposed to 
cadmium. However, these results were generated from only one NHU cell line, 
therefore repeats using additional independent NHU cell lines are needed in order to 
draw conclusions from this data. However, these results do suggest that in cultures 
treated with cadmium, H3K9me3 may play a role in suppressing the expression of 
KRT13, KRT20, UPK1A and UPK2. This is consistent with the role that H3K9me3 
plays in the MRES phenotype identified by Vallot et al. (2011) that was found to be 
associated with muscle-invasive tumours and in particular the CIS pathway of 
tumour progression. Therefore the observation that cadmium exposure leads to 
dysregulation of differentiation and global increases in repressive marks implicates a 
link between cadmium exposure and the CIS pathway. Further studies will need to be 
carried out to address whether the inhibitory effects of cadmium on differentiation 
are sustained after cadmium is removed. 
6.4 Inhibition of tumour suppressor genes 
Cadmium is predominantly non-genotoxic (Valverde et al., 2001) and therefore may 
induce carcinogenesis via epigenetic mechanisms by altering the expression levels of 
various critical genes (reviewed by Wang et al., 2012). CIS and invasive bladder 
cancer is traditionally associated with the inactivation of tumour suppressor genes, 
including p53 (Fujimoto et al., 1992) CDKN2A (Cairns et al., 1993) RB1 (Cairns et 
al., 1991) and PTEN (Aveyard et al., 1999). Numerous other tumour suppressor 
genes have been implicated in bladder cancer including APC, RUNX3 and TSC1 
(reviewed by Knowles & Hurst, 2015).  
The tumour suppressor genes, APC, p16, RASSF1A and RUNX3 were all observed 
to be downregulated in cadmium-exposed NHU cell cultures.  
The short arm of chromosome 9 (9p) contains a single region that encodes the known 
tumour suppressor genes p16 and p14 on alternate reading frames from the 
CDKN2A locus, and p15 from the CDKN2B locus (Cairns et al., 1994; Devlin et al., 
1994; Orlow et al., 1995; Williamson et al., 1995; Berggren et al., 2003). More than 
50% of all bladder tumours show chromosome 9 deletions (Cairns et al., 1993; 
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Linnenbach et al., 1993; Tsai et al., 1990). The majority of deletions are of 
CDKN2A. p16 is a negative regulator of the retinoblastoma (Rb) pathway and p14 is 
a negative regulator of the p53 pathway. CDKN2A deletions have been associated 
with high grade and stage bladder tumours (Chapman et al., 2005) and an increased 
risk of recurrence in Ta and T1 tumours (Bartoletti et al., 2007). However, a further 
study looking at homozygous deletions of exon 1B of CDKN2A found no 
association with tumour grade and stage (Berggren de Verdier et al., 2006).  
RASSF1A is a tumour suppressor whose inactivation is implicated in the 
development of many human cancers (Dammann et al., 2001; Yan et al., 2003; 
Schagdarsurengin et al., 2003). Loss or significant reductions of RASSF1A was 
identified in 62% of bladder tumours (Lee et al., 2001). RASSF1A is believed to 
mediate microtubule stability, cell cycle progression and the induction of apoptosis 
(Amin & Banerjee, 2012). Loss of function of RASSF1A has been shown to lead to 
accelerated cell cycle progression and resistance to apoptotic signals.  
RUNX3 is one of three Runt-domain transcription factors encoded by the RUNX 
gene family. In NHU cells exposed to cadmium RUNX3 microarray analysis showed 
-2.14 fold change compared to non-exposed cell cultures (p<0.05). 
The APC gene encodes for the adenomatous polyposis coli protein, which is a 
component of the β-catenin destruction complex. The destruction complex is 
responsible for the ubiquitylation and subsequent proteasomal degradation of β-
catenin. Inactivation of APC has been associated with human cancers including 
colon cancer (Markowitz & Bertagnolli, 2009).  
Expression of APC and RASSF1A has been found to be decreased in muscle-
invasive high-grade bladder cancer compared to non-muscle invasive low-grade 
bladder cancer and normal bladder mucosa (Bilgrami et al., 2014) and reduced 
expression of RASSF1A and p16 has previously been reported during cadmium-
induced malignant transformation of human prostate cells (Benbrahim-Tallaa et al., 
2007). Overall this suggests a link between cadmium exposure and invasive bladder 
cancer as cadmium exposure leads to the downregulation of tumour suppressor genes 
that are known to be associated with the CIS pathway and invasive high-grade 
bladder cancer. Future studies should identify if tumour suppressor genes remain 
downregulated in NHU cell cultures after cadmium exposure is removed. 
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The likely mechanism behind downregulation of tumour suppressor genes in 
cadmium-exposed cells may be DNA methylation as numerous reports have shown 
an association between reduced tumour suppressor expression and DNA 
hypermethylation. Hypermethylation of the RASSF1A promoter region is probably 
the most frequently described epigenetic inactivation event in human cancers (Pfeifer 
et al., 2002; Dammann et al., 2003). DNA hypermethylation of the RASSF1A 
promoter has been shown to correlate with overexpression of DNMT3b in cadmium-
transformed prostrate epithelial cells (Benbrahim-Tallaa et al., 2007). RUNX3 
inactivation by aberrant DNA methylation has been reported in bladder tumours 
(Kim at al., 2005), with a follow-up study by Kim et al. (2008) finding that RUNX3 
methylation significantly correlated with the development of invasive tumours. APC 
promoter methylation has been significantly associated with urothelial cancer 
progression (Yates et al., 2007). Furthermore, DNA hypermethylation was detected 
in the promoter region of APC in lung tumours from workers who had been exposed 
to the metal chromium, (Ali et al., 2011). Additionally, arsenic exposure has been 
shown to cause promoter methylation of RASSF1A and p16 (Cui et al., 2006; Marsit 
et al., 2006; Chanda et al., 2006; Zhang et al. 2007). This indicates that non-
genotoxic metals may share a similar mechanism that leads to aberrant DNA 
hypermethylation. Future work could utilise 5-azacytidine to identify if DNA 
methylation is responsible for APC, p16, RASSF1A and RUNX3 downregulation in 
cadmium exposed NHU cell cultures.  
6.5 Alterations of histone modifications by cadmium 
The greatest change observed in histone modifications in proliferative NHU cell 
cultures was in histone acetylation. Three independent NHU cell lines all showed a 
reduction in global acetylation at H2AK5, H3K9/14 and H4K8. Reduced acetylation 
will lead to more compact chromatin thereby resulting in gene repression and 
silencing (Grunstein, 1997; Turner, 2000). H4K20me3 global levels were shown to 
reduce slightly upon cadmium exposure. H4K20me3 is associated with repression of 
transcription when present at promoters (Wang et al., 2008). Additionally, loss of 
H4K20me3 has been identified as a hallmark of cancer (Fraga et al., 2005). Other 
epigenetic marks studied in proliferative NHU cell cultures were the repressive mark, 
H3K27me3 and the active mark H3K4me3. H3K27me3 is associated with promoter 
regions of repressed genes whereas H3K4me3 is found in promoter regions of 
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transcriptionally-active genes (Santos-Rosa et al., 2002; Mikkelsen et al., 2007).  10 
nM and 100 nM CdCl2 exposure led to an increase in these marks while 10 µM 
CdCl2 exposure led to slight decreases. A non-linear dose response has also been 
reported in cadmium treatments of normal human bronchial epithelial (BEAS-2B) 
cells, where elevations of global H3K4me3 and H3K9me2 were less at 5 µM CdCl2 
than those at 2.5 µM CdCl2 (Xiao et al., 2015). Additionally they also found that 
cadmium led to increases in global levels of a transcriptional activating mark and a 
repressing mark, this has also been reported in cells that have been exposed to other 
non-genotoxic metals including arsenic and nickel (Zhou et al., 2008; Zhou et al., 
2009).   
The use of a mass spectrometry (MS) approach to examine histone post-translational 
changes provides an unbiased method to quantify histone modifications and also 
offers the ability to examine the combinatorial nature of histone modifications 
(Britton et al., 2012). In this thesis two independent NHU cell lines underwent 
TZ/PD-induced differentiation either in the presence of absence of cadmium. Mass 
spectrometry results from the two cell lines showed that in both cell lines 
H3K18/23ac was decreased and H3K27me3 was increased upon cadmium treatment, 
indicating that cadmium exposure led to more repressive chromatin landscape. This 
may explain why microarray analysis, from Chapter 4, showed that 588 genes were 
downregulated but only 118 genes were upregulated during cadmium exposure.  
A couple of epigenetic marks showed differential changes between the two NHU cell 
lines upon exposure to cadmium. One cell line showed a decrease in H3K9me2 
alongside an increase in H3K9me3 whereas the other showed a slight increase in 
H3K9me2. This may be due to NHU cell lines being primary cells derived from 
different donors, therefore inter-individual variation in the epigenome may be 
present. Inter-individual variability of histone modifications and DNA methylation 
has been reported in rat and human cells (Rintisch et al., 2014; Wagner et al., 2014). 
Additionally, inter-individual variation in DNA repair gene expression was found 
between six independent NHU cell lines with the authors suggesting that donor 
genotype such as polymorphisms or epigenetic mechanisms may be responsible for 
the change in expression levels (Crallan et al., 2002). In order for conclusions to be 
drawn several NHU cell lines need to be analysed. This thesis has only used NHU 
cell cultures from two donors to quantify histone modifications by MS, therefore, 
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further independent NHU cell lines would need to be analysed to confirm histone 
modification changes. 
The MS approach utilised in this study to quantify post-translational histone 
modifications has previously been used to identify and quantify histone 
modifications in honey bees (Dickman et al., 2013). This approach has a limitation in 
its ability to recover H3K4 peptides containing di-and tri-methyl marks; because of 
this H4K4 methylation in cadmium treated NHU cell cultures were not quantified by 
MS. Further limitations of this MS approach were that only acetylation and 
methylation on histone H3 were examined and also some of the combinatorial marks 
on lysine 9 had to be excluded from the MS analysis as they did not show reduction 
in signal in line with the dilution factor. Additional histone modifications that were 
not examined in this study include phosphorylation, ubiquitnation, sumoylation, 
citrullination and ADP-ribosylation. 
The histone modification changes observed in western blots for NHU cell cultures 
where not as great as those that have recently been reported in HepG2 and BEAS-2B 
cells upon cadmium exposure (Cartularo et al., 2015; Xiao et al., 2015). However 
these two studies also showed contrasting results as global H3K9me2 was decreased 
in HepG2 cells upon cadmium exposure, whereas in BEAS-2B cell global H3K9me2 
was increased. This may suggest that different cell types may show differential 
changes to histone modifications upon cadmium exposure. 
The expression of numerous chromatin-remodelling genes involved in modifying 
histone modifications was analysed using Aglient microarrays. Genes analysed 
included those that encode for polycomb group proteins, HP1 proteins, histone 
acetyltransferases, histone deacetylases, lysine methyltransferases and lysine 
demethylases. 
Polycomb group proteins are vital for maintenance of cell-type identity and 
differentiation by creating and maintaining repressive chromatin environments. 
Polycomb group proteins form two polycomb repressive complexes, PRC1 and 
PRC2. PRC2 is responsible for the di-and tri-methyaltion of lysine 27 of histone H3 
(H3K27me2/3) by its catalytic subunits EZH1 and EZH2. H3K27me3 is then 
recognised by the CBX component of PRC1. The ubiquitin ligase RING1 then 
monoubiquitylates lysine 119 of histone H2A (H2AK119ub) leading to chromatin 
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compaction (Margueron & Reinberg, 2011). EZH2 has also been shown to serve as a 
recruitment platform for DNA methyltransfereases, thus forming a direct link 
between histone methylation and DNA methylation at represssed promoters (Vire et 
al., 2006).  
HP1 is a family of three proteins, encoded by CBX5, CBX1 and CBX3, which are 
vital for the formation of transcriptionally inactive heterochromatin. HP1 proteins 
contain a methyl lysine binding chromodomain that binds methylated H3K9 (Jacobs 
et al., 2001) and a chromo-shadow domain that binds other HP1 proteins as well as 
numerous other interacting proteins (Lomberk et al., 2006). HP1 mediated 
heterochromatin formation occurs via the recruitment of CBX5/CBX1 by 
H3K9me2/3 which then recruits the H3K9 methyltransferase SUV39H1 (KMT1A). 
This leads to propagation of the H3K9me3 mark and HP1 down the chromosome as 
well as the binding of additional proteins such as DNA methyltransfereases leading 
to heterochromatin formation and gene silencing (Tamaru & Selker, 2001; Maison & 
Almouzni, 2004). 
Histone acetyltransferases (HATs) acetylate lysine amino acids on histone proteins 
by transferring an acetyl group from acetyl-CoA. HATs can be grouped into several 
different families based on structural and functional similarity of their catalytic 
domains. The Gcn5-related N-acetyltransferase (GNAT) family are characterized by 
four conserved motifs found within the catalytic HAT domain and the presence of a 
bromodomain (Lee & Workman, 2007). The MYST family of HATs are 
characterized by the presence of the highly conserved MYST domain composed of 
an acetyl-CoA binding motif and a zinc finger (Avvakumov & Cote, 2007). The 
p300/CBP HATs have larger HAT domain than those present in the GNAT and 
MYST families, they also contain a bromodomain and three cysteine/histidine rich 
domains.  
Histone deacetylases (HDACs) remove acetyl groups from lysine amino acids. 
HDACs are divided into four classes based on function and DNA sequence 
similarity. Class I, II and IV HDACs (HDAC1-11) all contain a zinc dependent 
active site. 
Lysine methyltransferases (KMTs) catalyse mono-, di- or tri-methylation by 
transfering one, two or three methyl groups from S-adenosyl-L-methionine to the ε-
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amino group of a lysine residue. All KMTs contain a conserved SET domain 
possessing the enzymatic activity except for KMT4/DOTIL (Qian & Zhou, 2006). 
Most KMTs also contain a defined protein domain or homologous sequence that is 
used to classify KMTs into distinct families (Aravind et al., 2011). 
Two evolutionarily conserved families of histone demethylases, which utilise 
different reaction mechanisms to establish demethylation have been identified: LSD 
demethylases and Jumonji (JmjC) domain demethylases (Shi et al., 2004; Tsukada et 
al., 2006). Lysine demethylases (KDMs) are now classifed based on new 
nomenclature into several distinct groups based on their substrate specificities and 
protein domain organisation (Allis et al., 2007).    
No significant changes in the expression of chromatin remodelling genes responsible 
for the reported histone modification changes were observed except for KDM1B. 
Cadmium has previously been shown to decrease H3 autophosphorylation in vitro by 
inhibition of the human vaccinia-related kinase VRK1/2 (Barcia-Sanjurjo et al., 
2013); this study is one example of how cadmium exposure can impact histone 
modifications via inhibition of histone modifying enzymes without affecting 
expression of these enzymes. A more recent study has also reported histone 
modification changes that occurred due to cadmium inhibiting the activity rather than 
modulating the protein levels of two lysine demethylases, KDM5A and KDM3A 
(Xiao et al., 2015). Cd2+ ions have an analogous electron configuration with Zn2+ and 
despite having a larger radius (0.95 versus 0.74 Å), Cd2+ can often substitute for Zn2+ 
in zinc-dependent enzymes and disturb or abolish the biochemical functions of these 
proteins (Beyersmann, 1995; Nieboer et al., 1999; Hartwig, 2001). This may be a 
possible mechanism affecting chromatin remodelling proteins as many epigenetic 
enzymes bind zinc including class I, II and IV histone deacetylases and various 
histone acetyltransferases, lysine methyltransferases and lysine demethylases.  
A two fold decrease in expression of KDM1B was observed upon cadmium 
exposure. However, upon TSA treatment this decrease in expression was reversed. 
KDM1B/LSD2 is a demethylase that can remove mono- and di-methyl but not tri-
methyl groups from H3K4 (Karytinos et al., 2009).  By contrast to its homologue 
KDM1A/LSD1, which functions at promoters, KDM1B removes intragenic H3K4 
methylation (Fang et al., 2010). Changes in the epigenetic marks H3K4me1 and 
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H3K4me2 were not investigated in this thesis, therefore future work could include 
the examination of H3K4me1 and H4K4me2 changes in cadmium exposed cells as 
well as investigating histone modification positioning at either promoter or intragenic 
regions. 
Future studies may consider: 
• Investigating whether histone modification changes persist in NHU cell 
cultures through multiple generations after removal of cadmium from the 
medium. In the recently published study by Cartularo and colleagues (2015) 
cadmium chloride was removed from the cell culture media and HepG2 cells 
were then cultured for a further 72 hours in order to see if epigenetic changes 
caused by cadmium exposure persisted through at least three generations. It 
was found that histone H3 and H4 pan acetylation levels remained 
diminished, but not to the levels seen directly following treatment. Globally 
reduced levels of H4K16ac and H3K9me2 also remained diminished after 72 
hours.  
• Utilising in vitro assays in order to examine whether cadmium affects the 
activity of chromatin remodelling proteins. As it is has been proposed that 
cadmium may be affecting histone post-translational modifications during 
urothelial differentiation by modifying the activity of chromatin remodelling 
enzymes by substituting for zinc in zinc-dependent enzymes.  
6.6 Cadmium molecular mechanism 
As discussed above some of the effects of cadmium are thought to arise due to 
disruption of zinc-dependent processes, due to the structural and physical similarities 
between zinc and cadmium ions (Waalkes, 2003). Cadmium is believed to compete 
with zinc for a multitude of important binding sites within biomolecules, including 
sites important in gene regulation or enzymatic activity. This is supported by a study 
by Takiguchi and colleagues (2003) that showed that cadmium may inhibit DNMT 
activity by interacting with the DNA binding site, a zinc-binding domain. Cadmium 
ions exert high affinity towards SH groups, therefore potential targets are zinc finger 
proteins. Zinc finger proteins are a family of proteins where zinc is complexed 
through four cysteine and/or histidine residues to form a zinc finger domain. Zinc 
finger domains are mainly involved in DNA binding but can also be involved in 
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protein-protein interactions. Zinc replacement by cadmium in different eukaryotic 
zinc fingers has been studied with particular attention to the modulation of DNA 
binding activity, as cadmium substitution can lead to improper folding and structural 
rearrangement affecting the position of side chains involved in DNA recognition  
(Petering et al., 2000; Huang et al., 2004; Malgieri et al., 2011).   
Kothinti el al. (2010) have reported that cadmium inhibited the DNA binding affinity 
of the transcription factor Sp1 by replacing zinc in its zinc finger DNA binding 
domain. Therefore it is possible that cadmium is substituting for zinc in some of the 
transcription factors involved in urothelial differentiation and affecting their ability 
to bind DNA, as their expression at mRNA level is still upregulated but their 
downstream targets are not. Urothelial transcription factors that contain zinc fingers 
include GATA3 and KLF5.  
SOX9 is a transcription factor that is upregulated in basal and intermediate urothelial 
cells in response to injury and has been shown to be induced in CIS and invasive 
bladder tumours as well as many other types of cancer (Dong et al., 2004; Jo et al., 
2014). SOX9 induction in urothelial carcinoma cell lines has been shown to occur 
through ligand-stimulated activation of EGFR and subsequent MAPK pathway 
activation (Ling et al., 2011). SOX9 was expressed in proliferative NHU cell cultures 
and downregulated upon differentiation by PPARγ activation. Panza et al. (2013) 
also found that PPARγ activation by a synthetic agonist for PPARγ (rosiglitazone) 
led to reduced expression of SOX9 mRNA in two colon cancer cell lines (CaCo2 and 
HT-29). When cadmium was present during urothelial cell differentiation SOX9 
failed to downregulate. As SOX9 transcript failed to downregulate in the presence of 
cadmium it could be hypothesised that SOX9 may be inhibiting urothelial 
cytodifferentiation by promoting a proliferative phenotype. SOX9 protein expression 
was visualised by immunofluorescence microscopy. Decreased levels of SOX9 
within nuclei were observed upon differentiation. This was consistent with CaCo2 
cells that had been treated with rosiglitazone that also showed decreased levels of 
SOX9 staining within nuclei (Panza et al., 2013). Further investigation using 
immunoblotting techniques will need to be performed in order to fully characterise 
SOX9 protein expression changes upon cadmium exposure, with further study 
needed to investigate if SOX9 plays a role in the inhibition of urothelial 
differentiation and cadmium carcinogenesis. 
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CTCF is a highly conserved zinc finger protein involved in many cellular processes 
including transcriptional regulation, insulator activity and regulation of chromatin 
architecture (Phillips & Corces, 2009). Recently, Jose et al (2014) have shown that 
nickel, a non-genotoxic metal carcinogen, disrupted H3K9me2 domains, resulting in 
the spreading of H3K9me2 into active regions, which led to gene silencing in these 
regions. They found reduced CTCF binding at these sites, suggesting that a loss of 
CTCF-mediated insulation function maybe a potential reason for H3K9me2 domain 
disruption and spreading. Nickel, like cadmium, has also been linked with disrupting 
the structure and function of zinc finger domains of several transcription factors and 
enzymes leading to inhibition of DNA binding and alteration of DNA-binding 
specificity (Asmuss et al., 2000; Hartwig, 2001; Bal et al., 2003). Results from our 
laboratory show that greater amounts of CTCF are extracted in cadmium exposed 
cells following cytoskeletal salt extraction. This indicates that CTCF binding is 
weaker or reduced in cadmium exposed cells compared to control, suggesting that 
the mechanism of gene silencing described by Jose et al. may be present in NHU cell 
cultures exposed to cadmium. 
The hypothesis that cadmium competes with zinc is supported by a recent study that 
found that cadmium exposure (10 µM CdCl2) of HepG2 cells for 24 hours led to a 
large increase (93%) in intracellular zinc with cadmium displacing zinc from the zinc 
proteome (Urani et al., 2015). The study also reported the upregulation of the zinc 
transporter SLC30A1; this is in agreement with the upregulation of three zinc 
transporters (SLC30A1, SLC30A2 and SLC30A3) observed in differentiating NHU 
cell cultures exposed to cadmium. The SLC30 family of zinc transporters transport 
zinc and/or other metal ions from the cytoplasm into the lumen of intracellular 
organelles or to the outside of the cell (Palmiter & Huang, 2004). Therefore this 
upregulation of zinc transporters may be a way of regulating zinc homeostasis in 
NHU and HepG2 cell cultures by transporting excess Zn2+ ions out of the cytoplasm. 
Zinc transporters have also been implicated in the transport of Cd2+ into cells. The 
ZIP family of zinc transporters (SLC39) are responsible for the transport of zinc from 
the extracellular space or organellar lumen into the cytoplasm (Eide, 2004). ZIP8 
(SLC39A8) and ZIP14 (SLC39A14) transporters have been shown to be responsible 
for Cd2+ transport in kidney, intestine and testis (Dalton et al., 2005; Girijashanker et 
al., 2008; Liu et al., 2008; He et al., 2009). Ajjimaporn et al. (2012) have shown that 
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ZIP8 is expressed in normal urothelium. Additional candidates for the transport of 
cadmium into cells include the Fe2+/H+ cotransporter divalent metal transporter 1 
(DMT/SLC11A2; Gunshin et al., 1997; Bannon et al., 2003), TRPM7 ion channel 
(Monteilh-Zoller et al., 2003) and CaV3.1 T-type Ca2+ channels (Lacinova et al., 
2000, Diaz et al., 2005). Future studies examining NHU cell cultures for ZIP zinc 
transporters and other candidates proposed in cadmium transport would give insights 
into how cadmium is transported across the urothelial barrier and into urothelial 
cells. 
6.7 Conclusions  
Cadmium exposure changed the epigenome of NHU cells, leading to a more 
repressive chromatin landscape as evidenced by an increase in repressive marks such 
as H3K9me3 and H327me3 and a decrease in activation-associated acetylation marks 
including H3K18/23ac. Enzyme-catalysed post-translational modification of histones 
plays an important role in transcriptional processes. Disruption of the balance of 
histone modifications in cadmium-exposed cells could affect the normal expression 
of genes and contribute to cadmium carcinogenesis. Preliminary evidence supports a 
role for H3K9me3 inhibiting the expression of four representative differentiation-
associated genes in NHU cell cultures exposed to cadmium. It was also found that 
cadmium exposure led to the downregulation of tumour suppressor genes p16, 
RASSF1A, APC and RUNX3. The inactivation of these tumour suppressor genes has 
previously been implicated in CIS and MIBC. Taken together, these observations 
provide evidence supporting the hypothesis that cadmium exposure gives rise to 
invasive urothelial cancers via epigenetic dysregulation of gene expression leading to 
field changes within the urothelium characteristic of dysplasia/carcinoma in situ. 
Additionally, cadmium exposure may play a role in bladder cancers caused by 
tobacco smoke, arylamines and polycyclic aromatic amines (Figure 6.1). Several 
studies have shown that cadmium inhibits DNA repair processes (Wieland et al., 
2009; Viau et al., 2008, Schwerdtle et al., 2010; Zhou et al., 2012). A deficiency in 
DNA repair allows more DNA damages to remain in cells causing an increase in the 
frequency of mutations and eventually leading to cancer progression.   
 
 
  Chapter 6 
 
203 
 
 
Figure 6.1. Hypothesis for the role of cadmium exposure in bladder cancer. 
 
Cadmium is a complex carcinogen and the mechanisms involved in cadmium 
carcinogenesis are multifactorial. The overall effect of cadmium is likely due to a 
coherence of several mechanisms. Future studies should investigate the heritability of 
epigenetic marks and correlate them to heritable gene expression patterns. 
Additionally, studies into whether changes occur in the promoter or regulatory 
regions of dysregulated genes will provide further insight into the epigenetic 
mechanisms involved in cadmium-induced carcinogenesis. 
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7 Appendices 
7.1 Appendix 1: List of Suppliers 
Supplier Contact details  
Abcam www.abcam.com 
Abnova www.abnova.com 
Active Motif www.activemotif.com 
Agilent Technologies www.agilent.com 
Ambion www.ambion.com 
Applied Biosystems (ABI) www.appliedbiosystems.com 
Axygen www.axygen.com 
BD Biosciences www.bdbiosciences.com 
Bioline www.bioline.com 
Bio-Rad www.bio-rad.com 
Bruker Daltonics www.bruker.com 
CA Hendley www.hendley-essex.com 
Calbiochem www.calbiochem.com 
Cambridge Bioscience www.bioscience.co.uk 
CE Instruments www.ceinstruments.co.uk 
Cell Path www.cellpath.co.uk 
Cell Signalling www.neb.uk.com 
Clontech www.clontec.com 
Dako www.dako.com 
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Diagenode www.diagenode.com 
Dionex www.dionex.com 
Dynex www.dynextechnologies.com 
ELGA www.elgalabwater.com 
Fisher Scientific www.fisher.co.uk 
Gibco www.thermofisher.com/uk/en 
Greiner www.greinerbioone.com 
Invitrogen www.invitrogen.com 
Leica www.leicabiosystems.com 
Li-Cor Biosciences www.licor.com 
Life Technologies www.thermofisher.com/uk/en 
Millipore www.millipore.com 
Molecular Probes www.invitrogen.com 
MSE www.mseuk.co.uk 
MWG Eurofins www.eurofinsgenomics.eu 
Nanoprop www.nanodrop.com 
New England Biolabs (NEB) www.neb.uk.com 
Nikon www.nikon.com 
Novex www.thermofisher.com/uk/en 
Nunc www.nalgenunc.com 
Olympus www.olympus.co.uk 
Philip Harris www.philipharris.co.uk 
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Pierce www.thermofisher.com/uk/en 
Promega www.promega.com 
Qiagen www.quigen.com 
R&D Systems www.rndsystems.com 
RA Lamb www.ralamb.co.uk 
Rockland www.rockland-inc.com 
Santa Cruz www.scbt.com 
Serotech www.abdserotec.com 
Sigma www.sigmaaldrich.com 
SLS www.scientificlabs.eu/ 
Star Lab www.starlab-group.com/en/ 
Sarstedt www.sarstedt.com 
Seralab www.seralab.co.uk 
Syngene www.syngene.com 
Thermo Scientific www.thermoscientific.com 
TissueGnostics www.tissuegnostics.com 
Tocris www.tocris.com 
Vector Labs www.vectorlabs.com 
VWR www.vwr.com 
World Precision Instruments www.wpiinc.com 
Zeiss www.zeiss.co.uk 
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7.2 Appendix 2: Buffers and Solutions 
General Solutions 
Phosphate Buffered Saline (PBS):  
137mM NaCl, 2.7mM KCl, 3.2mM Na2HPO4 and 147mM KH2PO4, pH 7.2 in dH2O 
PBS was prepared from tablets (Sigma) and autoclaved 
 
Cell Culture Solutions 
Cholera Toxin:  
Diluted to 30µg/ml in KSFM.  Diluted 1:1000 in KSFM for use. 
Collagenase IV: 
Diluted to 10,000 U in 100 mL Hank’s Balanced Salt Solution (with Ca2+ and Mg2+ 
ions), 10 mM HEPES 
Stripper Medium: 
500 mL Hank’s Balanced Salt Solution (without Ca2+ and Mg2+ ions), 10 mM 
HEPES, 500,000 kallikrein inactivating units (KIU) Trasylol and 0.1% (w/v) EDTA 
Transport Medium: 
500 mL Hank’s Balanced Salt Solution (with Ca2+ and Mg2+ ions), 10 mM HEPES 
and 500,000 (KIU) Trasylol 
10% (v/v) Formalin in PBSc: 
100 mL 37% formalin, 900 mL PBSc (PBS containing 0.5 mM MgCl2 and 0.9 mM 
CaCl2) 
 
Immunofluorescence Solutions 
TBS for IF: 
50mM Tris-HCl (pH 7.6), 150mM NaCl, 0.1% (w/v) NaN3 and 0.1% (w/v) BSA 
Antifade: 
5% N-propyl Gallate (w/v) in 95% glycerol and 5% PBS	   
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Histology Solutions 
Citric acid Buffer: 
0.8g Citric Acid in 350mls dH2O, adjusted to pH 6.0 with NaOH 
TBS Buffer for IHC: 
0.05M Tris-HCl, 0.15M NaCl, pH 7.6 in dH2O 
Haematoxylin:  
0.3g NaI, 1g Citric acid, 50g Chloral hydrate, 50g Aluminium potassium sulphate 
added sequentially to 850ml dH2O, 20ml ethanol containing 15% (w/v) 
haematoxylin, and 120ml glycerol. 
Scott’s Tap Water: 
2% (w/v) MgSO4 and 0.35% (w/v) NaHCO3 in dH2O 
 
Western Blotting Buffers 
2x SDS Sample Buffer: 
20% (v/v) glycerol, 2% (w/v) SDS, 125 mM Tris- HCl (pH 6.8), 200 mM NaF, 0.1 
mM Na3PO4, 33 mM Na3PO4, with freshly added 13 mM DTT and 1:100 dilution 
of protease inhibitor cocktail (Sigma Aldrich) 
Transfer Buffer: 
20 % (v/v) methanol and 80 % (v/v) H2O with final concentrations of 12 mM Tris 
and 96 mM glycine 
Tris Buffered Saline (TBS): 
10 mM Tris (adjusted to pH 7.4 with HCl) and 140 mM NaCl in H2O  
TBS – Tween 20: 
0.1% Tween-20, 10 mM Tris (adjusted to pH 7.4 with HCl) and 140 mM NaCl in 
H2O  
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Chromatin Immunoprecipitation Buffers 
Swelling Buffer: 
5mM PIPES (pH8) with 85 mM KCl in H2O  
TE buffer: 
10 mM Tris-HCl (pH 8.0), 10 mM EDTA 
Radioimmunoprecipitation assay (RIPA) Buffer: 
10 mM Tris-HCl (pH 7.5), 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% (v/v) 
Triton X-100 and 0.1% (w/v) SDS 
RIPA-ChIP Buffer: 
10 mM Tris-HCl (pH 7.5), 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% (v/v) 
Triton X-100, 0.1% (w/v) SDS with freshly added 1 mM PMSF and 1:100 dilution of 
protease inhibitor cocktail (Sigma Aldrich) 
Elution Buffer: 
20 mM Tris-HCl (pH 7.5), 5 mM EDTA and 50 mM NaCl 
Complete Elution Buffer: 
20 mM Tris-HCl (pH 7.5), 5 mM EDTA and 50 mM NaCl with freshly added 1% 
(w/v) SDS and 50 µg/mL proteinase K  
 
Acid- Extraction Buffers 
Hypotonic Lysis Buffer: 
10 mM Tris-HCl (pH 8.0), 1 mM KCl, 1.5 mM MgCl2, with freshly added 1 mM 
DTT, 1 mM PMSF, 1:100 dilution of protease inhibitor cocktail (Sigma Aldrich) and 
1:100 dilution of phosphatase inhibitor cocktails 2 and 3 (Sigma Aldrich) 
Coomassie Brilliant Blue Solution: 
0.1% (w/v) Brilliant Blue G-250 (BioRad), 50% methanol, 10% acetic acid in dH2O 
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7.3 Appendix 3: Representative Western Blots 
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7.3.4 Claudin 4 
 
7.3.5 Claudin 5 
 
7.3.6 H2AK5ac 
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7.3.7 H3 
 
7.3.8 H3K4me3 
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7.3.10 H3K9me3 
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7.3.13 H3K18ac 
 
7.3.14 H3K23ac 
 
7.3.15 H3K27me3 
 
kDa$
250$
$
150$
$
$
100$
$
$
75$
$
50$
$
$
37$
$
25$
20$
15$
10$
H3K18ac$
H3K23ac'
kDa'
250'
150'
'
100'
'
75'
'
50'
'
'
37'
'
25'
20'
15'
'
10'
kDa$
250$
150$
$
100$
$
75$
$
50$
$
$
37$
$
25$
20$
$
$
15$
$
10$
H3K27me3$
  Appendices 
 
215 
 
7.3.16 H4K8ac 
 
7.3.17 H4K20me3 
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7.4 Appendix 4 
7.4.1 Genes upregulated by >2-fold change during cadmium exposure (p > 
0.05) 
ADCK3 HERC2 NCF2 
ALDH3A1 HMOX1 NOX1 
ANKRD35 HRG NTNG2 
AQP7P1 HSPB8 OTUB2 
ARHGAP6 IGSF3 PALD1 
ARID5B ITGB7 PAMR1 
ASB2 KRT14 PART1 
ATP6V0A1 KRT16 PCDHGB2 
BIRC7 KRT16P2 PLA2G4C 
C17orf51 KRT42P PLAC1 
C21orf37 KRTAP10-5 PPAP2C 
C3orf35 LHFPL1 PRDM15 
C9orf172 LINC00633 PTGDR 
CCDC172 LINC01121 PTPRG 
CCDC178 LOC100505874 RABGEF1 
CCK LOC100506379 RBM14 
CCNB3 LOC100506790 RBP7 
CD164L2 LOC100506795 RDH12 
CDHR2 LOC101927789 RNF32 
CLEC4GP1 LOC101929553 S100A12 
CRABP2 LOC284561 S100A8 
CST7 LOC285629 SECISBP2 
CTSG LOC344887 SLC30A1 
CYP2A7P1 LRP1B SLC6A2 
CYP4Z1 MAPK8IP2 SLC9B1 
DAB2 MEIOB SRD5A2 
DDIT4L METTL10 SSTR5 
EEF1A2 MGC21881 STXBP5-AS1 
EMILIN2 MT1A TBC1D21 
ERC2 MT1B TMEM71 
FLJ13744 MT1E TREM1 
FLJ32255 MT1F TRIL 
FOXL2 MT1G TSPAN7 
FPGT-TNNI3K MT1H TTC24 
FXYD2 MT1HL1 TTYH2 
GATM MT1IP UCHL1 
GIMAP6 MT1L UGT2B15 
GNAT2 MT1M USP44 
GPR63 MT1X  
GPR78 MT2A  
  Appendices 
 
217 
 
7.4.2 Genes downregulated by >2-fold change during cadmium exposure (p > 
0.05) 
A4GNT C20orf166-AS1 CMTM5 ENDOU 
ABAT C20orf201 CNNM1 ENTHD1 
ABCC12 C3orf49 CNTLN ENTPD1 
ABL2 C4BPB COG6 EPHA10 
ACAP1 C5AR2 COL6A3 EPHA8 
ACBD7 C5orf48 COL6A4P1 ERCC5 
ACP1 C5orf64 CPNE2 ERMN 
ACSM4 C7orf13 CREB3L3 EXOG 
ADAM2 C7orf33 CRHBP F7 
ADAM5 C7orf69 CRYBA1 FAM159B 
ADH1A C8orf44-SGK3 CSN2 FAM19A3 
ADRA1D C9orf169 CSN3 FAM205B 
AICDA CA6 CT64 FAM230C 
ANKRD20A9P CACNA2D2 CXorf21 FAM90A7P 
ANKRD62 CALB1 CXorf27 FAM92B 
APOL5 CALML3-AS1 CXorf38 FAM95B1 
AQP4 CARD8 CYP26C1 FAM99A 
AQP6 CASC15 CYP4Z2P FBN1 
ARAP1-AS2 CCDC147 DAB1 FCAMR 
ARMCX4 CCDC64 DAW1 FCN1 
ASB11 CD177 DBF4 FCN2 
ASPM CD1C DCAF4L2 FCRL1 
AZU1 CD200R1 DCD FCRL5 
BARHL2 CD247 DCLK2 FENDRR 
BCOR CD27-AS1 DEC1 FGF18 
BLK CD300LD DEFA3 FGF5 
BNC2 CD34 DEFB110 FGF8 
BOLL CD4 DEFB127 FGG 
BPI CDH26 DEFB130 FHL5 
BRIP1 CDH6 DGKB FLCN 
BRWD1-AS1 CDKN2B-AS1 DHDDS FLJ35282 
BSX CDRT15 DLX1 FLJ37786 
C10orf53 CENPF DMRTA2 FLJ43903 
C10orf68 CENPW DNTT FLJ45482 
C10orf71-AS1 CHGB DOCK2 FLJ46284 
C12orf39 CHRNA3 DOK7 FLT1 
C12orf42 CHRNB2 DSCR8 FMNL3 
C14orf64 CKLF DTX1 FNDC1 
C15orf54 CLDN22 DYNAP FOXP2 
C17orf74 CLEC2L EBF1 FP2234 
C1orf111 CLEC4M EBF2 FRG2 
C1orf227 CMA1 ECEL1P2 FXYD4 
C1orf61 CMAHP EML5 GALNT15 
C1QL1 CMKLR1 EN1 GAS2L3 
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GATA1 ITGA4 LINC00669 LOC100507308 
GATA3-AS1 IZUMO3 LINC00684 LOC100507353 
GFRAL JPH3 LINC00689 LOC100507431 
GGNBP1 KCNA6 LINC00698 LOC100507477 
GIGYF2 KCNJ9 LINC00858 LOC100507642 
GIMAP4 KCNQ5 LINC00881 LOC100653005 
GNAT3 KCTD21-AS1 LINC00893 LOC100996267 
GNG3 KDM1B LINC00894 LOC100996345 
GOLGA6A KIAA1211 LINC00911 LOC100996490 
GPER1 KIRREL3-AS3 LINC00944 LOC100996701 
GPR146 KLF6 LINC00950 LOC101805491 
GPR179 KLK13 LINC01060 LOC101927165 
GPR61 KLK14 LINC01088 LOC101927367 
GPRIN1 KRT40 LINC01094 LOC101927381 
GPX6 KRT8 LINC01095 LOC101927668 
GRAMD1B LAMB4 LINC01102 LOC101928058 
GREB1 LDB2 LINGO1 LOC101928105 
GRIN2A LENG8 LIX1 LOC101928423 
GTSE1 LGI4 LOC100127972 LOC101928895 
GYG2P1 LHFPL3-AS1 LOC100128164 LOC101928956 
HAVCR2 LIG4 LOC100128787 LOC101929125 
HCG9 LINC00167 LOC100128840 LOC101929154 
HCN2 LINC00200 LOC100129083 LOC101929416 
HFE LINC00208 LOC100129373 LOC101929578 
HGC6.3 LINC00222 LOC100129393 LOC149351 
HIST1H1D LINC00277 LOC100129917 LOC151475 
HIST1H4B LINC00278 LOC100130071 LOC283177 
HIST1H4D LINC00299 LOC100130433 LOC283674 
HIVEP3 LINC00307 LOC100130954 LOC284688 
HLA-B LINC00320 LOC100131510 LOC284751 
HLX LINC00327 LOC100131581 LOC284933 
HMBOX1 LINC00328 LOC100131756 LOC284950 
HMMR LINC00348 LOC100131894 LOC285000 
HOXC12 LINC00403 LOC100132005 LOC285043 
HPD LINC00446 LOC100132014 LOC285762 
HSFY1P1 LINC00471 LOC100132069 LOC340515 
HSPBAP1 LINC00473 LOC100133145 LOC388282 
IDO2 LINC00478 LOC100133315 LOC400655 
IFNA21 LINC00494 LOC100270679 LOC440416 
IGFBP7-AS1 LINC00506 LOC100288102 LOC441204 
IGSF1 LINC00544 LOC100288728 LOC441666 
IGSF9B LINC00582 LOC100289361 LOC441728 
IKZF1 LINC00599 LOC100291323 LOC643037 
IL12RB2 LINC00615 LOC100506272 LOC644852 
IL20 LINC00622 LOC100506674 LOC645427 
IL21R LINC00643 LOC100506792 LOC646736 
IL2RA LINC00659 LOC100506827 LOC650226 
IMPG1 LINC00661 LOC100506837 LOC727710 
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LOC728095 NDUFA6-AS1 PSIP1 SNORD116-13 
LOC728715 NECAB1 PTF1A SNORD42A 
LOC729506 NEK3 PTGER3 SNORD59B 
LOC729860 NKX2-2 PTGFR SNORD84 
LOC729930 NPPC PTPN5 SNORD97 
LOC731779 NPSR1-AS1 QRFP SORCS1 
LONP2 NPW RACGAP1P SOX14 
LOXHD1 NPY2R RASGEF1A SOX30 
LOXL1 NRAP RAX SPIC 
LPPR4 NRK RBMY2EP SSMEM1 
LRFN5 NRXN1 REM1 ST8SIA6 
LRRIQ4 NSD1 RERG STC1 
LRRTM2 NUDT4 RGS6 STX1B 
LSM11 ODF3B RNA28S5 STXBP5-AS1 
LST1 OR10A4 RNF17 SULT6B1 
MAGEA4 OR10J1 RNU11 SYNGAP1 
MAGEA6 OR10K1 RPL13A SYT1 
MAML3 OR10R3P RSPH4A TBC1D29 
MAP3K19 OR10W1 RUNX3 TCEB3C 
MAPK15 OR13G1 RXFP2 TCL6 
MATN2 OR14A16 S100G TCP10 
MCHR2 OR1L3 SCARNA10 TDGF1 
MED27 OR2T4 SCARNA22 TEX11 
MEGF11 OR4C12 SCARNA9L TEX13A 
METTL21EP OR4S2 SCGB1D4 TEX26-AS1 
MEX3D OR51I1 SCN7A TGIF2LY 
MGAT4C OR51Q1 SCTR TINAG 
MGC27382 OR52B6 SEC16B TMEM114 
MIEF2 OR52J3 SHISA3 TMEM14E 
MIPEPP3 OR5D16 SIGLEC9 TMEM151B 
MIR181A1HG OR5J2 SLA2 TMEM194A 
MIRLET7DHG OR5M3 SLC17A9 TMEM262 
MMP21 OR8A1 SLC22A24 TMEM56 
MNDA OTUD7A SLC22A8 TMEM88B 
MPPED1 PIGK SLC24A4 TMPO 
MROH2A PIKFYVE SLC25A23 TNFSF11 
MROH7 PNCK SLC2A13 TNP1 
MS4A2 PNPLA1 SLC38A6 TNS1 
MS4A8 POLR2M SLC39A12 TPH2 
MSMP POM121L9P SLC9A1 TPTE2 
MTRNR2L1 POU4F3 SMDT1 TRERF1 
MUC12 PPP6R1 SMTN TRIM15 
MUC5AC PRAMEF15 SNAR-G1 TRIM61 
MUC6 PRB4 SNORA2B TRPA1 
NAIP PRDM14 SNORD113-5 TSG1 
NCAN PRKACG SNORD114-14 TSPAN16 
NDNF PRRG3 SNORD116-11 TSPEAR 
NDST3 PRX SNORD116-12 TTTY1 
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TTTY11 
UNC80 
UNC93A 
VCAM1 
VRTN 
VWA3A 
WDR33 
WDR49 
WIPF3 
WNT2 
WRAP53 
WTAP 
XKR5 
ZBTB20 
ZC3H12D 
ZC3H13 
ZEB2 
ZNF29P 
ZNF311 
ZNF316 
ZNF365 
ZNF43 
ZNF496 
ZNF705B 
ZNF732 
ZNF804A 
ZNF888 
ZYG11A 
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7.4.3 Genes upregulated by >2-fold change by TSA (p > 0.05) 
ABL2 DNER IGSF6 LOC100996455 
ACR DNMT3B IL21R LOC101060442 
ADORA2A-AS1 DOC2B IL27 LOC101928761 
AEBP1 DPF3 INE1 LOC101929765 
AKAP4 DUX4L9 INTS1 LOC101930210 
ALX4 ECEL1 JAKMIP2 LOC284757 
ANKRD19P EIF5A2 KCNA6 LOC339442 
APBB1IP EN1 KCNN1 LOC344887 
AXIN2 ENTPD1 KCNV2 LOC388906 
BMP4 ETV1 KCTD21-AS1 LOC644277 
BMS1P20 EVX2 KIAA1161 LOC650226 
BPI F5 KRT8 LOC654841 
BPIFB4 FAM189A2 KRTAP9-1 LOC728093 
C12orf40 FAM216B LGI3 LOC728445 
C12orf42 FAM230C LIF LOC729739 
C1orf189 FAM99A LIMD2 LOC729866 
C8orf44-SGK3 FBLN2 LINC00205 LRCOL1 
CABP1 FCAMR LINC00240 LRRTM4 
CACNA1F FERMT1 LINC00244 MAPT 
CACNA2D2 FGF22 LINC00299 MNX1 
CADPS FLJ25363 LINC00307 MROH2A 
CALML5 FRMPD4 LINC00313 MS4A3 
CD3G FRY LINC00445 MSMP 
CHGA FUT10 LINC00462 MT1DP 
CLEC2A GLYATL2 LINC00478 MUC12 
CLVS2 GNAS LINC00630 MUC19 
CNTLN GNAZ LINC00840 MUC3 
COL6A4P2 GOLGA6A LINC00879 MYH11 
COMP GOLGA7B LINC00906 MYO3A 
CPA5 GPR156 LINC00908 MZB1 
CPA6 GPSM1 LINC01060 NHS 
CPNE9 GSX2 LINC01088 NMNAT2 
CRABP1 GYS2 LOC100128429 NPY2R 
CRB1 HBA2 LOC100130761 NR5A1 
CRLF1 HIST1H2APS1 LOC100131131 NR5A2 
CT60 HLA-DPB2 LOC100133612 NRARP 
CYP24A1 HRK LOC100505902 NRK 
CYP3A43 HSPA2 LOC100506351 OLAH 
DCLK2 HSPB11 LOC100507236 OR14A16 
DIO2 IFNA7 LOC100996380 OR1D5 
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OR2H1 SEPT12 WDR33  
OR51E2 SERPINA9 WFDC6  
OR52I2 SFRP1 ZBTB20-AS1  
OR52K2 SH2B2 ZFYVE28  
OR6C76 SLC24A4 ZNF29P  
OR7D4 SLC4A1   
OR8H1 SLC5A1   
OTOG SLC6A18   
OTUD7A SLCO4C1   
P2RY10 SNCB   
PADI2 SNORA39   
PCDHGA9 SNORD113-5   
PCDHGC4 SNORD114-9   
PDXK SOGA1   
PER3 SPATA25   
PHOSPHO2-KLHL23 SPDYE4   
PKN2 SPINK7   
PNKD SSX7   
PON1 STX1A   
PRMT8 STXBP5-AS1   
PROKR2 SUSD5   
PRPH SYNGAP1   
PTCH1 SYNJ2   
PTN SYT12   
PTPN5 TACR2   
PTPRVP TAS2R41   
RAB43 TCP10   
RAP1GAP TDGF1   
RIMS1 TEX35   
RNF216 TEX37   
RPL36AP33 TMEM59L   
RRN3P2 TNFRSF4   
SATL1 TNS1   
SBK1 TREM1   
SBK2 TRERF1   
SBNO2 UCMA   
SCN5A UNC80   
SCUBE1 VAX1   
SEC14L3 VCY   
SEMA6B VWA3B   
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7.4.4 Genes downregulated by >2-fold change by TSA (p > 0.05) 
ABLIM2 LOC100129516 ZC3H12D 
ACTG1 LOC100505716 ZNF577 
ADH4 LOC100506207  
ADORA3 LOC100506276  
AKT1S1 LOC100506421  
ANGPT1 LOC101927630  
ANKRD20A12P LOC101928427  
ANKRD35 LOC101930083  
APCDD1L-AS1 LOC283484  
ARMC12 LOC643406  
BOD1L2 NR2E1  
C9orf172 OR2T8  
CAPN14 OTC  
CARTPT OXCT2  
CD70 PABPC3  
CHL1 PCDHGA5  
COX8C PCDHGB2  
CRX PEG3-AS1  
CYCSP52 PIP5K1B  
CYP2A7P1 PPP1R14A  
DCAF8 PPP1R27  
FAM133B PRKCQ-AS1  
FGFBP1 PRUNE2  
FLNC PTPN11  
GBP1P1 SDCCAG8  
GIMAP7 SEMA3E  
GUCY1B3 SH3RF3  
ICMT SHANK2  
IL18RAP SLC3A1  
IL36RN SLC9B1  
KRTAP29-1 SPATA41  
LINC00112 TAGAP  
LINC00371 TBC1D21  
LINC00424 TDRG1  
LINC00617 TEX9  
LINC00683 TMEM33  
LINC00841 TRIM36  
LINC00963 TUBA3FP  
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8 Abbreviations 
The following abbreviations are used throughout the text: 
5aza 5-azacytidine (DNA methyltransferase inhibitor) 
ABS Adult bovine serum 
ABS/Ca2+ Treatment with 5% Adult bovine serum and 2 mM calcium 
AUM Asymmetric unit membrane 
bp Base pairs 
BPE Bovine pituitary extract 
BSA Bovine serum albumin 
Ca2+ Calcium 
Cd2+ Cadmium 
CdCl2 Cadmium chloride 
ChIP Chromatin Immunoprecipitation 
CIS Carcinoma in situ 
CK Cytokeratin protein 
CMF Cell multiplication factor (final cell number/initial cell number) 
DAB Diaminobenzidine 
DEPC Diethyl pyrocarbonate 
DMSO Dimethyl sulfoxide 
DNMT DNA methyltransferase 
dNTP Deoxynucleotide triphosphate 
DPBS Dulbecco’s phosphate buffered saline 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
EZH2 Enhancer of zeste homolog 2 
FBS Fetal bovine serum 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
HAT Histone acetyltransferase 
HBSS Hank’s balanced salt solution 
HDAC Histone deacetylase  
HPLC High performance liquid chromatography 
IEGs Immediate early response genes 
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IF Immunofluorescence 
IHC Immunohistochemistry 
kDa Kilo Dalton 
KDM Lysine demethylase 
KMT Lysine methyltransferase 
KRT Cytokeratin gene 
KSFM(c) Keratinocyte serum free medium (complete) 
LDS Lithium dodecyl sulfate 
lncRNA Long non-coding RNA 
MAPK Mitogen-activated protein kinase 
MBD Methyl-CpG-binding domain 
MIBC Muscle invasive bladder cancer 
miRNA Micro RNA 
MRE Metal response element 
MRES Multiple regional epigenetic silencing 
MS Mass spectrometry 
MT Metallothionein 
MTF1 Metal regulatory transcription factor 1 
NGFR Nerve growth factor receptor 
NHU Normal human urothelial 
NMIBC Non-muscle invasive bladder cancer 
PBS Phosphate buffered saline 
PD PD153035 (EGFR inhibitor) 
PPAR Peroxisome proliferator activated receptor 
PPRE Peroxisome proliferator response element 
PRC1 Polycomb repressive complex 1 
PRC2 Polycomb repressive complex 2 
PVDF Polyvinyldifluoride 
RT-QPCR Reverse transcriptase - quantitative polymerase chain reaction 
SAM S-adenosyl methionine 
SDS Sodium dodecyl sulfate 
Shh Sonic hedgehog 
TBS Tris buffered saline 
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TER Transepithelial electrical resistance 
TJ Tight junction 
TSA Trichostatin A (HDAC inhibitor)  
TZ Troglitazone (PPARγ agonist) 
TZ/PD Treatment with 1 µM troglitazone and 1 µM PD153035 
UC Urothelial carcimona 
UPK Uroplakin 
Zn2+ Zinc 
ZO Zona occludens 
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